Celsion CORP Form 424B5 September 28, 2009 Table of Contents

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-158402

PROSPECTUS SUPPLEMENT

(TO PROSPECTUS DATED APRIL 17, 2009)

2,018,153 Shares of Common Stock Warrants to Purchase 1,009,076 Shares of Common Stock

Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to 2,018,153 shares of our common stock and warrants to purchase up to 1,009,076 shares of our common stock to selected institutional investors under one or more common stock subscription agreements, each dated on or about September 25, 2009, between us and each of the investors. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock, at an initial exercise price of \$5.24 per share. Each unit will be sold at a negotiated price of \$3.50 per unit. Units will not be issued or certificated. The shares of common stock and warrants are immediately separable and will be issued separately.

Our common stock is listed on the NASDAQ Global Market under the symbol CLSN. On September 25, 2009, the last reported sale price of our common stock, as reported on the NASDAQ Global Market, was \$4.77 per share. The warrants are not and will not be listed for trading on the NASDAQ Global Market.

We have retained Needham & Company, LLC to act as the placement agent in connection with this offering. The placement agent is not purchasing or selling any of these securities nor is it required to sell any specific number or dollar amount of securities, but has agreed to use its reasonable best efforts to sell the securities offered by this prospectus supplement.

INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE RISK FACTORS BEGINNING ON PAGE S-4 OF THIS PROSPECTUS SUPPLEMENT AND PAGE 4 OF THE ACCOMPANYING PROSPECTUS, AS WELL AS THE RISKS DISCUSSED UNDER THE CAPTION RISK FACTORS BEGINNING ON PAGE 9 OF OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2008 AND BEGINNING ON PAGE 18 OF OUR QUARTERLY REPORT ON FORM 10-Q FOR THE THREE-MONTH PERIOD ENDED JUNE 30, 2009, EACH OF WHICH IS INCORPORATED BY REFERENCE IN THIS PROSPECTUS SUPPLEMENT.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

	Per Unit	Aggregate Offering Amount
Public offering price	\$ 3.50	\$ 7,063,535.50
Placement agent s fees	\$.2625	\$ 529,765.16
Proceeds, before expenses	\$ 3.2375	\$ 6,533,770.34

We estimate the total expenses of this offering, excluding the placement agent s fee, will be approximately \$233,500. We are not required to sell any specific number or dollar amount of the units offered in this offering, but the placement agent will use its reasonable best efforts to arrange for the sale of all of the units offered. Pursuant to an escrow agreement among us, the placement agent and an escrow agent, the funds received in payment for the units sold in this offering will be wired to a non-interest bearing escrow account and held until we and the placement agent notify the escrow agent that this offering has closed, indicating the date on which the shares of common stock and the warrants to purchase common stock are to be delivered to the purchasers and the proceeds are to be delivered to us. Delivery of the units is expected to be made on or about September 30, 2009, against payment for such units to be received by us on the same date.

Needham & Company, LLC

The date of this prospectus supplement is September 25, 2009

Table of Contents

TABLE OF CONTENTS

PROSPECTUS SUPPLEMENT

	Page
About This Prospectus Supplement	S-1
Prospectus Supplement Summary	S-2
Risk Factors	S-4
Cautionary Statement Regarding Forward-Looking Statements	S-5
<u>Use of Proceeds</u>	S-6
Determination of Offering Price	S-6
Description of Securities We Are Offering	S-6
Capitalization	S-8
<u>Dilution</u>	S-9
Plan of Distribution	S-10
Legal Matters	S-11
<u>Experts</u>	S-11
Where You Can Find More Information	S-11
Incorporation of Certain Documents by Reference	S-11

PROSPECTUS

	Page
About This Prospectus	(ii)
Prospectus Summary	1
Risk Factors	4
Forward-Looking Statements	5
Use of Proceeds	6
Description of Capital Stock	7
Description of Warrants	12
Description of Rights	14
Description of Units	15
Plan of Distribution	17
Legal Matters	19
Experts	19
Where You Can Find More Information	19

i

Table of Contents

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of the securities we are offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission, or the SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date for example, a document incorporated by reference in the accompanying prospectus the statement in the document having the later date modifies or supersedes the earlier statement.

In this prospectus supplement, unless we indicate otherwise, we, us, our and Company refer to Celsion Corporation.

This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed on April 3, 2009, with the SEC using a shelf registration process with respect to \$50,000,000 in securities that may be sold thereunder. The shelf registration statement was declared effective by the SEC on April 17, 2009.

Under the shelf registration process, we may offer and sell any combination of securities described in the accompanying prospectus in one or more offerings. The accompanying prospectus provides you with a general description of the securities we may offer. Each time we use the accompanying prospectus to offer securities, we will provide a prospectus supplement that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in the prospectus. The purpose of this prospectus supplement is to provide supplemental information regarding us in connection with this offering of common stock.

You should read this prospectus supplement, along with the accompanying prospectus and the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus carefully before you invest. Both documents contain important information you should consider when making your investment decision.

You may rely only on the information contained in this prospectus supplement and the accompanying prospectus and the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide information or to make representations that are different. Neither this prospectus supplement nor the accompanying prospectus is an offer to sell or a solicitation of an offer to buy any securities other than those registered by this prospectus, nor is it an offer to sell or a solicitation of an offer to buy securities where an offer or solicitation would be unlawful. Neither the delivery of this prospectus supplement and the accompanying prospectus, nor any sale made under this prospectus supplement nor the accompanying prospectus, means that the information contained in this prospectus supplement is correct as of any time after the date of this prospectus supplement and the accompanying prospectus.

Table of Contents

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights certain information appearing elsewhere in this prospectus supplement and in the accompanying prospectus and in the documents we incorporate by reference. After you read this summary, you should read and consider carefully the more detailed information and financial statements and related notes that we include in and/or incorporate by reference into this prospectus supplement and the accompanying prospectus, especially the sections entitled Risk Factors. If you invest in our securities, you are assuming a high degree of risk.

Our Company

We are an innovative oncology drug development company focused on improving treatment for those suffering with highly aggressive and difficult to treat forms of cancer. We are working to develop and commercialize more efficient, effective, targeted chemotherapeutic oncology drugs based on our proprietary heat-activated liposomal technology. The promise of this drug technology is to maximize efficacy while minimizing side-effects common to cancer treatments.

Our lead product ThermoDox® is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer. ThermoDox® is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

We also are developing a product pipeline of cancer drugs that employ our heat activated liposomal technology. We are developing a liposomal formulation of docetaxel and plan to develop a number of other liposomal formulations for existing chemotherapeutic cancer drugs where we believe that our technology can improve efficacy and safety. We have formed a joint research agreement with Royal Phillips Electronics that is evaluating the combination of Phillips high intensity focused ultrasound with our heat activated liposomal technology to develop new cancer drugs.

For certain indications, we may seek licensing partners to share in the development and commercialization costs. We also will evaluate licensing cancer products from third parties for cancer treatments to expand our development pipeline.

In December 2008, we entered into a licensing agreement with Yakult Honsha under which Yakult was granted the exclusive right to commercialize and market ThermoDox® for the Japanese market. We received a \$2.5 million up-front licensing fee and we may receive an additional \$18 million upon receipt of marketing approval by the Japanese Ministry of Health, Labor and Welfare. We also may receive additional milestone payments tied to the achievement of certain levels of sales and approval for new indications. We will receive double digit escalating royalties on the sale of ThermoDox® in Japan, if and when any such sales occur. We also will be the exclusive supplier of ThermoDox® to Yakult.

In 2005, the Company made a strategic decision to divest its medical device business. The Company sold this business to Boston Scientific Corporation, or Boston Scientific, for approximately \$60 million in June 2007. In 2008, the Company collected a \$15 million installment payment from the sale of these assets and received a final payment of \$14.9 million from Boston Scientific in June 2009. The results of operations for the medical device business for the year ended December 31, 2007 have been reclassified as a discontinued operation.

Corporate Information

We were founded in 1982 and are a Delaware corporation. Our principal executive offices are located at 10220-L Old Columbia Road, Columbia, Maryland 21046. Our telephone number is (410) 290-5390 and our website is www.celsion.com. The information available on or through our websites is not a part of this prospectus supplement and should not be relied upon.

Table of Contents

The Offering

Common stock offered by us 2,018,153 shares directly

1,009,076 shares issuable upon the exercise of warrants

Warrants Warrants to purchase up to 1,009,076 shares of common stock will be offered in this offering.

> The warrants will be exercisable at an initial exercise price of \$5.24 per share. The warrants are exercisable at any time on or after the six month anniversary of the date of issuance and expire on the sixty-six month anniversary of issuance. This prospectus also relates to the offering of

the shares of common issuable upon exercise of the warrants.

Common stock outstanding before this

offering (1) 10,095,814 shares

Common stock to be outstanding after

this offering (1) 12,113,967 shares

Price per unit \$3.50

Use of proceeds We currently intend to use the net proceeds from the sale of the units and pursuant to this

offering for general corporate purposes, including the funding of the clinical development of

our product pipeline of cancer drugs.

Risk Factors You should carefully consider, in addition to the other information contained in or incorporated

by reference into this prospectus supplement, the specific risks set forth under the caption Risk Factors section beginning on page S-4 of this prospectus supplement and page 4 of the accompanying prospectus, as well as the risks discussed under the caption Risk Factors beginning on page 9 of our Annual Report on Form 10-K for the year ended December 31,

2008 and beginning on page 18 of our Quarterly Report on Form 10-Q for the quarter ended

June 30, 2009, each of which is incorporated by reference in this prospectus supplement.

NASDAQ Capital Market symbol **CLSN**

Assumes 10,095,814 shares of common stock outstanding as of September 23, 2009 and excludes an aggregate of 1,775,414 shares of common stock subject to outstanding options, restricted stock awards and warrants, and 956,544 shares of common stock reserved for issuance under our equity incentive plans.

Table of Contents

RISK FACTORS

Investing in our common stock involves a high degree of risk. Before purchasing our securities, you should carefully review and consider the risk factors described below, the risk factors beginning on page 4 of the accompanying prospectus, as well as the risks discussed under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2008, and in our Quarterly Report on Form 10-Q for the three-month period ended June 30, 2009, each of which is incorporated by reference into this prospectus supplement. If any of these risks actually occur, our business, financial condition and results of operations would suffer. In that case, the trading price of our common stock would likely decline and you might lose all or part of your investment in our securities. Additional risks not presently known to us or that we currently deem immaterial may also impair our business, financial condition or results of operations. See also the information contained under the heading Special Note Regarding Forward-Looking Statements immediately below.

Risks Relating to this Offering and Ownership of Our Common Stock

The market price of our common stock may be volatile, and the value of your investment could decline significantly.

The trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including our historical and anticipated operating results, our financial situation, announcements of technological innovations or new products by us or our competitors, our ability or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions, some of which are beyond our control. These broad market fluctuations may lower the market price of our common stock and affect the volume of trading in our stock.

Future sales of our common stock in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. As of September 23, 2009, we had 10,095,814 shares of common stock outstanding, all of which shares, other than shares held by our directors and certain officers which are subject to ninety (90) day lock-up agreements in connection with this offering, were eligible for sale in the public market, subject in some cases to compliance with the requirements of Rule 144, including the volume limitations and manner of sale requirements. In addition, all of the shares offered under this prospectus supplement and the accompanying prospectus will be freely tradable without restriction or further registration upon issuance.

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways with which you may not agree. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested or otherwise used in a way that does not yield a favorable, or any, return for our company.

We have never declared or paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future.

Our business requires significant funding, and we currently invest available funds and earnings in product development. Therefore, we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently plan to invest all available funds and future earnings in the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of potential gain for the foreseeable future.

You will experience immediate dilution in the book value per share of the common stock you purchase.

You will suffer immediate dilution in the net tangible book value of the common stock you purchase in this

S-4

Table of Contents

offering because the price per share of our common stock being offered hereby is substantially higher than the book value per share of our common stock. Based on the public offering price of \$3.50 per unit in this offering (and attributing no value to the warrant included in each unit), if you purchase units in this offering, you will suffer immediate and substantial dilution of \$1.64 per share in the net tangible book value of the common stock. See Dilution on page S-9 for a more detailed discussion of the dilution you will incur in this offering.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained or incorporated by reference in this prospectus, in any applicable prospectus supplement and in any related free writing prospectus, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In addition, from time to time we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and other aspects of our present and future business operations and similar matters that also constitute such forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among other things:

•	unforeseen changes in the course of research and development activities and in clinical trials;
•	possible changes in cost and timing of development and testing, capital structure, and other financial items;
•	changes in approaches to medical treatment;
•	introduction of new products by others;
•	possible acquisitions of other technologies, assets or businesses;
•	possible actions by customers, suppliers, strategic partners, potential strategic partners, competitors and regulatory authorities; and
•	those listed under the header Risk Factors contained in the applicable prospectus supplement and any related free writing prospectus,

and under the same and similar headings in the other documents that are incorporated by reference into this prospectus.

plan, In some cases, you can identify forward-looking statements by terminology such as expect, anticipate, estimate, believe, will and words of similar import regarding the Company s expectations. Forward-looking statements are only will, should, predictions and actual events or results may differ materially. Although we believe that our expectations are based on reasonable assumptions within the bounds of our current knowledge of our industry, business and operations, we cannot guarantee that actual results will not differ materially from our expectations. In evaluating such forward-looking statements, you should specifically consider various factors, including the risks outlined under the heading Risk Factors contained in the applicable prospectus supplement and any related free writing prospectus, and in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC. The discussion of risks and uncertainties set forth in those filings is not necessarily a complete or exhaustive list of all risks facing the Company at any particular point in time. We operate in a highly competitive, highly regulated and rapidly changing environment, and our business is in a state of evolution. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time. It is not possible for management to predict all such risk factors or changes therein, or to assess either the impact of all such risk factors on our business or the extent to which any individual risk factor, combination of factors, or new or altered factors, may cause results to differ materially from those contained in any forward-looking statement. Also, these forward-looking statements represent our estimates and assumptions only as of the date such

Table of Contents

forward-looking statements are made. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the section entitled Where You Can Find Additional Information, and with the understanding that our actual future results may be materially different from what we expect.

Except as required by law, forward-looking statements speak only as of the date they are made, and we assume no obligation to update any forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available.

USE OF PROCEEDS

We estimate that our net proceeds from the sale of the securities offered pursuant to this prospectus supplement will be approximately \$6.3 million, after deducting the placement agent s fees and all estimated offering expenses that are payable by us. We currently intend to use the net proceeds from the sale of the securities pursuant to this offering for general corporate purposes, including the funding of the clinical development of our product pipeline of cancer drugs.

Pending the application of the net proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing securities.

DETERMINATION OF OFFERING PRICE

We determined the offering price of the securities being offered by this prospectus supplement principally by negotiations between us and the selected investors and our consideration of the closing prices (including high, low and average prices) and trading volumes of our common stock on the NASDAQ Global Market primarily during the 30 trading days preceding the date we determined the offering price. No independent appraisal or valuation was obtained to determine the offering price. The offering price of the units reflects a discount of approximately 26.6% from the reported closing price per share of our common stock of \$4.77 on September 25, 2009.

DESCRIPTION OF SECURITIES WE ARE OFFERING

In this offering, we are offering a maximum of 2,018,153 units, consisting of 2,018,153 shares of our common stock and warrants to purchase up to 1,009,076 shares of our common stock. Each unit consists of one share of common stock and a warrant to purchase 0.5 shares of common stock at an initial exercise price of \$5.24 per share. Each unit will be sold at a negotiated price of \$3.50 per unit. This prospectus supplement also relates to the offering of shares of our common stock upon exercise, if any, of the warrants. Units will not be issued or certificated. The shares of common stock and warrants are immediately separable and will be issued separately.

The units offered in this offering will be issued pursuant to subscription agreements between each of the purchasers and us. You should review a copy of the form of subscription agreement and the form of warrant, each of which have been filed by us as an exhibit to a Current Report on Form 8-K filed with the SEC in connection with this offering, for a complete description of the terms and conditions applicable to the units. This description of the units in this prospectus supplement is qualified in its entirety by reference to the warrants.

Common Stock

As of July 1, 2009, our authorized capital stock consists of 75,000,000 shares of common stock, \$0.01 par value per share, and 100,000 shares of preferred stock, \$0.01 par value per share, of which 15,000 shares of Series C Junior Participating Preferred Stock were reserved for issuance under our stockholder rights plan. A description of our stockholder rights plan and all other rights, privileges and preferences of our common stock we are offering pursuant to this prospectus supplement is set forth under the heading Description of Capital Stock, starting on page 8 of the accompanying prospectus.

Table of Contents

Warrants

The following is a brief summary of the warrants and is subject in all respects to the provisions contained in the warrants, the form of which is attached to this prospectus supplement.

Exercisability. Holders may exercise warrants at any time on or after the six month anniversary of the date of issuance up to 11:59 p.m., New York time, on the date that is 66 months after the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise discussed below). The holder of warrants does not have the right to exercise any portion of the warrant if the holder would beneficially own in excess of 4.99% of the shares of our common stock outstanding immediately after giving effect to such exercise. This percentage may, however, be raised or lowered to an amount not to exceed 9.99% at the option of the holder upon at least 61 days prior notice from the holder to us.

Cashless Exercise. At any time when a registration statement covering the resale of the shares of common stock issuable upon exercise of the warrants is not effective, the holder may, at its option, exercise its warrants on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.

Exercise Price. The exercise price of common stock purchasable upon exercise of the warrants is \$5.24 per share. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications or similar events affecting our common stock, and also upon any distributions of assets, including cash, stock or other property to our stockholders.

Transferability. The warrants may be transferred at the option of the holder upon surrender of the warrants with the appropriate instruments of transfer.

Purchase Rights, Fundamental Transactions and Change of Control. If we sell or grant any rights to purchase stock, warrants or securities or other property to our stockholders on a pro rata basis, we will provide the holders of warrants with the right to acquire, upon the same terms, the securities subject to such purchase rights as though the warrant had been exercised immediately prior to the declaration of such rights. If we consummate any fundamental transaction, as described in the warrants and generally including any consolidation or merger into another corporation, the consummation of a transaction whereby another entity acquires more than 50% of our outstanding common stock, the sale of all or substantially all of our assets, or another transaction in which our common stock is converted into or exchanged for other securities or other consideration, the holder of warrants will thereafter receive upon exercise of the warrants the securities or other consideration to which a holder of the number of shares of common stock then deliverable upon the exercise or conversion of such warrants would have been entitled upon such consolidation, merger or other transaction. In addition, in the event of a fundamental transaction that constitutes a change of control as defined in the warrants, we or any successor entity will pay at the holder s option, exercisable at any time concurrently with or within 90 days following the consummation of the transaction, an amount of cash equal to the value of the unexercised warrants held by such holder as determined in accordance with the Black-Scholes option pricing formula.

Exchange Listing. We do not plan on making an application to list the warrants on the NASDAQ Global Market, any national securities exchange or other nationally recognized trading system. Our common stock underlying the warrants is listed on the NASDAQ Global Market.

Rights as Stockholder. Except as otherwise provided in the warrants (such as the rights described above of a warrant holder upon our sale or grant of any rights to purchase stock, warrants or securities or other property to our stockholders on a pro rata basis) or by virtue of such holder s ownership of shares of our common stock, the holders of the warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their warrants.

Fractional Shares. No fractional shares of common stock will be issued upon the exercise of the warrants. Rather, the number of shares of common stock to be issued will be rounded down to the nearest whole number.

Table of Contents

CAPITALIZATION

The following table shows our unaudited capitalization and other data as of June 30, 2009:

- on an actual basis; and
- on a pro forma as adjusted basis to reflect this offering.

This table should be read in conjunction with, and is qualified in its entirety by reference to, our unaudited historical financial statements and the accompanying notes included in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, which are incorporated by reference herein.

	June 30, 2009 (unaudited)	
	Actual	As Adjusted
Stockholders equity:		
Common stock, par value \$0.01 per share; 250,000,000 shares authorized; 10,856,008		
shares issued; 10,095,814 shares outstanding	108,561	128,743
Additional paid-in capital	89,737,617	96,017,706
Accumulated deficit	(75,132,162)	(75,132,162)
Subtotal	14,714,016	21,014,287
Less: Treasury stock, at cost, 760,274 shares	(3,076,670)	(3,076,670)
Total stockholders equity	\$ 11,637,346	17,937,617

The information above is based on 10,095,814 shares of our common stock outstanding as of June 30, 2009 and does not include:

- 1,641,980 shares of common stock issuable upon exercise of options outstanding as of June 30, 2009, at a weighted average exercise price of \$3.96 per share;
- 135,100 shares of common stock issuable upon the vesting of outstanding restricted stock awards as of June 30, 2009; and
- 23,334 shares of common stock issuable upon the exercise of warrants outstanding as of June 30, 2009, at a weighted average exercise price of \$9.86 per share.

Table of Contents

DILUTION

Our net tangible book value as of June 30, 2009 was approximately \$11.6 million, or \$1.15 per share of common stock. Net tangible book value per share is calculated by subtracting our total liabilities from our total tangible assets, which is total assets less intangible assets, and dividing this amount by the number of shares of common stock outstanding. After giving effect to the sale by us of the 2,018,153 units offered in this offering, at a public offering price of \$3.50 per share (and attributing no value to the warrant included in each unit) and after deducting the placement agent s fees and estimated offering expenses payable by us, our net tangible book value as of June 30, 2009, would have been approximately \$17.9 million, or \$1.48 per share of common stock. This represents an immediate increase in net tangible book value of \$0.33 per share to our existing stockholders and an immediate and substantial dilution of \$1.64 per share to new investors. The following table illustrates this per share dilution:

Offering price per share included in each unit		\$ 3.12
Net tangible book value per share as of June 30, 2009	\$ 1.15	
Increase per share attributable to new investors	\$ 0.33	
Pro forma net tangible book value per share after this offering		\$ 1.48
Pro forma dilution per share to new investors		\$ 1.64

The above discussion and table is based on 10,095,814 shares of common stock outstanding as of June 30, 2009, and excludes:

- up to 1,641,980 shares of common stock that may be issued upon the exercise of outstanding options as of June 30, 2009 pursuant to our stock option plans at a weighted-average exercise price of \$3.96 per share;
- up to 135,100 shares of common stock issuable upon the vesting of outstanding restricted stock awards as of June 30, 2009; and
- up to 23,334 shares of common stock issuable upon the exercise of outstanding warrants as of June 30, 2009 at a weighted-average exercise price of \$9.86 per share.

Table of Contents

PLAN OF DISTRIBUTION

We are offering the units through a placement agent. Subject to the terms and conditions contained in the placement agency agreement, dated September 25, 2009, Needham & Company, LLC has agreed to act as the placement agent for the sale of up to 2,018,153 units. The placement agent is not purchasing or selling any units by this prospectus supplement or the accompanying prospectus nor is it required to arrange for the purchase or sale of any specific number or dollar amount of units, but has agreed to use its commercially reasonable best efforts to arrange for the sale of all units offered by us to the investors.

The placement agency agreement provides that the obligations of the placement agent and the investors are subject to certain conditions precedent, including the absence of any material adverse change in our business and the receipt of customary legal opinions, letters and certificates.

We will sell the offered units to selected institutional and other investors under one or more common stock subscription agreements entered into between us and each of the investors at the offering price stated on the cover of this prospectus supplement. We currently anticipate that closing of the sale of common stock offered hereby will take place on or about September 30, 2009. Investors will also be informed of the date and manner in which they must transmit the purchase price for their units.

On the scheduled closing date, the following will occur:

- we will receive funds in the amount of the aggregate purchase price for the units we sell;
- we will deliver to each of the investors, through the DWAC system or by book-entry, the shares of common stock being purchased; and
- Needham & Company, LLC will receive the placement agent s fee in accordance with the terms of the placement agency agreement.

In accordance with the terms of the placement agency agreement, we will pay the placement agent an aggregate commission equal to 7.5% of the gross proceeds of the sale of units in the offering. We have also agreed to reimburse the placement agent for certain fees and legal expenses incurred by it in connection with the offering. In no event will the total amount of compensation paid to the placement agent and other securities brokers and dealers upon completion of this offering exceed 8% of the gross proceeds of the offering. The estimated offering expenses payable by us, in addition to the placement agent a fee of \$529,765.16, are approximately \$233,500, which includes legal, accounting and printing costs and various other fees associated with registering and listing the common stock. After deducting certain fees due to the placement agent and our estimated offering expenses, we expect the net proceeds from this offering to be approximately \$6.3 million.

The placement agent has informed us that it will not engage in over-allotment, stabilizing transactions or syndicate covering transactions in connection with the offering. The placement agent may, from time to time, engage in transactions with and perform services for us in the ordinary course of its business.

We have agreed to indemnify the placement agent against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches of representations and warranties contained in the placement agency agreement. We have also agreed to contribute to payments the placement agent may be required to make in respect of such liabilities.

We, along with our executive officers and directors, have agreed to certain lock-up provisions with regard to future sales of our common stock for a period of ninety (90) days after the offering as set forth in the placement agency agreement.

The placement agency agreement is included as an exhibit to our Current Report on Form 8-K that we will file with the SEC in connection with the consummation of this offering.

S-10

Table of Contents

The transfer agent for our common stock to be issued in this offering is American Stock Transfer & Trust Company located at 6201 15th Avenue, 2nd Floor, Brooklyn, NY 11219. Its phone number is 800-937-5449.

Our common stock is traded on the NASDAQ Global Market under the symbol CLSN.

LEGAL MATTERS

Seyfarth Shaw LLP, New York, New York is passing upon the validity of the common stock and the warrants being offered hereby. Proskauer Rose LLP, New York, New York is acting as counsel for the placement agent.

EXPERTS

The financial statements incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended December 31, 2008 have been so incorporated in reliance on the report of Stegman & Company, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

WHERE YOU CAN FIND MORE INFORMATION

Federal securities laws require us to file information with the SEC concerning our business and operations. Accordingly, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we file at the SEC s public reference rooms, including those located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on public reference rooms. Our SEC filings are also available to the public from the SEC s web site at http://www.sec.gov.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The SEC allows us to incorporate by reference certain information we file with them in this prospectus supplement. This means that we can disclose important information to you by referring you to the other information we have filed with the SEC. The information that we incorporate by reference is considered to be part of this prospectus supplement. Information that we file later with the SEC will automatically update and supersede this information. Further, all filings we make under the Exchange prior to the termination of the offering shall be deemed to be incorporated by reference into this prospectus supplement. The following documents filed by us with the SEC and any future filings under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (File No. 001-15911) made prior to the termination of this offering are incorporated by reference:

our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 (including information specifically incorporated by reference into our Form 10-K from our definitive proxy statement on Schedule 14A relating to our annual meeting of stockholders held on May 15, 2009), as filed with the SEC on March 27, 2009;
• our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2009 and June 30, 2009, as filed with the SEC on May 12, 2009 and August 5, 2009, respectively;
• our Current Reports on Form 8-K as filed with the SEC on February 19, 2009, June 2, 2009 and September 28, 2009, and our Amended Current Report on Form 8-K/A as filed with the SEC on February 20, 2009;
• our definitive proxy statement on Schedule 14A, relating to our annual meeting of stockholders held on May 15, 2009, as filed with the SEC on April 2, 2009; and
• the description of our common stock contained in our registration statement on Form 8-A, as filed with the SEC on May 26, 2000, amended by a Form 8-A/A dated February 7, 2008, and any amendments or reports filed for the purpose of updating such description.

S-11

Table of Contents

This prospectus supplement may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this prospectus supplement. Reports we file with the SEC after the date of this prospectus supplement may also contain information that updates, modifies or is contrary to information in this prospectus supplement or in documents incorporated by reference in this prospectus supplement. Investors should review these reports as they may disclose a change in our business, prospectus, financial condition or other affairs after the date of this prospectus supplement.

Our website is www.celsion.com. Our website contains links to our filings available on the SEC website. We will also provide electronic or paper copies of our filings free of charge upon written or oral request. The information available on or through our websites is not a part of this prospectus supplement and should not be relied upon. You can request a free copy of the above filings or any filings subsequently incorporated by reference into this prospectus supplement by writing or calling us at:

Celsion Corporation

10220-L Old Columbia Road

Columbia, Maryland 21046-2364

Attention: Sean Moran, Chief Financial Officer

(410) 290-5390

Table of Contents
PROSPECTUS
\$50,000,000 Common Stock Preferred Stock Warrants
Rights Units
From time to time, we may offer up to \$50,000,000, in one or more series, any combination of the following securities of our company:
• common stock;
• preferred stock;
• warrants to purchase shares of common stock or preferred stock;
• rights to purchase shares of common stock or preferred stock; or
• units comprised of 2 or more of the foregoing securities.
We will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered.

Our common stock is traded on the NASDAQ Global Market under the symbol CLSN. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the NASDAQ Global Market or any securities market or other exchange of the securities covered by the applicable prospectus supplement.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading Risk Factors on page 4 of this Prospectus, in any applicable prospectus supplement and in any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus.

This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.

The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled Plan of Distribution in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.

The aggregate market value of our outstanding common equity held by non-affiliates as of March 24, 2009 was approximately \$29.3 million. We have not issued any securities pursuant to Instruction I.B.6. of Form S-3 during the 12 calendar month period that ends on and includes the date hereof.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is April 17, 2009

Table of Contents

TABLE OF CONTENTS

	Page
ABOUT THIS PROSPECTUS	(ii)
PROSPECTUS SUMMARY	1
RISK FACTORS	4
FORWARD-LOOKING STATEMENTS	5
<u>USE OF PROCEEDS</u>	6
DESCRIPTION OF CAPITAL STOCK	7
DESCRIPTION OF WARRANTS	12
DESCRIPTION OF RIGHTS	14
DESCRIPTION OF UNITS	15
<u>PLAN OF DISTRIBUTION</u>	17
<u>LEGAL MATTERS</u>	19
<u>EXPERTS</u>	19
WHERE YOU CAN FIND ADDITIONAL INFORMATION	19

i

Table of Contents

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the SEC) utilizing a shelf registration process. Under this shelf registration process, we may offer shares of our common stock and preferred stock, and warrants and/or rights to purchase shares of our common or preferred stock, either individually or in units, in one or more offerings, up to a total dollar amount of \$50,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of those securities. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also add, update or change in the prospectus supplement (and in any related free writing prospectus that we may authorize to be provided to you) any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the section entitled Where You Can Find Additional Information, in this prospectus before buying any of the securities being offered. THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.

You should rely only on the information that we have provided or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. We have not authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security.

This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled Where You Can Find Additional Information in this prospectus.

We obtained statistical data, market data and other industry data and forecasts used throughout, or incorporated by reference in, this prospectus from market research, publicly available information and industry publications. Industry publications generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy and completeness of the information. Similarly, while we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified the data, and we do not make any representation as to the accuracy of the information. We have not sought the consent of the sources to refer to their reports appearing or incorporated by reference in this prospectus.

This prospectus and the information incorporated herein by reference includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus are the property of their respective owners.

Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus to Celsion, we, our or similar references mean Celsion Corporation.

ii

Table of Contents

PROSPECTUS SUMMARY

The following summary highlights selected information contained or incorporated by reference in this prospectus. This summary does not contain all of the information you should consider before investing in the securities. Before making an investment decision, you should read the entire prospectus and any supplement hereto carefully, including the risk factors section as well as the financial statements and the notes to the financial statements incorporated herein by reference.

Our Company

Celsion Corporation (Celsion or the Company or we) is an innovative oncology drug development company focused on improving treatment for those suffering with highly aggressive and difficult to treat forms of cancer. We are working to develop and commercialize more efficient, effective, targeted chemotherapeutic oncology drugs based on our proprietary heat-activated liposomal technology. The promise of this drug technology is to maximize efficacy while minimizing side-effects common to cancer treatments.

Our lead product ThermoDox® is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer. ThermoDox® is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

Celsion is also developing a product pipeline of cancer drugs that employ its heat activated liposomal technology. We are developing a liposomal formulation of docetaxel and plan to develop a number of other liposomal formulations for existing chemotherapeutic cancer drugs where we believe that our technology can improve efficacy and safety. We have formed a joint research agreement with Royal Phillips Electronics that is evaluating the combination of Phillips high intensity focused ultrasound with Celsion s heat activated liposomal technology to develop new cancer drugs.

For certain indications, the Company may seek licensing partners to share in the development and commercialization costs. The Company will also evaluate licensing cancer products from third parties for cancer treatments to expand its development pipeline.

In December 2008, the Company entered into a licensing agreement with Yakult Honsha under which Yakult was granted the exclusive right to commercialize and market ThermoDox® for the Japanese market. Celsion was paid a \$2.5 million up-front licensing fee and Celsion has the potential to receive an additional \$18 million upon receipt of marketing approval by the Japanese Ministry of Health, Labor and Welfare. Celsion also has the potential to receive additional milestone payments tied to the achievement of certain levels of sales and approval for new indications. Celsion will receive double digit escalating royalties on the sale of ThermoDox® in Japan, if and when any such sales occur. Celsion also will be the exclusive supplier of ThermoDox® to Yakult.

In 2005, the Company made a strategic decision to divest its medical device business. The Company sold this business to Boston Scientific Corporation (Boston Scientific) for \$60 million. In 2008, the Company collected a \$15 million installment payment from the sale of these assets

and is due to receive the final \$15 million installment payment in June 2009. The results of operations for the medical device business for the year ended December 31, 2007 has been reclassified as a discontinued operation.

Our Executive Offices

Our principal executive offices are located at 10220-L Old Columbia Road, Columbia, Maryland 21046. Our telephone number is (410) 290-5390.

The Securities We May Offer

We may offer shares of our common stock and preferred stock, and warrants and/or rights to purchase shares of our common stock and preferred stock, either individually or in units, with a total value of up to \$50,000,000 from time to time under this prospectus at prices and on terms to be determined by market conditions at

1

Table of Contents

series of se	any offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or equities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other terms of the securities, including, to the extent applicable:
•	designation or classification;
•	aggregate offering price;
•	rates and times of payment of dividends, if any;
•	redemption, conversion, exercise, exchange or sinking fund terms, if any;
•	ranking;
•	restrictive covenants, if any;
•	voting or other rights, if any;
•	conversion prices, if any; and

The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.

important United States federal income tax considerations.

THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.

We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the

	cept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will the applicable prospectus supplement:
•	the names of those agents or underwriters;
•	applicable fees, discounts and commissions to be paid to them;
•	details regarding over-allotment options, if any; and
•	the net proceeds to us.

Common Stock. We may issue shares of our common stock from time to time. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of our common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock.

Preferred Stock. We may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will determine designations, powers (including voting), privileges, preferences and relative

Table of Contents

participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the holder s option and would be at prescribed conversion rates.

If we sell any series of preferred stock under this prospectus, we will fix the designations, powers (including voting), privileges, preferences and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.

Warrants. We may issue warrants for the purchase of our common stock or preferred stock, in one or more series. We may issue warrants independently or together with common stock or preferred stock, and the warrants may be attached to or separate from these securities. The warrants will be evidenced by warrant certificates issued under one or more warrant agreements, which are contracts between us and an agent for the holders of the warrants. In this prospectus, we have summarized certain general features of the warrants. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference into the registration statement of which this prospectus is a part, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the series of warrants we are offering before the issuance of the related series of warrants. We urge you to read the prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the applicable series of warrants.

Rights. We may issue rights to purchase our common stock or preferred stock, in one or more series. We may issue rights independently or together with other securities, and the rights may be attached or separate from these securities. In this prospectus, we have summarized certain general features of the rights. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of rights being offered, as well as any agreements that describe the terms of the rights we are offering before the issuance of the related rights.

Units. We may issue, in one or more series, units consisting of our common stock, preferred stock, and/or rights and/or warrants for the purchase of our common stock or preferred stock in any combination. Each series of units will be evidenced by unit certificates that we will issue, and units may be issued under a unit agreement that we enter into with a unit agent. In this prospectus, we have summarized certain general features of the units. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement and any supplemental agreements, including a form of unit certificate, that describe the terms of the series of units we are offering before the issuance of the related series of units. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of units being offered, as well as the complete unit agreement that contains the terms of the units.

Table of Contents

RISK FACTORS

Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading Risk Factors contained in the applicable prospectus supplement and any related free writing prospectus, and under the same and similar headings in the other documents that are incorporated by reference into this prospectus. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations.

4

Table of Contents

FORWARD-LOOKING STATEMENTS

Certain statements contained or incorporated by reference in this prospectus, in any applicable prospectus supplement and in any related free writing prospectus, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the Securities and Exchange Commission and within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and other aspects of our present and future business operations and similar matters that also constitute such forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among other things:

•	unforeseen changes in the course of research and development activities and in clinical trials;
•	possible changes in cost and timing of development and testing, capital structure, and other financial items;
•	changes in approaches to medical treatment;
•	introduction of new products by others;
•	possible acquisitions of other technologies, assets or businesses;
•	possible actions by customers, suppliers, strategic partners, potential strategic partners, competitors and regulatory authorities; and
and under	those listed under the header Risk Factorscontained in the applicable prospectus supplement and any related free writing prospectus, the same and similar headings in the other documents that are incorporated by reference into this prospectus.

In some cases, you can identify forward-looking statements by terminology such as expect, anticipate, estimate, plan, believe, could, int predict, may, will, should, will and words of similar import regarding the Company s expectations. Forward-looking statements are only predictions and actual events or results may differ materially. Although we believe that our expectations are based on reasonable assumptions within the bounds of our current knowledge of our industry, business and operations, we cannot guarantee that actual results will not differ materially from our expectations. In evaluating such forward-looking statements, you should specifically consider various factors, including the risks outlined under the heading. Risk Factors ontained in the applicable prospectus supplement and any related free writing prospectus, and in

our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC. The discussion of risks and uncertainties set forth in those filings is not necessarily a complete or exhaustive list of all risks facing the Company at any particular point in time. We operate in a highly competitive, highly regulated and rapidly changing environment, and our business is in a state of evolution. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time. It is not possible for management to predict all such risk factors or changes therein, or to assess either the impact of all such risk factors on our business or the extent to which any individual risk factor, combination of factors, or new or altered factors, may cause results to differ materially from those contained in any forward-looking statement. Also, these forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the section entitled. Where You Can Find Additional Information, and with the understanding that our actual future results may be materially different from what we expect.

Except as required by law, forward-looking statements speak only as of the date they are made, and we assume no obligation to update any forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available.

Table of Contents

USE OF PROCEEDS

We currently intend to use the net proceeds from the sale of the securities offered hereby for general corporate purposes, which may include the further development, manufacture and commercialization of our lead product candidate, ThermoDox®, and to fund research and development of other products, working capital, capital expenditures and other general corporate purposes. We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, as well as for capital expenditures. We have not specifically allocated the proceeds to those purposes as of the date of this prospectus. Pending these uses, we expect to invest the net proceeds in short-term, investment-grade securities. The precise amount and timing of the application of proceeds from the sale of securities will depend on our funding requirements and the availability and cost of other funds at the time of sale. Allocation of proceeds of a particular series of securities, or the principal reason for the offering if no allocation has been made, will be described in the applicable prospectus supplement or in any related free writing prospectus.

6

- I	•		\sim		
Tab	Ie.	Ωt	(`o	nte	nte

DESCRIPTION OF CAPITAL STOCK

General

Our authorized capital stock consists of 250,000,000 shares of common stock, \$0.01 par value per share, and 100,000 shares of preferred stock, \$0.01 par value per share, of which 15,000 shares of Series C Junior Participating Preferred Stock were reserved for issuance under the Stockholder Rights Plan (described below). As of March 31, 2009, there were 10,156,350 shares of our common stock outstanding and no shares of preferred stock outstanding.

The following summary description of our capital stock is based on the applicable provisions of the Delaware General Corporation Law (the DGCL) and on the provisions of our certificate of incorporation, as amended (our Certificate of Incorporation), and our bylaws, as amended (our Bylaws),. This information is qualified entirely by reference to the applicable provisions of the DGCL and our Certificate of Incorporation and Bylaws. For information on how to obtain copies of our Certificate of Incorporation and Bylaws, which are exhibits to the registration statement of which this prospectus is a part, see the section entitled Where You Can Find Additional Information in this prospectus.

Common Stock

Holders of common stock to be registered hereunder are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to any preferential rights of any outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the Board of Directors of the Company (the Board) out of funds legally available therefor. In the event of a dissolution, liquidation or winding-up of the Company, holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and any preferential rights of any outstanding preferred stock.

Holders of common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock which may be designated and issued in the future.

The Board is classified into three classes, designated as Class I, Class II and Class III, with each class to be elected for three year terms on a staggered basis. At each annual meeting of stockholders, the directors elected to succeed those whose terms are expiring succeed to the same class as the directors they replace and each such new director is elected for a term to expire at the third annual meeting of stockholders after his or her election and when his or her successor is duly elected and qualified.

Holders of common stock have rights under the Rights Agreement described below under the caption Anti-Takeover Considerations and Special Provisions of Our Certificate of Incorporation, Our Bylaws and the Delaware General Corporation Law - Stockholder Rights Plan .

Preferred Stock

Pursuant to our Certificate of Incorporation, our Board has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or NASDAQ rules), to designate and issue shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers (including voting), privileges, preferences and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations or restrictions thereof, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.

We will fix the designations, powers (including voting), privileges, preferences and relative participating, optional or other rights, if any, of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file

Table of Contents

	EC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the f that series of preferred stock. This description will include:
•	the title and stated value;
•	the number of shares we are offering;
•	the liquidation preference per share;
•	the purchase price;
•	the dividend rate, period and payment date and method of calculation for dividends;
•	whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
•	the procedures for any auction or remarketing, if any;
•	the provisions for a sinking fund, if any;
• repurchase	the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and rights;
•	any listing of the preferred stock on any securities exchange or market;
• how it will	whether the preferred stock will be convertible into or exchangeable for other securities, and, if applicable, the conversion price, or be calculated, and the conversion period;

•	voting rights, if any, of the preferred stock;
•	preemptive rights, if any;
•	restrictions on transfer, sale or other assignment, if any;
•	liability as to further calls or to assessment by the Company, if any;
•	a discussion of any material United States federal income tax considerations applicable to the preferred stock;
• affairs;	the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our
• stock as to	any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred dividend rights and rights if we liquidate, dissolve or wind up our affairs; and
•	any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
amendmen otherwise, adversely	provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an at to our Certificate of Incorporation if the amendment would change the par value or, unless the Certificate of Incorporation provided the number of authorized shares of the class or change the powers, preferences or special rights of the class or series so as to affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable of designation.
	8

Table of Contents

Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock or other securities. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock.

Anti-Takeover Considerations and Special Provisions of Our Certificate of Incorporation, Our Bylaws and the Delaware General Corporation Law

Stockholder Rights Plan

On August 6, 2002, our Board declared a dividend distribution of one preferred share purchase right (a Purchase Right) for each outstanding share of our common stock. The dividend was payable to the stockholders of record on August 6, 2002 (the Record Date), and with respect to shares of common stock issued thereafter until the Distribution Date (as defined below) and, in certain circumstances, with respect to shares of common stock issued after the Distribution Date. Except as set forth below, when it becomes exercisable, each Purchase Right entitles the registered holder to purchase from the Company one ten-thousandth (1/10,000) of a share of Series C Junior Participating Preferred Stock, par value \$0.01 per share, of the Company (the Series C Preferred Stock), at a price of \$66.90 per one ten-thousandth (1/10,000) of a share of Series C Preferred Stock (the Purchase Price), subject to adjustment. The description and terms of the Purchase Rights are set forth in a Rights Agreement between the Company and American Stock Transfer & Trust Company, as rights agent, dated as of August 15, 2002 (the Effective Date), as amended on January 16, 2003 (collectively, the Rights Agreement).

Initially, the Purchase Rights will be attached to all certificates representing shares of common stock outstanding as of the Record Date, and no separate certificates representing the Purchase Rights (Right Certificates) will be distributed. The Purchase Rights will separate from the common stock upon the earlier to occur of (A) a person or group of affiliated or associated persons having acquired beneficial ownership of fifteen percent (15%) or more of the outstanding shares of common stock or (B) ten (10) days (or such later date as the Board may determine) after the commencement of, or announcement of an intention to make, a tender offer or exchange offer the completion of which would result in a person or group of affiliated or associated persons becoming an Acquiring Person (as defined below) (in either case, the Distribution Date). A person or group whose acquisition of shares of common stock cause a distribution date pursuant to clause (A) above is an Acquiring Person, with certain exceptions set forth in the Rights Agreement. The date on which a person or group is first publicly announced to have become such by the Company or such Acquiring Person or an earlier date on which a majority of the then-sitting members of the Board becomes aware of the existence of such Acquiring Person is referred to below and in the Rights Agreement as the Stock Acquisition Date .

If any person becomes an Acquiring Person, each holder of a Purchase Right will thereafter have the right (the Flip-In Right) to receive, upon exercise, the number of shares of common stock (or, in certain circumstances, one ten-thousandth (1/10,000) of a share of Series C Preferred Stock) or other securities of the Company having a value (immediately before such triggering event) equal to two (2) times the exercise price of the Purchase Right. Notwithstanding the foregoing, after the Flip-In Right is triggered as described above, all Purchase Rights that are, or (under certain circumstances specified in the Rights Agreement) were, beneficially owned by any Acquiring Person or any affiliate or associate thereof will be null and void. The Board has the option, at any time after any person becomes an Acquiring Person but before an Acquiring Person becomes the beneficial owner of fifty percent (50%) or more of the Common Stock, to exchange all or part of the then-exercisable Purchase Rights (excluding those that have become void, as described in the immediately preceding sentence) for shares of common stock, at a one-to-one exchange ratio, appropriately adjusted to reflect any stock split, stock dividend or similar transaction having occurred since the Effective Date.

If, at any time after the Stock Acquisition Date, (A) the Company consolidates or mergers with another person, (B) any Person merges with and into the Company, with the Company being the surviving corporation and, in connection with such merger, all or part of the common stock is changed into or exchanged for stock or other securities of any other Person (or of the Company) or cash or any other property, or (C) the Company sells or otherwise transfers, in one or more transactions, assets or earning power aggregating fifty percent (50%) or more of its consolidated assets or earning power to any other Person, then each holder of a Purchase Right (except Purchase

Table of Contents

Rights which previously have been voided as set forth above) shall thereafter have the right (the Flip-Over Right) to receive, upon exercise, common shares of the acquiring company (or, in certain circumstances, its parent), having a value equal to two times the exercise price of the Purchase Right. The holder of a Right will continue to have the Flip-Over Right whether or not such holder exercises or surrenders the Flip-In Right.

Series C Preferred Stock purchasable upon exercise of the Purchase Rights will not be redeemable. Each share of Series C Preferred Stock will be entitled to ten thousand (10,0000) votes per share (subject to customary antidilution provisions) on matters submitted to a vote of the shareholders. Each share of Series C Preferred Stock will be entitled to a minimum preferential quarterly dividend payment of \$100 per share but, if greater, will be entitled to a total dividend per share of ten thousand (10,000) times the dividend declared per share of common stock. In the event of liquidation, the holders of shares of the Series C Preferred Stock will be entitled to a minimum preferential liquidation payment per share in an amount equal to the greater of \$66.90 or ten thousand (10,000) times the payment made per share of common stock plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment. Finally, in the event of any merger, consolidation or other transaction in which shares of common stock are exchanged, each share of Series C Preferred Stock will be entitled to receive ten thousand (10,000) times the amount received per share of common stock. These rights are protected by customary antidilution provisions.

At any time before the earlier to occur of (A) a person becoming an Acquiring Person or (B) the expiration of the Rights, and under certain other circumstances, the Company may redeem the Purchase Rights in whole, but not in part, at a price of \$0.01 per Purchase Right (the Redemption Price). The Purchase Rights are not exercisable until the Distribution Date and will expire on August 15, 2012, unless earlier redeemed.

Certificate of Incorporation and Bylaws

A number of provisions of our Certificate of Incorporation and our Bylaws concern matters of corporate governance and the rights of our stockholders. Provisions that grant our Board the ability to issue shares of preferred stock and to set the voting rights, preferences and other terms thereof may discourage takeover attempts that are not first approved by our Board, including takeovers that may be considered by some stockholders to be in their best interests, such as those attempts that might result in a premium over the market price for the shares held by stockholders. Certain provisions could delay or impede the removal of incumbent directors even if such removal would be beneficial to our stockholders, such as the classification of our Board and the lack of cumulative voting. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management.

These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or in our management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and in the policies they implement, and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.

These provisions also could discourage or make more difficult a merger, tender offer or proxy contest, even if they could be favorable to the interests of stockholders, and could potentially depress the market price of our common stock. Our Board believes that these provisions are appropriate to protect our interests and the interests of our stockholders.

Classification of Board and No Cumulative Voting. Our Certificate of Incorporation and Bylaws provide for our Board to be divided into three classes, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders representing a majority of the shares of common stock outstanding will be able to elect all of our directors due to be elected at each annual meeting of our stockholders.

10

Table of Contents

Meetings of and Actions by Stockholders. Our Bylaws provide that annual meetings of our stockholders may take place at the time and place designated by our Board. A special meeting of our stockholders may be called at any time by the Board, the chairman of the Board or the president. Subject to the rights of the holders of any series of preferred stock or any other class of stock or series thereof having a preference over the common stock as to dividends or upon liquidation, stockholders may take action only at a regular or special meeting of stockholders and not by written consent without a meeting.

Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our Bylaws provide that stockholders seeking to bring business before an annual meeting of stockholders or to nominate candidates for election as directors at an annual meeting of stockholders must provide timely notice in writing. To be timely, a stockholder s notice must be delivered to our principal executive offices not less than 120 days prior to the date specified in the Company s proxy statement released to stockholders in connection with the previous year s annual meeting. If no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than 30 days from the date contemplated at the time of the previous year s proxy statement, notice by the stockholder in order to be timely must be received by the Company no later than the close of business on the later of the 120th day prior to the date of such annual meeting or the tenth day following the day on which public announcement of the date of the meeting was first made. Our Bylaws also specify requirements as to the form and content of a stockholder s notice. These provisions may preclude stockholders from bringing matters before an annual meeting of stockholders or from making nominations for the election of directors at an annual meeting of stockholders.

Filling of Board Vacancies. Our Certificate of Incorporation and our Bylaws provide that vacancies in the Board and newly created directorships resulting from any increase in the authorized number of directors on the Board may be filled by a majority of the directors remaining in office, even though that number may be less than a quorum of the Board, or by a sole remaining director. A director so elected to fill a vacancy shall serve for the remaining term of the predecessor he or she replaced and until his or her successor is elected and has qualified, or until his or her earlier resignation, removal or death.

Amendment of the Certificate of Incorporation. Our Certificate of Incorporation may be amended, altered, changed or repealed at a meeting of the stockholders of the Company entitled to vote thereon by the affirmative vote of a majority of the outstanding stock entitled to vote thereon and a majority of the outstanding stock of each class entitled to vote thereon as a class, in the manner prescribed by the DGCL.

Amendment of the Bylaws. Our Bylaws may be altered, amended, changed, added-to or repealed (i) by the board of directors or (ii) by the stockholders entitled to vote. The bylaws can only be amended if such amendment would not conflict with the Certificate of Incorporation or applicable law. Any bylaw made or altered by the requisite number of stockholders may be altered or repealed by the Board or by the requisite number of stockholders.

Section 203 of the Delaware General Corporation Law

We are subject to Section 203 of the Delaware General Corporation Law (Section 203), which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

- before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
- upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

Table of Contents

• on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder.
In general, Section 203 defines a business combination to include the following:
any merger or consolidation involving the corporation and the interested stockholder;
• any sale, lease, transfer, pledge or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder;
• subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
• any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
• the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.
In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stoc of the corporation or any entity or person affiliated with or controlled by such entity or person.
Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, 6201 15th Avenue, 2nd Floor, Brooklyn, NY 11219. Its phone number is 1(800)-937-5449. The transfer agent for any series of preferred stock, warrants, rights or units that we may

offer under this prospectus will be named and described in the prospectus supplement for that series.

NASDAQ Global Market Listing

Our common stock is listed on the NASDAQ Global Market under the symbol CLSN.

DESCRIPTION OF WARRANTS

We may issue warrants for the purchase of our common stock or preferred stock, in one or more series. We may issue warrants independently or together with common stock or preferred stock, and the warrants may be attached to or separate from these securities.

The following description, together with the additional information we may include in any applicable prospectus supplement or free writing prospectus, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement or any applicable free writing prospectuses. If we indicate in the prospectus supplement or a free writing prospectus, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. However, no prospectus supplement or free writing prospectus shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement that includes this prospectus or as an exhibit to a current report on Form 8-K.

Table of Contents General We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including: the offering price and aggregate number of warrants offered; the currency for which the warrants may be purchased; if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; if applicable, the date on and after which the warrants and the related securities will be separately transferable; the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; if other than for cash, the property and manner in which the exercise price of the warrants may be paid; the minimum number of warrants that may be exercisable at any time; the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; the terms of any rights to redeem or call the warrants;

any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;

at the exe	rant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement or free writing prospectus rcise price that we describe in the applicable prospectus supplement or free writing prospectus. Unless we otherwise specify in the e prospectus supplement or free writing prospectus, holders of the warrants may exercise the warrants at any time up to 5:00 P.M. Time on the
Exercise	of Warrants
	ercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
•	any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
•	the terms of the securities issuable upon exercise of the warrants; and
•	a discussion of any material or special U.S. federal income tax consequences of holding or exercising the warrants;
•	the manner in which the warrant agreements and warrants may be modified;
	the dates on which the right to exercise the warrants will commence and expire;

Table of Contents

expiration date that we set forth in the applicable prospectus supplement or free writing prospectus. After the close of business on the expiration date, unexercised warrants will become void.

Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement or free writing prospectus the information that the holder of the warrant will be required to deliver to the warrant agent.

Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement or free writing prospectus, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.

Enforceability of Rights by Holders of Warrants

Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.

Governing Law

Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of Maryland.

Enforceability of Rights by Holders of Warrants

Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.

DESCRIPTION OF RIGHTS

We may issue rights to purchase our common stock or preferred stock, in one or more series. Rights may be issued independently or together with any other offered security and may or may not be transferable by the person purchasing or receiving the subscription rights. In connection with any rights offering to our stockholders, we may enter into a standby underwriting arrangement with one or more underwriters pursuant to which such underwriters will purchase any offered securities remaining unsubscribed after such rights offering. In connection with a rights offering to our stockholders, we will distribute certificates evidencing the rights and a prospectus supplement to our stockholders on the record date that we set for receiving rights in such rights offering.

The applicable prospectus supplement or free writing prospectus will describe the following terms of rights in respect of which this prospectus is being delivered:

the title of such rights;

14

Table of Contents

•	the securities for which such rights are exercisable;
•	the exercise price for such rights;
•	the date of determining the security holders entitled to the rights distribution;
•	the number of such rights issued to each security holder;
•	the extent to which such rights are transferable;
• such right	if applicable, a discussion of the material United States federal income tax considerations applicable to the issuance or exercise of is;
• extension	the date on which the right to exercise such rights shall commence, and the date on which such rights shall expire (subject to any);
•	the conditions to completion of the rights offering;
•	any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the rights;
•	the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities;
• with the r	if applicable, the material terms of any standby underwriting or other purchase arrangement that we may enter into in connection ights offering; and
•	any other terms of such rights, including terms, procedures and limitations relating to the exchange and exercise of such rights.

Each right will entitle the holder thereof the right to purchase for cash such amount of shares of common stock or preferred stock, or any combination thereof, at such exercise price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the rights offered thereby. Rights may be exercised at any time up to the close of business on the expiration date for such rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised rights will become void.

Rights may be exercised as set forth in the prospectus supplement relating to the rights offered thereby. Upon receipt of payment and the proper completion and due execution of the rights certificate at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement, we will forward, as soon as practicable, the shares of common stock and/or preferred stock purchasable upon such exercise. We may determine to offer any unsubscribed offered securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as set forth in the applicable prospectus supplement.

DESCRIPTION OF UNITS

We may issue, in one more series, units consisting of our common stock, preferred stock, and/or warrants and/or rights for the purchase of common stock or preferred stock in any combination. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any units offered under a prospectus supplement may differ from the terms described below.

We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement that describes the terms of the series of

Table of Contents

units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete unit agreement and any supplemental agreements that contain the terms of the units.

General

Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.

We will describe in the applicable prospectus supplement or free writing prospectus the terms of the series of units being offered, including:

- the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;
- any provisions of the governing unit agreement that differ from those described below; and
- any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.

The provisions described in this section, as well as those described under Description of Capital Stock, Description of Warrants, and Description of Rights will apply to each unit and to any common stock, preferred stock, warrant or right included in each unit, respectively.

Issuance in Series

We may issue units in such amounts and in such numerous distinct series as we determine.

Enforceability of Rights by Holders of Units

Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.

Table of Contents

PLAN OF DISTRIBUTION

Pursuant to General Instruction I.B.6 of Form S-3, we are permitted to utilize the registration statement of which this prospectus forms a part to sell a maximum amount of securities equal to one-third of the aggregate market value of the outstanding voting and non-voting common equity held by our non-affiliates in any 12 month period. We may, from to time, offer the securities registered hereby up to this maximum amount.
We may sell the securities, from time to time, to or through underwriters or dealers, through agents or remarketing firms, or directly to one or more purchasers pursuant to:
• underwritten public offerings;
• negotiated transactions;
• block trades;
• at the market offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise, at prevailing market prices;
• through a combination of these methods.
We may distribute securities from time to time in one or more transactions:
• at a fixed price or prices, which may be changed;
• at market prices prevailing at the time of sale;

at prices related to such prevailing market prices; or

• at negotiated prices.
A prospectus supplement or supplements will describe the terms of the offering of the securities, including:
• the name or names of the underwriters, if any;
• if the securities are to be offered through the selling efforts of brokers or dealers, the plan of distribution and the terms of any agreement, arrangement, or understanding entered into with broker(s) or dealer(s) prior to the effective date of the registration statement, and, if known, the identity of any broker(s) or dealer(s) who will participate in the offering and the amount to be offered through each;
• the purchase price of the securities and the proceeds we will receive from the sale;
• if any of the securities being registered are to be offered otherwise than for cash, the general purposes of the distribution, the basis upon which the securities are to be offered, the amount of compensation and other expenses of distribution, and by whom they are to be borne;
any delayed delivery arrangements;
any over-allotment options under which underwriters may purchase additional securities from us;
17

Table of Contents

prospectus supplement.

•	any agency fees or underwriting discounts and other items constituting agents or underwriters compensation;
•	any public offering price;
•	any discounts, commissions or commissions allowed or reallowed or paid to dealers;
•	the identity and relationships of any finders, if applicable; and
•	any securities exchange or market on which the securities may be listed.
Only unde	erwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement.
more tran purchase public thr indicated by the pro- concessio	riters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or sactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the rough underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Unless otherwise in the prospectus supplement, subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered espectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material tip. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.
will act as the securi	use a remarketing firm to offer the securities in connection with a remarketing arrangement upon their purchase. Remarketing firms s principals for their own account or as agents for us. These remarketing firms will offer or sell the securities pursuant to the terms of ties. A prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe eht ng firm s compensation. Remarketing firms may be deemd to be underwriters in connection the securities they remarket.

We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states

If we offer and sell securities through a dealer, we or an underwriter will sell the securities to the dealer, as principal. The dealer may resell the

securities to the public at varying prices to be determined by the dealer at the time of resale. Any such dealer may be deemed to be an underwriter of the securities offered and sold. The name of the dealer and the terms of the transaction will be set forth in the applicable

otherwise, our agent will act on a best-efforts basis for the period of its appointment.

We may sell securities directly to one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act.

We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.

We may provide agents and underwriters with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with

18

Table of Contents

respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.

We may offer new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.

Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

Any underwriters that are qualified market makers on the NASDAQ Global Market may engage in passive market making transactions in the common stock on the NASDAQ Global Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker s bid, however, the passive market maker s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

LEGAL MATTERS

The validity of the securities being offered by this prospectus will be passed upon by Venable LLP, Baltimore, Maryland. Any underwriter, dealer or agent may be advised about issues relating to any offering by its own legal counsel.

EXPERTS

The financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2008 have been so incorporated in reliance on the report of Stegman & Company, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document we file at the SEC s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the public reference room. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, Celsion Corporation. The SEC s Internet site can be found at www.sec.gov.

The SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring you to another document that we have filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this prospectus.

Table of Contents

We incorporate by reference the following information or documents that we have filed with the SEC (Commission	n File N	No. 001-159	/11):
--	----------	-------------	-------

- our annual report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 27, 2009;
- our current report in Form 8-K, filed with the SEC on February 19, 2009, as amended by a Form 8-K/A filed on February 20, 2009;
- our current report in Form 8-K, filed with the SEC on March 3, 2009;
- the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on Form 8-A, filed with the SEC on May 26, 2000, as amended by a Form 8-A/A dated February 7, 2008; and
- the description of our Preferred Share Purchase Rights, which are registered under Section 12 of the Exchange Act, in our registration statement on Form 8-A, filed with the SEC on September 9, 2002, as amended by a Form 8-A/A dated February 11, 2003 and a Form 8-A/A dated February 7, 2008.

Any information in any of the foregoing documents will automatically be deemed to be modified or superseded to the extent that information in this prospectus or in a later filed document that is incorporated or deemed to be incorporated herein by reference modifies or replaces such information.

We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.

We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. Requests should be directed to: Celsion Corporation, Attention: Corporate Secretary, 10220-L Old Columbia Road, Columbia, MD 21046-2364, telephone (410) 290-5390.

Edgar Filing: C	Celsion	CORP -	Form	424B5
-----------------	---------	--------	------	-------

m	. 1		c	\sim			
Tal	hl	e	Ωt	\mathbf{C}	าท	te	nts

2,018,153 Shares of Common Stock

Warrants to Purchase 1,009,076 Shares of Common Stock

CELSION CORPORATION

PROSPECTUS SUPPLEMENT

NEEDHAM & COMPANY, LLC

September 25, 2009

 $x; padding-top: 2px; padding-bottom: 2px; padding-right: 2px; "> Long-term fixed-rate loans \end{substitute} \label{eq:padding-bottom}$

\$ 22,458,429

\$ 248,926

4.45 %	
\$ 21,772,579	
\$ 243,817	
4.49 % Long-term variable-rate loans	
886,257	
6,097	
2.76	
751,460	
4,987	
2.66	
Line of credit loans	
1,330,776	
8,588	
2.59	
1,046,826	
5,553	

2.13

TDR loans ⁽²⁾
12,929
222
6.89
13,505
231
6.86
Other income, net ⁽³⁾
(306
_
_
(281
<u> </u>
Total loans
24,688,391
263,527
4.28
23,584,370

254,307
4.32
Cash, time deposits and investment securities
528,158
2,296
1.74
761,354
2,849
1.50
Total interest-earning assets
\$ 25,216,549
\$ 265,823
4.23 %
\$ 24,345,724
\$ 257,156
4.24 % Other assets, less allowance for loan losses

526,627

624,014		
Total assets		
\$		
\$ 25,743,176		
\$ 24,969,738		
24,505,750		
Liabilities:		

Short-term debt	
\$ 2,998,298	
\$ 10,116	
1.35 %	
\$ 3,037,831	
\$ 5,409	
0.71 % Medium-term notes	
3,375,389	
27,544	
3.27	
3,399,885	
24,705	
2.91	
Collateral trust bonds	
7,637,919	

85,321		
4.48		
7,256,608		
84,951		
4.70		
Guaranteed Underwriter Program n	otes payable	
5,066,574		
35,688		
2.83		
4,862,958		
36,216		
2.99		
Farmer Mac notes payable		
2,496,587		
11,947		
1.92		
2,288,013		
7,587		

1.33

Other notes paya	ıble		
35,295			
201			
391			
4.44			
41,026			
41,020			
458			
4.48			
Subordinated det	farrabla dabt		
	citable debt		
742,319			
9,417			
5.09			
3.09			
742,187			
9,411			
),111			
5.09			
Subordinated cer	tificates		
1,415,352			
14,746			
14,740			
4.18			
1,442,871			
1,772,0/1			

14,917
4.15
Total interest-bearing liabilities
\$ 23,767,733
\$ 195,170
3.29 %
\$ 23,071,379
\$ 183,654
3.19
% Other liabilities
842,246
1,101,635

Total liabilities

24,609,979



Net interest spread ⁽⁴⁾
0.94 %
1.05 % Impact of non-interest bearing funding ⁽⁵⁾
0.18
0.16
Net interest income/net interest yield ⁽⁶⁾
\$ 70,653
1.12 %
\$ 73,502

1.21

Adjusted net interest income/adjusted net interest yield:

Interest income

\$ 265,823

4.23 %

\$ 257,156

4.24 %
Interest expense

195,170

3.29
183,654
3.19
Add: Net accrued periodic derivative cash settlements ⁽⁷⁾
19,635
0.72
21,587
0.81
Adjusted interest expense/adjusted average cost ⁽⁸⁾
\$ 214,805
3.63 %
\$ 205,241
3.57 %

Adjusted net interest spread ⁽⁴⁾
0.60 %
0.67 % Impact of non-interest bearing funding
0.21
0.19
Adjusted net interest income/adjusted net interest yield ⁽⁹⁾ \$
51,018 0.81 %

\$ 51,915			
0.86 %			
8			

	Six Months Ended November 30,							
(Dollars in thousands)	2017	•			2016	•		
Assets:	Average Balance	Interest Income/Expen			Average	Interest Income/Expen	Avera	_
Long-term fixed-rate loans ⁽¹⁾	\$22,414,622		4.43		\$21,698,651	\$ 487,945	4.49	
Long-term variable-rate loans	864,494	11,960	2.76	70	740,594	9,514	2.56	70
Line of credit loans	1,342,124	17,295	2.57		1,045,303	11,519	2.20	
TDR loans ⁽²⁾	13,026	448	6.86		15,374	449	5.83	
Other income, net ⁽³⁾	_	(538)			_	(565)		
Total loans	24,634,266	527,455	4.27		23,499,922	508,862	4.32	
Cash, time deposits and investment securities	445,452	4,283	1.92		687,575	5,129	1.49	
Total interest-earning assets	\$25,079,718	\$ 531,738	4.23	%	\$24,187,497	\$ 513,991	4.24	%
Other assets, less allowance for loan losses	543,490				643,236			
Total assets	\$25,623,208				\$24,830,733			
Liabilities:								
Short-term borrowings	\$3,111,502	\$ 20,655		%	\$2,980,748	\$ 10,291	0.69	%
Medium-term notes	3,192,063	52,660	3.29		3,341,054	48,290	2.88	
Collateral trust bonds Guaranteed Underwriter Program	7,636,669	170,598	4.46		7,255,508	170,000	4.67	
notes payable	5,030,955	71,290	2.83		4,818,512	71,988	2.98	
Farmer Mac notes payable	2,502,096	23,437	1.87		2,292,798	14,486	1.26	
Other notes payable	35,269	781	4.42		40,996	916	4.46	
Subordinated deferrable debt	742,302	18,833	5.06		742,171	18,837	5.06	
Subordinated certificates	1,416,619	29,647	4.17		1,442,753	29,926	4.14	
Total interest-bearing liabilities	\$23,667,475	\$ 387,901	3.27	%	\$22,914,540	\$ 364,734	3.17	%
Other liabilities	847,751				1,127,727			
Total liabilities	24,515,226				24,042,267			
Total equity	1,107,982				788,466			
Total liabilities and equity	\$25,623,208				\$24,830,733			
Net interest spread ⁽⁴⁾			0.96	%			1.07	%
Impact of non-interest bearing			0.18				0.16	
funding ⁽⁵⁾								
Net interest income/net interest yield ⁽⁶⁾		\$ 143,837	1.14	%		\$ 149,257	1.23	%
yicid								
Adjusted net interest income/adjusted								
net interest yield:								
Interest income		\$ 531,738		%		\$ 513,991	4.24	%
Interest expense		387,901	3.27			364,734	3.17	
Add: Net accrued periodic derivative cash settlements ⁽⁷⁾		39,857	0.74			44,977	0.85	
Adjusted interest expense/adjusted average cost ⁽⁸⁾		\$ 427,758	3.60	%		\$ 409,711	3.57	%
-								
Adjusted net interest spread ⁽⁴⁾			0.63	%			0.67	%

Impact of non-interest bearing	0.20	0.19		
funding	0.20		0.19	
Adjusted net interest income/adjusted	\$ 103,980	0.83 %	\$ 104,280	0.86 %
net interest yield ⁽⁹⁾	Ψ 105,700	0.03 /6	Ψ 104,200	0.00 //

⁽¹⁾Interest income on long-term, fixed-rate loans includes loan conversion fees, which are generally deferred and recognized as interest income using the effective interest method.

⁽²⁾Troubled debt restructuring ("TDR") loans.

⁽³⁾Consists of late payment fees and net amortization of deferred loan fees and loan origination costs.

- (4)Net interest spread represents the difference between the average yield on interest-earning assets and the average cost of interest-bearing liabilities. Adjusted net interest spread represents the difference between the average yield on total interest-earning assets and the adjusted average cost of total interest-bearing liabilities.
- (5)Includes other liabilities and equity.
- ⁽⁶⁾Net interest yield is calculated based on annualized net interest income for the period divided by total average interest-earning assets for the period.
- ⁽⁷⁾Represents the impact of net accrued periodic derivative cash settlements during the period, which is added to interest expense to derive non-GAAP adjusted interest expense. The average (benefit)/cost associated with derivatives is calculated based on annualized net accrued periodic derivative cash settlements during the period divided by the average outstanding notional amount of derivatives during the period. The average outstanding notional amount of derivatives was \$10,902 million and \$10,651 million for the three months ended November 30, 2017 and 2016, respectively. The average outstanding notional amount of derivatives was \$10,791 million and \$10,494 million for the six months ended November 30, 2017 and 2016, respectively.
- ⁽⁸⁾Adjusted interest expense represents interest expense plus net accrued periodic derivative cash settlements during the period. Net accrued periodic derivative cash settlements are reported on our consolidated statements of operations as a component of derivative gains (losses). Adjusted average cost is calculated based on annualized adjusted interest expense for the period divided by total average interest-bearing liabilities during the period.
- (9)Adjusted net interest yield is calculated based on annualized adjusted net interest income for the period divided by total average interest-earning assets for the period.

Table 3 displays the change in net interest income between periods and the extent to which the variance is attributable to: (i) changes in the volume of our interest-earning assets and interest-bearing liabilities or (ii) changes in the interest rates of these assets and liabilities. The table also presents the change in adjusted net interest income between periods.

Table 3: Rate/Volume Analysis of Changes in Interest Income/Interest Expense

Three Months Ended November 30, Six Months Ended Novem 30,	ber			
2017 versus 2016 2017 versus 2016	2017 versus 2016			
Variance due to:(1) Variance due to	:(1)			
(Dollars in thousands) Total Variance Volume Rate Variance Volume Rate Variance Volume Rate				
Interest income:				
Long-term fixed-rate loans \$5,109 \$7,680 \$(2,571) \$10,345 \$16,100 \$(5,7)	55)			
Long-term variable-rate loans 1,110 895 215 2,446 1,592 854				
Line of credit loans 3,035 1,506 1,529 5,776 3,271 2,505				
Restructured loans (9) (10) 1 (1) (69) 68				
Other income, net $(25) - (25) 27 - 27$				
Total loans 9,220 10,071 (851) 18,593 20,894 (2,30	1)			
Cash, time deposits and investment securities (553) (873) 320 (846) (1,806) 960				
Interest income 8,667 9,198 (531) 17,747 19,088 (1,34	1)			
Interest expense:				
Short-term borrowings 4,707 (70) 4,777 10,364 451 9,913				
Medium-term notes 2,839 (178) 3,017 4,370 (2,153) 6,523				
Collateral trust bonds 370 4,464 (4,094) 598 8,931 (8,33)				
Guaranteed Underwriter Program notes payable (528) 1,518 (2,046) (698) 3,174 (3,875)	-			
Farmer Mac notes payable 4,360 692 3,668 8,951 1,322 7,629				
Other notes payable (67) (64) (3) (135) (128) (7)			
Subordinated deferrable debt 6 2 4 (4) 3 (7)			
Subordinated certificates (171) (285) 114 (279) (542) 263				
Interest expense 11,516 6,079 5,437 23,167 11,058 12,10	9			
Net interest income \$(2,849) \$3,119 \$(5,968) \$(5,420) \$8,030 \$(13,				
Adjusted net interest income:				
Interest income \$8,667 \$9,198 \$(531) \$17,747 \$19,088 \$(1,3)	41)			
Interest expense 11,516 6,079 5,437 23,167 11,058 12,10				
Net accrued periodic derivative cash settlements ⁽²⁾ $(1,952)$ 508 $(2,460)$ $(5,120)$ 1,276 $(6,39)$				
Adjusted interest expense ⁽³⁾ 9,564 6,587 2,977 18,047 12,334 5,713				
Adjusted net interest income \$(897) \$2,611 \$(3,508) \$(300) \$6,754 \$(7,0)				

⁽¹⁾The changes for each category of interest income and interest expense are divided between the portion of change attributable to the variance in volume and the portion of change attributable to the variance in rate for that category. The amount attributable to the combined impact of volume and rate has been allocated to each category based on the proportionate absolute dollar amount of change for that category.

⁽²⁾For net accrued periodic derivative cash settlements, the variance due to average volume represents the change in derivative cash settlements resulting from the change in the average notional amount of derivative contracts outstanding. The variance due to average rate represents the change in derivative cash settlements resulting from the

net difference between the average rate paid and the average rate received for interest rate swaps during the period. (3)See "Non-GAAP Financial Measures" for additional information on our adjusted non-GAAP measures.

Net interest income of \$71 million for the current quarter decreased by \$3 million, or 4%, from the same prior-year quarter, driven by a decrease in net interest yield of 7% (9 basis points) to 1.12%, which was partially offset by an increase in average interest-earning assets of 4%.

Net interest income of \$144 million for the six months ended November 30, 2017 decreased by \$5 million, or 4%, from the same prior-year period, driven by a decrease in net interest yield of 7% (9 basis points) to 1.14%, which was partially offset by an increase in average interest-earning assets of 4%.

Average Interest-Earning Assets: The increase in average interest-earning assets for the current quarter and six months ended November 30, 2017 was primarily attributable to growth in average total loans of \$1,104 million, or 5% and \$1,134 million, or 5%, respectively, over the same prior-year periods, as members obtained advances to fund capital investments and refinanced with us loans made by other lenders.

Net Interest Yield: The decrease in the net interest yield for the current quarter and six months ended November 30, 2017 was largely due to an increase in our average cost of funds, as the average yield on interest-earning assets remained relatively stable. Our average cost of funds increased by 10 basis points during both the current quarter and six months ended November 30, 2017 to 3.29% and 3.27%, respectively, largely due to increases in the cost of our short-term and variable-rate debt resulting from an increase in short-term interest rates. The 3-month London Interbank Offered Rate ("LIBOR") was 1.49% as of November 30, 2017, an increase of 55 basis points from the same prior-year period, while the federal funds rate ranged from 1.00% to 1.25% as November 30, 2017, up 75 basis points from the end of the same prior-year period.

Adjusted net interest income of \$51 million for the current quarter decreased by \$1 million, or 2%, from the same prior-year quarter, driven by a decrease in the adjusted net interest yield of 6% (5 basis points) to 0.81%, which was partially offset by an increase in average interest-earning assets of 4%. The decrease in the adjusted net interest yield was primarily attributable to an increase in the adjusted average cost of funds of 6 basis points to 3.63%.

Adjusted net interest income of \$104 million for the six months ended November 30, 2017 was flat compared to the same prior-year period. The decrease in the adjusted net interest yield of 3% (3 basis points) to 0.83% was offset by an increase in average interest-earning assets of 4%. The decrease in the adjusted net interest yield was primarily attributable to an increase in the adjusted average cost of funds of 3 basis points to 3.60%.

Our adjusted net interest income and adjusted net interest yield include the impact of net accrued periodic derivative cash settlements during the period. We recorded net periodic derivative cash settlement expense of \$20 million and \$22 million for the three months ended November 30, 2017 and 2016, respectively, and \$40 million and \$45 million for the six months ended November 30, 2017 and 2016, respectively. See "Non-GAAP Financial Measures" for additional information on our adjusted measures.

Provision for Loan Losses

Our provision for loan losses in each period is primarily driven by the level of allowance that we determine is necessary for probable incurred loan losses inherent in our loan portfolio as of each balance sheet date.

We recorded a benefit for loan losses of less than \$1 million for the current quarter and \$1 million for the six months ended November 30, 2017, respectively, compared with a provision for loan losses of \$1 million and \$3 million, respectively, for the same prior-year periods. The credit quality and performance statistics of our loan portfolio continued to remain strong. We experienced no charge-offs during the three and six months ended November 30, 2017 and we had no loans classified as nonperforming as of the end of the period. In comparison, we recorded a net charge-off of \$2 million during the six months ended November 30, 2016.

We provide additional information on our allowance for loan losses under "Credit Risk—Allowance for Loan Losses" and "Note 4—Loans and Commitments" of this Report. For additional information on our allowance methodology, see "MD&A—Critical Accounting Policies and Estimates" and "Note 1—Summary of Significant Accounting Policies" in our 2017 Form 10-K.

Non-Interest Income

Non-interest income consists of fee and other income, gains and losses on derivatives not accounted for in hedge accounting relationships and results of operations of foreclosed assets.

We recorded non-interest income of \$131 million and \$89 million for the three and six months ended November 30, 2017, respectively. In comparison, we recorded non-interest income of \$345 million and \$160 million for the three and six months ended November 30, 2016, respectively. The significant variances in non-interest income for the three and six months ended November 30, 2017 from the same prior year periods were primarily attributable to changes in net derivative gains recognized in our consolidated statements of operations.

Table 4 presents the components of non-interest income recorded in our condensed consolidated results of operations for the three and six months ended November 30, 2017 and 2016.

Table 4: Non-Interest Income

	Three Months Ended		Six Months Ended		
	November 30,		Novembe	r 30,	
(Dollars in thousands)	2017	2016	2017	2016	
Non-interest income:					
Fee and other income	\$5,542	\$5,097	\$9,487	\$9,627	
Derivative gains	125,593	340,660	79,395	152,367	
Results of operations of foreclosed assets	(10)	(549)	(34)	(1,661)	
Total non-interest income	\$131,125	\$345,208	\$88,848	\$160,333	

Derivative Gains (Losses)

Our derivative instruments are an integral part of our interest rate risk management strategy. Our principal purpose in using derivatives is to manage our aggregate interest rate risk profile within prescribed risk parameters. The derivative instruments we use primarily include interest rate swaps, which we typically hold to maturity. The primary factors affecting the fair value of our derivatives and derivative gains (losses) recorded in our results of operations include changes in interest rates, the shape of the yield curve and the composition of our derivative portfolio. We generally do not designate our interest rate swaps, which currently account for all of our derivatives, for hedge accounting. Accordingly, changes in the fair value of interest rate swaps are reported in our consolidated statements of operations under derivative gains (losses). We did not have any derivatives designated as accounting hedges as of November 30, 2017 or May 31, 2017.

We currently use two types of interest rate swap agreements: (i) we pay a fixed rate and receive a variable rate ("pay-fixed swaps") and (ii) we pay a variable rate and receive a fixed rate ("receive-fixed swaps"). The benchmark rate for the substantial majority of the floating rate payments under our swap agreements is LIBOR. Table 5 displays the average notional amount outstanding, by swap agreement type, and the weighted-average interest rate paid and received for derivative cash settlements during the three and six months ended November 30, 2017 and 2016. As indicated in Table 5, our derivative portfolio currently consists of a higher proportion of pay-fixed swaps than receive-fixed swaps. The profile of our derivative portfolio, however, may change as a result of changes in market conditions and actions taken to manage our interest rate risk.

Table 5: Derivative Average Notional Amounts and Average Interest Rates

	Three Month	hs End	ed N	ovembe	er 30	*				
(Dollars in thousands	2017 Average Notional Balance	Weig Aver Rate	age	Avera Rate	age	Average Notional Balance	Weig Aver Rate	_	Avera Rate	age
Pay-fixed swaps	\$7,052,629	2.84	%	1.35	%	\$6,786,130	2.91	%	0.82	%
Receive-fixed swaps	3,849,001	1.91		2.63		3,864,934	1.24		2.78	
Total	\$10,901,630	2.51	%	1.80	%	\$10,651,06	4 2.31	%	1.53	%
Six Months Ended November 30, 2017 2016										
	Notional	Weigh Averag Rate P	ge aid	Weight Averag Rate Receive	e j	Average Notional Balance	Weigh Avera Rate P	ge	Weight Averag Rate Receiv	ge
Pay-fixed swaps	\$7,003,898	2.84	%	1.31	%	\$6,812,841	2.91	%	0.75	%
Receive-fixed swaps	3,787,525	1.87		2.63		3,680,967	1.14		2.80	
Total	\$10,791,423	2.50	%	1.77	%	\$10,493,808	2.29	%	1.47	%

The average remaining maturity of our pay-fixed and receive-fixed swaps was 19 years and four years, respectively, as of November 30, 2017, unchanged from fiscal year end May 31, 2017. In comparison, the average remaining maturity of our pay-fixed and receive-fixed swaps was 18 years and three years, respectively, as of November 30, 2016.

Pay-fixed swaps generally decrease in value as interest rates decline and increase in value as interest rates rise. In contrast, receive-fixed swaps generally increase in value as interest rates decline and decrease in value as interest rates rise. Because our pay-fixed and receive-fixed swaps are referenced to different maturity terms along the swap yield curve, different changes in the swap yield curve— parallel, flattening or steepening—will result in differences in the fair value of our derivatives. The chart below provides comparative swap yield curves as of the end of November 30, 2017, August 31, 2017, May 31, 2017, November 30, 2016 and May 31, 2016.

Benchmark rates obtained from Bloomberg.

Table 6 presents the components of net derivative gains (losses) recorded in our condensed consolidated results of operations for the three and six months ended November 30, 2017 and 2016. Derivative cash settlements represent the net periodic contractual interest amount for our interest-rate swaps for the reporting period. Derivative forward value gains (losses) represent the change in fair value of our interest rate swaps during the reporting period due to changes in expected future interest rates over the remaining life of our derivative contracts.

Table 6: Derivative Gains (Losses)

	Three Months Ended		Six Month	s Ended
	November 30,		November	30,
(Dollars in thousands)	2017	2016	2017	2016
Derivative gains (losses) attributable to:				
Derivative cash settlements	\$(19,635)	\$(21,587)	\$(39,857)	\$(44,977)
Derivative forward value gains	145,228	362,247	119,252	197,344
Derivative gains	\$125,593	\$340,660	\$79,395	\$152,367

The net derivative gains of \$126 million and \$79 million for the three and six months ended November 30, 2017, respectively, were largely attributable to a net increase in the fair value of our pay-fixed swaps as interest rates increased across the yield curve.

The net derivative gains of \$341 million and \$152 million for the three and six months ended November 30, 2016, respectively, were primarily attributable to net increase in the fair value of our pay-fixed swaps due to an increase in medium-term and longer-term interest rates and a general steepening of the yield curve during the periods.

See "Note 8—Derivative Instruments and Hedging Activities" for additional information on our derivative instruments.

Results of Operations of Foreclosed Assets

Results of operations of foreclosed assets consists of the operating results of entities controlled by CFC that hold foreclosed assets, impairment charges related to those entities, gains or losses related to the disposition of the entities and potential subsequent charges related to those assets. On July 1, 2016, we completed the sale of Caribbean Asset Holdings, LLC ("CAH"). As a result, we did not carry any foreclosed assets on our consolidated balance sheet as of November 30, 2017 or May 31, 2017.

We recorded charges related to CAH of less than \$1 million for the three and six months ended November 30, 2017. These charges were attributable to legal fees. We recorded charges related to CAH of \$1 million and \$2 million for the three and six months ended November 30, 2016, respectively, attributable to the combined impact of adjustments recorded at the closing date of the sale of CAH, post-closing purchase price adjustments and certain legal costs incurred pertaining to CAH.

In connection with the sale of CAH, \$16 million of the sale proceeds was deposited into escrow to fund potential indemnification claims for a period of 15 months following the closing. On September 27, 2017, we received a claim notice from the purchaser of CAH asserting potential indemnification claims and seeking funding from the escrow. On November 10, 2017, funds held in escrow totaling \$13 million were released to CFC. The remaining \$3 million remains in escrow for claims under evaluation for indemnification.

Non-Interest Expense

Non-interest expense consists of salaries and employee benefit expense, general and administrative expenses, losses on early extinguishment of debt and other miscellaneous expenses.

Table 7 presents the components of non-interest expense recorded in our condensed consolidated results of operations for the three and six months ended November 30, 2017 and 2016.

Table 7: Non-Interest Expense

	Three Months Ended		Six Months Ended	
	November 30,		November	30,
(Dollars in thousands)	2017	2016	2017	2016
Non-interest expense:				
Salaries and employee benefits	\$(12,009)	\$(11,451)	\$(23,832)	\$(22,875)
Other general and administrative expenses	(9,905)	(9,181)	(19,718)	(18,616)
Other non-interest expense	(618)	(517)	(1,140)	(960)
Total non-interest expense	\$(22,532)	\$(21,149)	\$(44,690)	\$(42,451)

Non-interest expense of \$23 million for the current quarter increased by \$1 million, or 7%, from the same prior-year quarter. Non-interest expense of \$45 million for the six months ended November 30, 2017 increased by \$2 million, 5%, from the prior-year period. These increases were primarily attributable to higher expenses related to salaries and employee benefits and other general and administrative operating expenses.

Net Income (Loss) Attributable to Noncontrolling Interests

Net income (loss) attributable to noncontrolling interests represents 100% of the results of operations of NCSC and RTFC, as the members of NCSC and RTFC own or control 100% of the interest in their respective companies. The

fluctuations in net income (loss) attributable to noncontrolling interests are primarily due to changes in the fair value of NCSC's derivative instruments recognized in NCSC's earnings.

We recorded net income attributable to noncontrolling interests of \$1 million during both the three and six months ended November 30, 2017. In comparison, we recorded net income attributable to noncontrolling interests of \$3 million and \$2 million for the three and six months ended November 30, 2016, respectively.

CONSOLIDATED BALANCE SHEET ANALYSIS

Total assets of \$25,880 million as of November 30, 2017 increased by \$675 million, or 3%, from May 31, 2017, primarily due to growth in our loan portfolio. Total liabilities of \$24,640 million as of November 30, 2017 increased by \$533 million, or 2%, from May 31, 2017, largely due to debt issuances to fund loan growth. Total equity increased by \$141 million to \$1,240 million as of November 30, 2017, attributable to our reported net income of \$188 million for the six months ended November 30, 2017, which was partially offset by patronage capital retirement of \$45 million.

Following is a discussion of changes in the major components of our assets and liabilities during the six months ended November 30, 2017. Period-end balance sheet amounts may vary from average balance sheet amounts due to liquidity and balance sheet management activities that are intended to manage liquidity requirements for the company and our customers, and our market risk exposure in accordance with our risk appetite.

Loan Portfolio

We offer long-term fixed- and variable-rate loans and line of credit variable-rate loans. The substantial majority of loans in our portfolio represent advances under secured long-term facilities with terms up to 35 years. Borrowers have the option of selecting a fixed or variable interest rate for each advance for periods ranging from one year to the final maturity of the facility. Line of credit loans are typically revolving facilities and are generally unsecured.

Loans Outstanding

Table 8 summarizes loans to members, by loan type and by member class, as of November 30, 2017 and May 31, 2017. As indicated in Table 8, long-term fixed-rate loans accounted for 90% and 91% of loans to members as of November 30, 2017 and May 31, 2017, respectively.

Table 8: Loans Outstanding by Type and Member Class

	November 30	0, 2017	May 31, 201	Increase/	
(Dollars in thousands)	Amount	% of Total	Amount	% of Total	(Decrease)
Loans by type:					
Long-term loans:					
Fixed-rate	\$22,415,833	90 %	\$22,136,690	91 %	\$279,143
Variable-rate	906,453	4	847,419	3	59,034
Total long-term loans	23,322,286	94	22,984,109	94	338,177
Lines of credit	1,491,256	6	1,372,221	6	119,035
Total loans outstanding	24,813,542	100	24,356,330	100	457,212
Deferred loan origination costs	11,149		10,714		435
Loans to members	\$24,824,691	100%	\$24,367,044	100%	\$457,647
Loans by member class:					
CFC:					
Distribution	\$19,230,740	78 %	\$18,825,366	77 %	\$405,374
Power supply	4,414,257	18	4,504,791	19	(90,534)
Statewide and associate	57,107		57,830		(723)
CFC total	23,702,104	96	23,387,987	96	314,117
NCSC	739,707	3	613,924	3	125,783
RTFC	371,731	1	354,419	1	17,312

Total loans outstanding	24,813,542	100	24,356,330	100	457,212
Deferred loan origination costs	11,149		10,714		435
Loans to members	\$24,824,691	100%	\$24,367,044	100%	\$457,647

Loans to members totaled \$24,825 million as of November 30, 2017, an increase of \$458 million, or 2%, from May 31, 2017. The increase was primarily due to an increase in CFC distribution loans of \$405 million, an increase in NCSC loans of \$126 million and an increase in RTFC loans of \$17 million, which was partially offset by a decrease in CFC power supply loans of \$91 million. Long-term loan advances totaled \$1,127 million during the six months ended November 30, 2017, with approximately 58% of those advances for capital expenditures by members and 31% for the refinancing of loans made by other lenders.

We provide additional information on our loan product types in "Item 1. Business—Loan Programs" and "Note 4—Loans and Commitments" in our 2017 Form 10-K. See "Debt—Secured Borrowings" below for information on encumbered and unencumbered loans and "Credit Risk Management" for information on the credit risk profile of our loan portfolio.

Loan Retention Rate

Table 9 presents a comparison between the historical retention rate of CFC's long-term fixed-rate loans that repriced during the six months ended November 30, 2017 and loans that repriced during fiscal year 2017, and provides information on the percentage of loans that repriced to either another fixed-rate term or a variable rate. The retention rate is calculated based on the election made by the borrower at the repricing date. The average annual retention rate of CFC's repriced loans has been 97% over the last three fiscal years.

Table 9: Historical Retention Rate and Repricing Selection⁽¹⁾

ruble 3. Historical Recention Rate and Reprieting Selection								
	Six Montl	ns	Fiscal Year					
	Ended		Ended					
	November 2017	r 30,	May 31, 2	017				
(Dollars in thousands)	Amount	% of Total	Amount	% of Total				
Loans retained:								
Long-term fixed rate selected	\$440,556	85 %	\$824,415	84 %				
Long-term variable rate selected	77,746	15	137,835	14				
Loans repriced and sold by CFC	_		1,401					
Total loans retained by CFC	518,302	100	963,651	98				
Total loans repaid	1,165		23,675	2				
Total	\$519,467	100%	\$987,326	100%				

⁽¹⁾Does not include NCSC and RTFC loans.

Debt

We utilize both short-term and long-term borrowings as part of our funding strategy and asset/liability interest rate risk management. We seek to maintain diversified funding sources across products, programs and markets to manage funding concentrations and reduce our liquidity or debt roll-over risk. Our funding sources include a variety of secured and unsecured debt securities in a wide range of maturities to our members and affiliates and in the capital markets.

Debt Outstanding

Table 10 displays the composition, by product type, of our outstanding debt as of November 30, 2017 and May 31, 2017. Table 10 also displays the composition of our debt based on several additional selected attributes.

Table 10: Total Debt Outstanding			
(Dollars in thousands)	November 30, 2017	May 31, 201	7 Increase/ (Decrease)
Debt product type:			(= ::::::)
Commercial paper:			
Members, at par	\$1,133,057	\$928,158	\$204,899
Dealer, net of discounts	579,859	999,691	(419,832)
Total commercial paper	1,712,916	1,927,849	(214,933)
Select notes to members	770,376	696,889	73,487
Daily liquidity fund notes to members	866,065	527,990	338,075
Medium-term notes:	,	,	,
Members, at par	612,402	612,951	(549)
Dealer, net of discounts	2,758,190	2,364,671	393,519
Total medium-term notes	3,370,592	2,977,622	392,970
Collateral trust bonds	7,637,324	7,634,048	3,276
Guaranteed Underwriter Program notes payable	5,059,943	4,985,484	74,459
Farmer Mac notes payable	2,491,463	2,513,389	
1 0			
Other notes payable	35,332	35,223	109
Subordinated deferrable debt	742,341	742,274	67
Members' subordinated certificates:	(20.201	620.000	202
Membership subordinated certificates	630,391	630,098	293
Loan and guarantee subordinated certificates	548,187	567,830	(19,643)
Member capital securities	221,097	221,097	
Total members' subordinated certificates	1,399,675	1,419,025	(19,350)
Total debt outstanding	\$24,086,027	\$23,459,793	8 \$626,234
Security type:			
Unsecured debt	37 %	5 35	%
Secured debt	63	65	
Total	100 %	5 100	%
Funding source:			
Members	20 %	5 18	%
Private placement:			
Guaranteed Underwriter Program notes payable	21	21	
Farmer Mac notes payable	10	11	
Other	_	_	
Total private placement	31	32	
Capital markets	49	50	
Total		50 100	%
Total	100 //	7 100	70
Interest rate type:	72 ~	7.4	CI.
Fixed-rate debt		5 74 26	%
Variable-rate debt	27	26	C 4
Total	100 %	5 100	%
Interest rate type, including the impact of swaps:			
Fixed-rate debt ⁽¹⁾		87	%
Variable-rate debt ⁽²⁾	14	13	
Total	100 %	5 100	%

Maturity classification: ⁽³⁾ Short-term borrowings Long-term and subordinated debt ⁽⁴⁾	15 85	% 14 86	%		
Total	100	% 100	%		
19					

Our outstanding debt volume generally increases and decreases in response to member loan demand. As outstanding loan balances increased during the six months ended November 30, 2017, our debt volume also increased. Total debt outstanding was \$24,086 million as of November 30, 2017, an increase of \$626 million, or 3%, from May 31, 2017. The increase was primarily attributable to a net increase in member commercial paper and daily liquidity fund notes of \$543 million, a net increase in dealer medium-term notes of \$394 million and a net increase in notes payable under the Guaranteed Underwriter Program of \$74 million. These increases were partially offset by a net decrease in dealer commercial paper outstanding of \$420 million.

Below is a summary of significant financing activities during the six months ended November 30, 2017.

On November 9, 2017, we closed a \$750 million committed loan facility ("Series M") from the Federal Financing Bank under the Guaranteed Underwriter Program.

On November 20, 2017, we amended and restated the three-year and five-year committed bank revolving line of credit agreements to extend the maturity dates to November 20, 2020 and November 20, 2022, respectively, and to terminate certain third-party bank commitments.

Member Investments

Debt securities issued to our members represent an important, stable source of funding. Table 11 displays outstanding member debt, by debt product type, as of November 30, 2017 and May 31, 2017.

Table 11: Member Investments

	November 30	, 2017	May 31, 2017		
		% of		% of	Increase/
(Dollars in thousands)	Amount	Total	Amount	Total	(Decrease)
		(1)		(1)	
Commercial paper	\$1,133,057	66 %	\$928,158	48 %	\$204,899
Select notes	770,376	100	696,889	100	73,487
Daily liquidity fund notes	866,065	100	527,990	100	338,075
Medium-term notes	612,402	18	612,951	20	(549)
Members' subordinated certificates	1,399,675	100	1,419,025	100	(19,350)
Total outstanding member debt	\$4,781,575		\$4,185,013		\$596,562
Percentage of total debt outstanding	20 %		18 %		

⁽¹⁾ Includes variable-rate debt that has been swapped to a fixed rate, net of any fixed-rate debt that has been swapped to a variable rate.

⁽²⁾ Includes fixed-rate debt that has been swapped to a variable rate, net of any variable-rate debt that has been swapped to a fixed rate. Also includes commercial paper notes, which generally have maturities of less than 90 days. The interest rate on commercial paper notes does not change once the note has been issued; however, the interest rate for new commercial paper issuances changes daily.

⁽³⁾ Borrowings with an original contractual maturity of one year or less are classified as short-term borrowings. Borrowings with an original contractual maturity of greater than one year are classified as long-term debt.

⁽⁴⁾ Consists of long-term debt, subordinated deferrable debt and total members' subordinated debt reported on the condensed consolidated balance sheets. Maturity classification is based on the original contractual maturity as of the date of issuance of the debt.

(1) Represents outstanding debt attributable to members for each debt product type as a percentage of the total outstanding debt for each debt product type.

Member investments accounted for 20% and 18% of total debt outstanding as of November 30, 2017 and May 31, 2017, respectively. Over the last three fiscal years, outstanding member investments have averaged \$4,273 million on a quarterly basis.

Short-Term Borrowings

Short-term borrowings consist of borrowings with an original contractual maturity of one year or less and do not include the current portion of long-term debt. Short-term borrowings totaled \$3,557 million and accounted for 15% of total debt

outstanding as of November 30, 2017, compared with \$3,343 million, or 14%, of total debt outstanding as of May 31, 2017. See Table 27 under "Liquidity Risk" for the composition of our short-term borrowings.

Long-Term and Subordinated Debt

Long-term debt, defined as debt with an original contractual maturity term of greater than one year, primarily consists of medium-term notes, collateral trust bonds, notes payable under the Guaranteed Underwriter Program and notes payable under our note purchase agreement with Farmer Mac. Subordinated debt consists of subordinated deferrable debt and members' subordinated certificates. Our subordinated deferrable debt and members' subordinated certificates have original contractual maturity terms of greater than one year.

Long-term and subordinated debt totaled \$20,529 million and accounted for 85% of total debt outstanding as of November 30, 2017, compared with \$20,117 million, or 86%, of total debt outstanding as of May 31, 2017. As discussed above, the increase in total debt outstanding, including long-term and subordinated debt, was primarily due to the issuance of debt to fund the growth in our loan and investments portfolios.

Collateral Pledged

We are required to pledge loans or other collateral in borrowing transactions under our collateral trust bond indentures, note purchase agreements with Farmer Mac and bond agreements under the Guaranteed Underwriter Program. We are required to maintain pledged collateral equal to at least 100% of the face amount of outstanding borrowings. However, we typically maintain pledged collateral in excess of the required percentage to ensure that required collateral levels are maintained and to facilitate the timely execution of debt issuances by reducing or eliminating the lead time to pledge additional collateral. Under the provisions of our committed bank revolving line of credit agreements, the excess collateral that we are allowed to pledge cannot exceed 150% of the outstanding borrowings under our collateral trust bond indentures, Farmer Mac note purchase agreements or the Guaranteed Underwriter Program. In certain cases, provided that all conditions of eligibility under the different programs are satisfied, we may withdraw excess pledged collateral or transfer collateral from one borrowing program to another to facilitate a new debt issuance.

Table 12 displays the collateral coverage ratios as of November 30, 2017 and May 31, 2017 for the debt agreements noted above that require us to pledge collateral.

Table 12: Collateral Pledged

Ç	Requirement/Limit						
			Comn	nitted	Actual	(1)	
			Bank				
	Debt		Revol	ving			
Debt Agreement	Inde	Indenture Line of		Novembango,1,		303,1,	
	Minimum		n Credit	t	2017	2017	7
			Agree	ments			
			Maxir	num			
Collateral trust bonds 1994 indenture	100	%	150	%	115 %	117	%
Collateral trust bonds 2007 indenture	100		150		113	115	
Guaranteed Underwriter Program notes payable	100		150		116	117	
Farmer Mac notes payable	100		150		115	117	
Clean Renewable Energy Bonds Series 2009A	100		150		106	113	

⁽¹⁾ Calculated based on the amount of collateral pledged divided by the face amount of outstanding secured debt.

Of our total debt outstanding of \$24,086 million as of November 30, 2017, \$15,202 million, or 63%, was secured by pledged loans totaling \$17,691 million. In comparison, of our total debt outstanding of \$23,460 million as of May 31, 2017, \$15,146 million, or 65%, was secured by pledged loans totaling \$17,941 million. Total debt outstanding on our condensed consolidated balance sheet is presented net of unamortized discounts and issuance costs. However, our collateral pledging requirements are based on the face amount of secured outstanding debt, which does not take into consideration the impact of net unamortized discounts and issuance costs.

Table 13 displays the unpaid principal balance of loans pledged for secured debt, the excess collateral pledged and unencumbered loans as of November 30, 2017 and May 31, 2017.

Table 13: Unencumbered Loans

(Dollars in thousands)	November 30, 2017	May 31, 2017
Total loans outstanding ⁽¹⁾	\$24,813,542	\$24,356,330
Less: Loans required to be pledged for secured debt (2)	(15,482,581)	(15,435,062)
Loans pledged in excess of requirement (2)(3)	(2,208,115)	(2,505,804)
Total pledged loans	(17,690,696)	(17,940,866)
Unencumbered loans	\$7,122,846	\$6,415,464
Unencumbered loans as a percentage of total loans	29 %	26 %

⁽¹⁾ Reflects unpaid principal balance. Excludes unamortized deferred loan origination costs of \$11 million as of both November 30, 2017 and May 31, 2017.

As displayed above in Table 13, we had excess loans pledged as collateral totaling \$2,208 million and \$2,506 million as of November 30, 2017 and May 31, 2017, respectively. We typically pledge loans in excess of the required amount for the following reasons: (i) our distribution and power supply loans are typically amortizing loans that require scheduled principal payments over the life of the loan, whereas the debt securities issued under secured indentures and agreements typically have bullet maturities; (ii) distribution and power supply borrowers have the option to prepay their loans; and (iii) individual loans may become ineligible for various reasons, some of which may be temporary.

We provide additional information on our borrowings, including the maturity profile, below in "Liquidity Risk." Refer to "Note 4—Loans and Commitments—Pledging of Loans" for additional information related to pledged collateral. Also refer to "Note 6—Short-Term Borrowings," "Note 7—Long-Term Debt," "Note 8—Subordinated Deferrable Debt" and "Note 9—Members' Subordinated Certificates" in our 2017 Form 10-K for a more detailed description of each of our debt product types.

Equity

Total equity increased by \$141 million to \$1,240 million as of November 30, 2017. The increase was primarily attributable to our net income of \$188 million for the six months ended November 30, 2017, which was partially offset by patronage capital retirement of \$45 million in September 2017.

In July 2017, the CFC Board of Directors authorized the allocation of fiscal year 2017 adjusted net income as follows: \$90 million to members in the form of patronage capital; \$43 million to members' capital reserve; and \$1 million to the Cooperative Educational Fund. The amount of patronage capital allocated each year by CFC's Board of Directors is based on adjusted non-GAAP net income, which excludes the impact of derivative forward value gains (losses). See "Non-GAAP Financial Measures" for information on adjusted net income.

In July 2017, the CFC Board of Directors authorized the retirement of patronage capital totaling \$45 million, which represented 50% of the fiscal year 2017 allocation of patronage capital of \$90 million. We returned the \$45 million to members in cash in September 2017. The remaining portion of the allocated amount will be retained by CFC for 25 years under guidelines adopted by the CFC Board of Directors in June 2009.

⁽²⁾ Reflects unpaid principal balance of pledged loans.

⁽³⁾ Excludes cash collateral pledged to secure debt. If there is an event of default under most of our indentures, we can only withdraw the excess collateral if we substitute cash or permitted investments of equal value.

The CFC Board of Directors is required to make annual allocations of adjusted net income, if any. CFC has made annual retirements of allocated net earnings in 38 of the last 39 fiscal years; however, future retirements of allocated amounts are determined based on CFC's financial condition. The CFC Board of Directors has the authority to change the current practice for allocating and retiring net earnings at any time, subject to applicable laws. See "Item 1. Business—Allocation and Retirement of Patronage Capital" of our 2017 Form 10-K for additional information.

OFF-BALANCE SHEET ARRANGEMENTS

In the ordinary course of business, we engage in financial transactions that are not presented on our condensed consolidated balance sheets, or may be recorded on our condensed consolidated balance sheets in amounts that are different from the full contract or notional amount of the transaction. Our off-balance sheet arrangements consist primarily of guarantees of member obligations and unadvanced loan commitments intended to meet the financial needs of our members.

Guarantees

We provide guarantees for certain contractual obligations of our members to assist them in obtaining various forms of financing. Table 14 displays the notional amount of our outstanding guarantee obligations, by guarantee type and by company, as of November 30, 2017 and May 31, 2017.

Table 14: Guarantees Outstanding

	B			
(Dollars in thousands)	November	May 31,	Increase/	
(Donars in thousands)	30, 2017	2017	(Decrease)	
Guarantee type:				
Long-term tax-exempt bonds	\$318,425	\$468,145	\$(149,720)	
Letters of credit	230,117	307,321	(77,204)	
Other guarantees	113,954	114,151	(197)	
Total	\$662,496	\$889,617	\$(227,121)	
Company:				
CFC	\$645,695	\$874,920	\$(229,225)	
NCSC	15,227	13,123	2,104	
RTFC	1,574	1,574	_	
Total	\$662,496	\$889,617	\$(227,121)	

Of the total notional amount of our outstanding guarantee obligations of \$662 million and \$890 million as of November 30, 2017 and May 31, 2017, respectively, 54% and 67%, respectively, were secured by a mortgage lien on substantially all of the assets and future revenue of the borrowers. We recorded a guarantee liability of \$8 million and \$15 million as of November 30, 2017 and May 31, 2017, respectively, related to the contingent and noncontingent exposures for guarantee and liquidity obligations associated with our members' debt.

We were the liquidity provider for long-term variable-rate, tax-exempt bonds issued for our member cooperatives totaling \$251 million as of November 30, 2017. We also provide a guarantee of payment of principal and interest for \$251 million of these long-term variable-rate, tax-exempt bonds, which is included above in Table 14 as a component of the long-term tax-exempt bonds of \$318 million as of November 30, 2017. As liquidity provider on these tax-exempt bonds, we may be required to purchase bonds that are tendered or put by investors. Investors provide notice to the remarketing agent that they will tender or put a certain amount of bonds at the next interest rate reset date. If the remarketing agent is unable to sell such bonds to other investors by the next interest rate reset date, we have unconditionally agreed to purchase such bonds. We were not required to perform as liquidity provider pursuant to these obligations during the six months ended November 30, 2017 or the prior fiscal year.

We had outstanding letters of credit for the benefit of our members totaling \$230 million as of November 30, 2017, which are related to obligations for which we may be required to advance funds based on various trigger events specified in the letters of credit agreements. If we are required to advance funds, the member is obligated to repay the advance amount, and accrued interest, to us.

In addition to the letters of credit presented in Table 14, we had master letter of credit facilities in place as of November 30, 2017, under which we may be required to issue up to an additional \$65 million in letters of credit to third parties for the benefit of our members. All of our master letter of credit facilities as of November 30, 2017 were subject to material adverse

change clauses at the time of issuance. Prior to issuing a letter of credit under these facilities, we confirm that there has been no material adverse change in the business or condition, financial or otherwise, of the borrower since the time the loan was approved and that the borrower is currently in compliance with the letter of credit terms and conditions.

Table 15 presents the maturities for each of the next five fiscal years and thereafter of the notional amount of our outstanding guarantee obligations as of November 30, 2017.

Table 15: Maturities of Guarantee Obligations

Outstanding	Maturities	of	Guaranteed	Obligations
-------------	------------	----	------------	--------------------

(Dollars in thousands)	Amount	2018	2019	2020	2021	2022	Thereafter
Guarantees	\$ 662,496	\$168,729	\$108,460	\$52,057	\$109,486	\$31,613	\$192,151

We provide additional information about our guarantee obligations in "Note 10—Guarantees."

Unadvanced Loan Commitments

Unadvanced loan commitments represent approved and executed loan contracts for which funds have not been advanced to borrowers. Our line of credit commitments include both contracts that are subject to material adverse change clauses and contracts that are not subject to material adverse change clauses, while our long-term loan commitments are typically subject to material adverse change clauses.

Table 16 displays the amount of unadvanced loan commitments, which consist of line of credit and long-term loan commitments, as of November 30, 2017 and May 31, 2017.

Table 16: Unadvanced Loan Commitments

	November 30	0, 2017	May 31, 201	7	Increase/
(Dollars in thousands)	Amount	% of Total	Amount	% of Total	(Decrease)
Line of credit commitments:					
Conditional ⁽¹⁾	\$4,790,605	38 %	\$5,170,393	41 %	\$(379,788)
Unconditional ⁽²⁾	2,784,511	22	2,602,262	21	182,249
Total line of credit unadvanced commitments	7,575,116	60	7,772,655	62	(197,539)
Total long-term loan unadvanced commitments ⁽¹⁾	4,950,905	40	4,802,319	38	148,586
Total unadvanced loan commitments	\$12,526,021	100%	\$12,574,974	100%	\$(48,953)

⁽¹⁾Represents amount related to facilities that are subject to material adverse change clauses.

Table 17 presents the amount of unadvanced loan commitments, by loan type, as of November 30, 2017 and the maturities of the commitment amounts for each of the next five fiscal years and thereafter.

Table 17: Notional Maturities of Unadvanced Loan Commitments

	Available	Notional Maturities of Unadvanced Loan Commitments							
(Dollars in thousands)	Balance	2018	2019	2020	2021	2022	Thereafter		
Line of credit loans	\$7,575,116	\$342,159	\$4,343,222	\$641,613	\$950,998	\$773,772	\$523,352		
Long-term loans	4,950,905	215,806	986,952	649,436	676,899	1,885,338	536,474		
Total	\$12,526,021	\$557,965	\$5,330,174	\$1,291,049	\$1,627,897	\$2,659,110	\$1,059,826		

⁽²⁾Represents amount related to facilities that are not subject to material adverse change clauses.

Unadvanced line of credit commitments accounted for 60% of total unadvanced loan commitments as of November 30, 2017, while unadvanced long-term loan commitments accounted for 40% of total unadvanced loan commitments.

Unadvanced line of credit commitments are typically revolving facilities for periods not to exceed five years. Unadvanced line of credit commitments generally serve as supplemental back-up liquidity to our borrowers. Historically, borrowers have not drawn the full commitment amount for line of credit facilities, and we have experienced a very low utilization rate on line of credit loan facilities regardless of whether or not we are obligated to fund the facility where a material adverse change exists. Our unadvanced long-term loan commitments have a five-year draw period under which a borrower may advance funds prior to the expiration of the commitment. We expect that the majority of the long-term unadvanced loan commitments of \$4,951 million will be advanced prior to the expiration of the commitment.

Because we historically have experienced a very low utilization rate on line of credit loan facilities, which account for the majority of our total unadvanced loan commitments, we believe the unadvanced loan commitment total of \$12,526 million as of November 30, 2017 is not necessarily representative of our future funding cash requirements.

Unadvanced Loan Commitments—Conditional

The substantial majority of our line of credit commitments and all our unadvanced long-term loan commitments include material adverse change clauses. Unadvanced loan commitments subject to material adverse change clauses totaled \$9,741 million and \$9,973 million as of November 30, 2017 and May 31, 2017, respectively, and accounted for 78% and 79% of the combined total of unadvanced line of credit and long-term loan commitments as of November 30, 2017 and May 31, 2017, respectively. Prior to making advances on these facilities, we confirm that there has been no material adverse change in the borrower's business or condition, financial or otherwise, since the time the loan was approved and confirm that the borrower is currently in compliance with loan terms and conditions. In some cases, the borrower's access to the full amount of the facility is further constrained by use of proceeds restrictions, imposition of borrower-specific restrictions, or by additional conditions that must be met prior to advancing funds. Since we generally do not charge a fee for the borrower to have an unadvanced amount on a loan facility that is subject to a material adverse change clause, our borrowers tend to request amounts in excess of their immediate estimated loan requirements.

Unadvanced Loan Commitments—Unconditional

Unadvanced loan commitments not subject to material adverse change clauses at the time of each advance consisted of unadvanced committed lines of credit totaling \$2,785 million and \$2,602 million as of November 30, 2017 and May 31, 2017, respectively. For contracts not subject to a material adverse change clause, we are generally required to advance amounts on the committed facilities as long as the borrower is in compliance with the terms and conditions of the facility.

Syndicated loan facilities, where the pricing is set at a spread over LIBOR as agreed upon by all of the participating banks based on market conditions at the time of syndication, accounted for 85% of unconditional line of credit commitments as of November 30, 2017. The remaining 15% represented unconditional committed line of credit loans which under any new advance would be made at rates determined by us based on our cost, and we have the option to pass on to the borrower any cost increase related to the advance.

Table 18 presents the maturities for each of the next five fiscal years and thereafter of the notional amount of unconditional committed lines of credit not subject to a material adverse change clause as of November 30, 2017.

Table 18: Maturities of Notional Amount of Unconditional Committed Lines of Credit

	Available Balance	Notional Maturities of Unconditional Committed Lines of Credit						
(Dollars in thousands)		2018	2019	2020	2021	2022	Thereafter	

Committed lines of credit \$2,784,511 \$130,000 \$517,130 \$395,711 \$630,631 \$677,818 \$433,221

See "MD&A—Off-Balance Sheet Arrangements" in our 2017 Form 10-K for additional information on our off-balance sheet arrangements.

RISK MANAGEMENT

Overview

We face a variety of risks that can significantly affect our financial performance, liquidity, reputation and ability to meet the expectations of our members, investors and other stakeholders. As a financial services company, the major categories of risk exposures inherent in our business activities include credit risk, liquidity risk, market risk and operational risk. These risk categories are summarized below.

Credit risk is the risk that a borrower or other counterparty will be unable to meet its obligations in accordance with agreed-upon terms.

Liquidity risk is the risk that we will be unable to fund our operations and meet our contractual obligations or that we will be unable to fund new loans to borrowers at a reasonable cost and tenor in a timely manner.

Market risk is the risk that changes in market variables, such as movements in interest rates, may adversely affect the match between the timing of the contractual maturities, re-pricing and prepayments of our financial assets and the related financial liabilities funding those assets.

Operational risk is the risk of loss resulting from inadequate or failed internal controls, processes, systems, human error or external events. Operational risk also includes compliance risk, fiduciary risk, reputational risk and litigation risk.

Effective risk management is critical to our overall operations and in achieving our primary objective of providing cost-based financial products to our rural electric members while maintaining the sound financial results required for investment-grade credit ratings on our debt instruments. Accordingly, we have a risk management framework that is intended to govern the principal risks we face in conducting our business and the aggregate amount of risk we are willing to accept, referred to as risk appetite, in the context of CFC's mission and strategic objectives and initiatives. We provide information on our risk management framework in our 2017 Form 10-K under "Item 7. MD&A—Risk Management—Risk Management Framework."

CREDIT RISK

Our loan portfolio, which represents the largest component of assets on our balance sheet, and guarantees account for the substantial majority of our credit risk exposure. We also engage in certain non-lending activities that may give rise to credit and counterparty settlement risk, including the purchase of investment securities and entering into derivative transactions to manage our interest rate risk. Our primary credit exposure is to rural electric cooperatives that provide essential electric services to end-users, the majority of which are residential customers. We also have a limited portfolio of loans to not-for-profit and for-profit telecommunication companies.

Credit Risk Management

We manage portfolio and borrower credit risk consistent with credit policies established by the CFC Board of Directors and through credit underwriting, approval and monitoring processes and practices adopted by management. Our board-established credit policies include guidelines regarding the types of credit products we offer, limits on credit we extend to individual borrowers, approval authorities delegated to management, and use of syndications and loan sales. We maintain an internal risk rating system in which we assign a rating to each borrower and credit facility. We review and update the risk ratings at least annually. Assigned risk ratings inform our credit approval, borrower monitoring and portfolio review processes. Our Corporate Credit Committee approves individual credit actions within its own authority and together with our Credit Risk Management group, establishes standards for credit underwriting,

oversees credits deemed to be higher risk, reviews assigned risk ratings for accuracy, and monitors the overall credit quality and performance statistics of our loan portfolio and guarantees.

Loan and Guarantee Portfolio Credit Risk

Below we provide information on the credit risk profile of our loan portfolio and guarantees, including security provisions, loan concentration, credit performance and our allowance for loan losses.

Security Provisions

Except when providing line of credit loans, we generally lend to our members on a senior secured basis. Long-term loans are generally secured on parity with other secured lenders (primarily RUS), if any, by all assets and revenue of the borrower with exceptions typical in utility mortgages. Line of credit loans are generally unsecured. In addition to the collateral pledged to secure our loans, distribution and power supply borrowers also are required to set rates charged to customers to achieve certain specified financial ratios.

Table 19 presents, by loan type and by company, the amount and percentage of secured and unsecured loans in our loan portfolio as of November 30, 2017 and May 31, 2017. Of our total loans outstanding, 92% were secured and 8% were unsecured as of both November 30, 2017 and May 31, 2017.

Table 19: Loan Portfolio Security Profile⁽¹⁾

	November 30, 2017							
(Dollars in thousands)	Secured	% of Total	Unsecured	% of Total	Total			
Loan type:								
Long-term loans:								
Long-term fixed-rate loans	\$21,825,249	97 %	\$590,584	3 %	\$22,415,833			
Long-term variable-rate loans	857,907	95	48,546	5	906,453			
Total long-term loans	22,683,156	97	639,130	3	23,322,286			
Line of credit loans	72,505	5	1,418,751	95	1,491,256			
Total loans outstanding	\$22,755,661	92 %	\$2,057,881	8 %	\$24,813,542			
Company:								
CFC	\$21,814,316	92 %	\$1,887,788	8 %	\$23,702,104			
NCSC	588,161	80	151,546	20	739,707			
RTFC	353,184	95	18,547	5	371,731			
Total loans outstanding	\$22,755,661	92 %	\$2,057,881	8 %	\$24,813,542			

	May 31, 2017						
(Dollars in thousands)	Secured	% of Total	Unsecured	% of Total	Total		
Loan type:							
Long-term loans:							
Long-term fixed-rate loans	\$21,503,871	97 %	\$632,819	3 %	\$22,136,690		
Long-term variable-rate loans	795,326	94	52,093	6	847,419		
Total long-term loans	22,299,197	97	684,912	3	22,984,109		
Line of credit loans	54,258	4	1,317,963	96	1,372,221		
Total loans outstanding	\$22,353,455	92	\$2,002,875	8	\$24,356,330		
Company:							
CFC	\$21,591,723	92 %	\$1,796,264	8 %	\$23,387,987		
NCSC	424,636	69	189,288	31	613,924		
RTFC	337,096	95	17,323	5	354,419		
Total loans outstanding	\$22,353,455	92	\$2,002,875	8	\$24,356,330		

⁽¹⁾ Excludes deferred loan origination costs of \$11 million as of both November 30, 2017 and May 31, 2017.

As part of our strategy in managing our credit risk exposure, we entered into a long-term standby purchase commitment agreement with Farmer Mac on August 31, 2015, as amended on May 31, 2016. Under this agreement, we may designate certain loans to be covered under the commitment, as approved by Farmer Mac, and in the event any such loan later goes into payment default for at least 90 days, upon request by us, Farmer Mac must purchase such loan at par value. The outstanding principal balance of loans covered under this agreement totaled \$792 million as of November 30, 2017, compared with \$843 million as of May 31, 2017. No loans have been put to Farmer Mac for purchase pursuant to this agreement. In addition, RUS guaranteed long-term loans totaling \$164 million and \$167 million as of November 30, 2017 and May 31, 2017, respectively.

Credit Concentration

As a tax-exempt, member-owned finance cooperative, CFC's principal purpose is to provide funding to America's rural electric utility cooperatives to assist them in acquiring, constructing and operating electric distribution, transmission and related facilities. We serve electric and telecommunications members throughout the United States and its territories, including 49 states, the District of Columbia, American Samoa and Guam. Texas had the largest concentration of outstanding loans to borrowers in any one state, with approximately 15% of total loans outstanding as of both November 30, 2017 and May 31, 2017. Our consolidated membership totaled 1,459 members and 217 associates as of November 30, 2017. As such, we have a loan portfolio with single-industry and single-obligor concentration risk. Outstanding loans to electric utility organizations represented approximately 99% of the total outstanding loan portfolio as of November 30, 2017, unchanged from May 31, 2017. The remaining outstanding loans in our portfolio were to RTFC members, affiliates and associates in the telecommunications industry.

Single-Obligor Concentration

Table 20 displays the outstanding exposure of the 20 largest borrowers, by exposure type and by company, as of November 30, 2017 and May 31, 2017. The 20 largest borrowers consisted of 10 distribution systems, 9 power supply systems and 1 NCSC associate member as of both November 30, 2017 and May 31, 2017. The largest total outstanding exposure to a single borrower or controlled group represented approximately 2% of total loans and guarantees outstanding as of both November 30, 2017 and May 31, 2017.

Table 20: Credit Exposure to 20 Largest Borrowers

	November 30, 2017		May 31, 201	Change	
(Dollars in thousands)	Amount	% of Total	Amount	% of Total	Change
By exposure type:					
Loans	\$5,832,139	23 %	\$5,749,885	23 %	\$82,254
Guarantees	129,070		354,619	1	(225,549)
Total exposure to 20 largest borrowers	5,961,209	23	6,104,504	24	(143,295)
Less: Loans covered under Farmer Mac standby purchase commitment	(367,464)	(1)	(351,699)	(1)	(15,765)
Net exposure to 20 largest borrowers	\$5,593,745	22 %	\$5,752,805	23 %	\$(159,060)
By company:					
CFC	\$5,711,341	22 %	\$5,899,709	23 %	\$(188,368)
NCSC	249,868	1	204,795	1	45,073
Total exposure to 20 largest borrowers	5,961,209	23	6,104,504	24	(143,295)
Less: Loans covered under Farmer Mac standby purchase commitment	(367,464)	(1)	(351,699)	(1)	(15,765)
Net exposure to 20 largest borrowers	\$5,593,745	22 %	\$5,752,805	23 %	\$(159,060)

Credit Performance

As part of our credit risk management process, we monitor and evaluate each borrower and loan in our loan portfolio and assign numeric internal risk ratings based on quantitative and qualitative assessments. Our ratings are intended to align with the federal banking regulatory credit risk rating classification definitions of pass, special mention, substandard and doubtful. The special mention, substandard, and doubtful categories are intended to comply with the definition of criticized loans by the banking regulatory authorities. Internal risk ratings and payment status trends are indicators, among others, of the level of credit risk in our loan portfolio.

The overall credit risk of our loan portfolio remained low, as evidenced by our strong asset quality metrics, including senior secured positions on most of our loans and low levels of criticized exposure, nonaccrual loans and charge-offs. As displayed in Table 19 above, 92% of our total outstanding loans were secured as of both November 30, 2017 and May 31, 2017. As displayed in "Note 4—Loans and Commitments," 0.5% of the loans in our portfolio were classified as criticized as of both November 30, 2017 and May 31, 2017. Below we provide information on certain additional credit quality indicators, including modified loans that are considered to be troubled debt restructurings ("TDRs"), nonperforming loans and net charge-offs.

Troubled Debt Restructurings

We actively monitor problem loans and, from time to time, attempt to work with borrowers to manage such exposures through loan workouts or modifications that better align with the borrower's current ability to pay. A loan restructuring or modification of terms is accounted for as a TDR if, for economic or legal reasons related to the borrower's financial difficulties, a concession is granted to the borrower that we would not otherwise consider. TDR loans generally are initially placed on nonaccrual status, although in many cases such loans were already on nonaccrual status prior to modification. Interest accrued but not collected at the date a loan is placed on nonaccrual status is reversed against earnings. These loans may be returned to performing status and the accrual of interest resumed if the borrower performs under the modified terms for an extended period of time, and we expect the borrower to continue to perform in accordance with the modified terms. In certain limited circumstances in which a TDR loan is current at the

modification date, the loan may remain on accrual status at the time of modification.

Table 21 presents the carrying value of loans modified as TDRs in prior periods as of November 30, 2017 and May 31, 2017. These loans were considered individually impaired as of the end of each period presented.

Table 21: TDR Loans

Tuble 21. TER Edulis						
	Novemb			May 31,		
(Dollars in thousands)	Carrying Amount	% of To Loans Outstan		Carrying Amount		
TDR loans:						
CFC	\$6,507	0.03	%	\$6,581	0.02	%
RTFC	6,341	0.02		6,592	0.03	
Total TDR loans	\$12,848	0.05	%	\$13,173	0.05	%
Performance status of TDR loans:						
Performing TDR loans	\$12,848	0.05	%	\$13,173	0.05	%

As indicated in Table 21, we did not have any TDR loans classified as nonperforming as of November 30, 2017 or May 31, 2017. TDR loans classified as performing as of November 30, 2017 and May 31, 2017 were performing in accordance with the terms of their respective restructured loan agreement and on accrual status as of the respective reported dates.

Nonperforming Loans

In addition to TDR loans that may be classified as nonperforming, we also may have nonperforming loans that have not been modified as a TDR loan. We classify such loans as nonperforming at the earlier of the date when we determine: (i) interest or principal payments on the loan is past due 90 days or more; (ii) as a result of court proceedings, the collection of interest or principal payments based on the original contractual terms is not expected; or (iii) the full and timely collection of interest or principal is otherwise uncertain. Once a loan is classified as nonperforming, we generally place the loan on nonaccrual status. Interest accrued but not collected at the date a loan is placed on nonaccrual status is reversed against earnings. We had no loans classified as nonperforming as of November 30, 2017 or May 31, 2017. In addition, we did not have any past due loans as of either November 30, 2017 or May 31, 2017.

We provide additional information on the credit quality of our loan portfolio in "Note 4—Loans and Commitments."

Net Charge-Offs

Table 22 presents charge-offs, net of recoveries, and the net charge-off rate for the three and six months ended November 30, 2017 and 2016.

Table 22: Net Charge-Offs (Recoveries)

1 4010 22. 110t Charge Offs (1000	0 (01105)					
	Three Months	Ended	Six Months Ended November			
	November 30,		30,			
(Dollars in thousands)	2017	2016	2017	2016		
Charge-offs:						
RTFC	\$ —	\$ —	\$ —	\$2,119		
Recoveries:						
CFC		(53)		(106)		
Net charge-offs (recoveries)	\$—	\$(53)	\$ —	\$2,013		
Average total loans outstanding	\$24,688,391	\$23,584,370	\$24,634,266	\$23,499,922		

Net charge-off rate(1)	 % —	% —	% 0.02	%	

As displayed in Table 22, we experienced no charge-offs during the current quarter and the six months ended November 30, 2017. Charge-offs totaled \$2 million during the six months ended November 30, 2016, all of which were related to

⁽¹⁾Calculated based on annualized net charge-offs (recoveries) for the period divided by average total outstanding loans for the period.

telecommunications loans in the RTFC portfolio. Our average annual net charge-off rate has been less than 0.01% over the last three fiscal years.

Allowance for Loan Losses

The allowance for loan losses is determined based upon evaluation of the loan portfolio, past loss experience, specific problem loans, economic conditions and other pertinent factors that, in management's judgment, could affect the risk of loss in the loan portfolio. We review and adjust the allowance quarterly to cover estimated probable losses inherent in our loan portfolio as of each balance sheet date.

Table 23 summarizes changes in the allowance for loan losses for the three and six months ended November 30, 2017 and 2016, and provides a comparison of the allowance by company as of November 30, 2017 and May 31, 2017.

Table 23: Allowance for Loan Losses

Table 23: Allowance for Loan Losses						
	Three Months Ended November 30,		Six Months Ended Noven 30,			
(Dollars in thousands)	2017	2016	2017	2016		
Beginning balance	\$37,078	\$33,120	\$37,376	\$33,258		
(Benefit) provision for loan losses	(304)	738	(602)	2,666		
Net recoveries (charge-offs)		53		(2,013)	
Ending balance	\$36,774	\$33,911	\$36,774	\$33,911		
Allowance for loan losses by company:			November 30 2017	May 31, 2017	7	
CFC			\$28,799	\$29,499		
NCSC			3,117	2,910		
RTFC			4,858	4,967		
Total			\$36,774	\$37,376		
Allowance coverage ratios:						
Loans to members			\$24,824,691	\$24,367,044		
Percentage of loans to members			0.15	6 0.15	%	

The allowance for loan losses of \$37 million as of November 30, 2017 decreased slightly from fiscal year end May 31, 2017, while the allowance coverage ratio remained unchanged at 0.15%. The credit quality and performance statistics of our loan portfolio continued to remain strong. We experienced no charge-offs during the three and six months ended November 30, 2017 and we had no loans classified as nonperforming as of the end of the period. In comparison, we recorded a net charge-off of \$2 million during the six months ended November 30, 2016. Loans designated as individually impaired totaled \$13 million as of both November 30, 2017 and May 31, 2017, and the specific allowance related to these loans totaled \$1 million and \$2 million, respectively.

For additional information on our methodology for determining the allowance for loan losses, see "Note 1—Summary of Significant Accounting Policies" in our 2017 Form 10-K. See "Note 4—Loans and Commitments" of this Report for additional information on the credit quality of our loan portfolio and the allowance for loan losses.

Counterparty Credit Risk

We are exposed to counterparty risk related to the performance of the parties with which we entered into financial transactions, primarily for derivative instruments, cash, time deposits and investment securities that we have with various financial institutions. To mitigate this risk, we only enter into these transactions with financial institutions with investment-grade ratings. Our cash and time deposits with financial institutions generally have an original maturity of less than one year.

We manage our derivative counterparty credit risk by requiring that derivative counterparties participate in one of our committed bank revolving line of credit agreements, monitoring the overall credit worthiness of each counterparty, using counterparty specific credit risk limits, executing master netting arrangements and diversifying our derivative transactions among multiple counterparties. Our derivative counterparties had credit ratings ranging from A1 to Baa2 by Moody's Investors Service ("Moody's") and from AA- to A- by S&P Global Ratings ("S&P") as of November 30, 2017. Our largest counterparty exposure, based on the outstanding notional amount, represented approximately 23% of the total outstanding notional amount of derivatives as of both November 30, 2017 and May 31, 2017, respectively.

Credit Risk-Related Contingent Features

Our derivative contracts typically contain mutual early termination provisions, generally in the form of a credit rating trigger. Under the mutual credit rating trigger provisions, either counterparty may, but is not obligated to, terminate and settle the agreement if the credit rating of the other counterparty falls to a level specified in the agreement. If a derivative contract is terminated, the amount to be received or paid by us would be equal to the mark-to-market value, as defined in the agreement, as of the termination date.

Our senior unsecured credit ratings from Moody's and S&P were A2 and A, respectively, as of November 30, 2017. Both Moody's and S&P had our ratings on stable outlook as of November 30, 2017. Table 24 displays the notional amounts of our derivative contracts with rating triggers as of November 30, 2017, and the payments that would be required if the contracts were terminated as of that date because of a downgrade of our unsecured credit ratings or the counterparty's unsecured credit ratings below A3/A-, below Baa1/BBB+ to or below Baa2/BBB, below Baa3/BBB- or to or below Ba2/BB+ by Moody's or S&P, respectively. In calculating the payment amounts that would be required upon termination of the derivative contracts, we assumed that the amounts for each counterparty would be netted in accordance with the provisions of the counterparty's master netting agreements. The net payment amounts are based on the fair value of the underlying derivative instrument, excluding the credit risk valuation adjustment, plus any unpaid accrued interest amounts.

Table 24: Rating Triggers for Derivatives

(Dollars in thousands)	Notional Amount	Payable Due From CFC	Receivable Due to CFC	Net (Payable)/Receivab	ole
Impact of rating downgrade trigger:					
Falls below A3/A-(1)	\$56,985	\$(11,670)	\$ —	\$ (11,670)
Falls below Baa1/BBB+	7,236,383	(143,459)	7,428	(136,031)
Falls to or below Baa2/BBB (2)	455,152		1,577	1,577	
Falls below Baa3/BBB-	264,981	(18,102)		(18,102)
Total	\$8,013,501	\$(173,231)	\$ 9,005	\$ (164,226)

⁽¹⁾ Rating trigger for CFC falls below A3/A-, while rating trigger for counterparty falls below Baa1/BBB+ by Moody's or S&P, respectively.

The aggregate fair value amount, including the credit risk valuation adjustment, of all interest rate swaps with rating triggers that were in a net liability position was \$173 million as of November 30, 2017. There were no counterparties that fell below the rating trigger levels in our interest swap contracts as of November 30, 2017. If a counterparty has a credit rating that falls below the rating trigger level specified in the interest swap contract, we have the option to terminate all derivatives with the counterparty. However, we generally do not terminate such agreements early because our interest rate swaps are critical to our matched funding strategy.

⁽²⁾ Rating trigger for CFC falls to or below Baa2/BBB, while rating trigger for counterparty falls to or below Ba2/BB+ by Moody's or S&P, respectively.

See "Item 1A. Risk Factors" in our 2017 Form 10-K for additional information about credit risk related to our business.

LIQUIDITY RISK

We consider liquidity to be the ability to access funding or convert assets to cash quickly and efficiently, or to rollover or issue new debt, both under normal operating conditions and under periods of market stress, at a reasonable cost to ensure that we can meet borrower loan requests and other short-term cash obligations.

Liquidity Risk Management

Our liquidity risk management framework is designed to meet our liquidity objectives of providing a reliable source of funding to members, meet maturing debt and other obligations, issue new debt and fund our operations on a cost-effective basis under normal operating conditions as well as under CFC-specific and/or market stress conditions. We engage in various activities to manage liquidity risk and achieve our liquidity objectives. Our Asset Liability Committee establishes guidelines that are intended to ensure that we maintain sufficient, diversified sources of liquidity to cover potential funding requirements as well as unanticipated contingencies. Our Treasury group develops strategies to manage our targeted liquidity position, projects our funding needs under various scenarios, including adverse circumstances, and monitors our liquidity position on an ongoing basis.

Liquidity Reserve

As part of our strategy in meeting our liquidity objectives, we seek to maintain access to liquidity in the form of both on-balance sheet and off-balance sheet funding sources that are readily accessible for immediate liquidity needs. Table 25 below presents the components of our liquidity reserve and a comparison of the amounts available as of November 30, 2017 and May 31, 2017.

Table 25: Liquidity Reserve

	Novemb	er 30, 201	7	May 31,	2017		
(Dollars in millions)	Total	Accessed	l Available	e Total	Accessed	l Available	
Cash and cash equivalents	\$280	\$ <i>—</i>	\$ 280	\$167	\$ <i>—</i>	\$ 167	
Committed bank revolving line of credit	3,085	2	3,083	3,165	1	3,164	
agreements—unsecured	-,	_	-,	-,		2,10.	
Guaranteed Underwriter Program committed	6,548	5,173	1,375	5,798	5,073	725	
facilities—secured	,	,	,	,	,		
Farmer Mac revolving note purchase agreement, dated	4,500	2,491	2,009	4,500	2,513	1,987	
March 24, 2011—secured	-,	_,	_,~~	1,000	_,	-,	
Farmer Mac revolving note purchase agreement, dated	300		300	300		300	
July 31, 2015—secured	200		200	200		200	
Total	\$14,713	\$ 7,666	\$ 7,047	\$13,930	\$ 7,587	\$ 6,343	

⁽¹⁾ The accessed amount of \$2 million and \$1 million as of November 30, 2017 and May 31, 2017, respectively, relates to letters of credit issued pursuant to the line of credit agreement.

Borrowing Capacity

In addition to cash, our liquidity reserve includes access to funds under committed revolving line of credit agreements with banks, committed loan facilities under the Guaranteed Underwriter Program and our revolving note purchase agreements with Farmer Mac. Following is a discussion of our borrowing capacity and key terms and conditions

⁽²⁾ The committed facilities under the Guaranteed Underwriting Program are not revolving.

⁽³⁾ Availability subject to market conditions.

under each of these facilities.

Committed Bank Revolving Line of Credit Agreements—Unsecured

Our committed bank revolving lines of credit may be used for general corporate purposes; however, we generally rely on them as a backup source of liquidity for our member and dealer commercial paper. We had \$3,085 million of commitments under committed bank revolving line of credit agreements as of November 30, 2017. Under our current committed bank revolving line of credit agreements, we have the ability to request up to \$300 million of letters of credit, which would result in a reduction in the remaining available amount under the facilities.

On November 20, 2017, we amended and restated the three-year and five-year committed bank revolving line of credit agreements to extend the maturity dates to November 20, 2020 and November 20, 2022, respectively, and to terminate certain third-party bank commitments totaling \$40 million under the three-year agreement and \$40 million under the five-year agreement. As a result, the total commitment amount from third-parties under the three-year facility and the five-year facility is \$1,493 million and \$1,592 million, respectively, resulting in a combined total commitment amount under the two facilities of \$3,085 million.

Table 26 presents the total commitment, the net amount available for use and the outstanding letters of credit under our committed bank revolving line of credit agreements as of November 30, 2017. We did not have any outstanding borrowings under our bank revolving line of credit agreements as of November 30, 2017.

Table 26: Committed Bank Revolving Line of Credit Agreements November 30, 2017

	1 10 10111	<i>DCI DO</i> ,	2017			
(Dollars in millions)	Total Commi	Letters Credit tment Outsta		Net Available for Advance	Maturity	Annual Facility Fee (1)
3-year agreement 5-year agreement Total	\$1,493 1,592 \$3,085	2		\$ 1,493 1,590 \$ 3,083	November 20, 2020 November 20, 2022	*

⁽¹⁾Facility fee based on CFC's senior unsecured credit ratings in accordance with the established pricing schedules at the inception of the related agreement.

Our committed bank revolving line of credit agreements do not contain a material adverse change clause or rating triggers that would limit the banks' obligations to provide funding under the terms of the agreements; however, we must be in compliance with the covenants to draw on the facilities. We have been and expect to continue to be in compliance with the covenants under our committed bank revolving line of credit agreements. As such, we could draw on these facilities to repay dealer or member commercial paper that cannot be rolled over. See "Debt Covenants and Financial Ratios" below for additional information, including the specific financial ratio requirements under our committed bank revolving line of credit agreements.

Guaranteed Underwriter Program Committed Facilities—Secured

Under the Guaranteed Underwriter Program we can borrow from the Federal Financing Bank and use the proceeds to refinance existing indebtedness. As part of the program, we pay fees, based on outstanding borrowings, that support the USDA Rural Economic Development Loan and Grant program. The borrowings under this program are guaranteed by RUS.

On November 9, 2017, we closed on a \$750 million committed loan facility ("Series M") from the Federal Financing Bank under the Guaranteed Underwriter Program. Pursuant to this facility, we may borrow any time before July 15,

2022. Each advance is subject to quarterly amortization and a final maturity not longer than 20 years from the advance date. The closing of this committed loan facility increased the amount available for access under the Guaranteed Underwriter Program to \$1,375 million as of November 30, 2017. Of this amount, \$250 million is available for advance through January 15, 2019, \$375 million is available for advance through October 15, 2019 and \$750 million is available through July 15, 2022.

We are required to pledge eligible distribution system or power supply system loans as collateral in an amount at least equal to the total outstanding borrowings under the Guaranteed Underwriter Program. See "Consolidated Balance Sheet Analysis—Debt—Collateral Pledged" and "Note 4—Loans and Commitments" for additional information on pledged collateral

Farmer Mac Revolving Note Purchase Agreements—Secured

As indicated in Table 25, we have two revolving note purchase agreements with Farmer Mac, which together allow us to borrow up to \$4,800 million from Farmer Mac. Under the terms of the first revolving note purchase agreement with Farmer Mac dated March 24, 2011, as amended, we can borrow, subject to market conditions, up to \$4,500 million at any time through January 11, 2020, and such date shall automatically extend on each anniversary date of the closing for an additional year, unless prior to any such anniversary date, Farmer Mac provides us with a notice that the draw period will not be extended beyond the remaining term. This revolving note purchase agreement allows us to borrow, repay and re-borrow funds at any time through maturity, as market conditions permit, provided that the outstanding principal amount at any time does not exceed the total available under the agreement. Each borrowing under the note purchase agreement is evidenced by a pricing agreement setting forth the interest rate, maturity date and other related terms as we may negotiate with Farmer Mac at the time of each such borrowing. We may select a fixed rate or variable rate at the time of each advance with a maturity as determined in the applicable pricing agreement. We had outstanding secured notes payable totaling \$2,491 million and \$2,513 million as of November 30, 2017 and May 31, 2017, respectively, under the Farmer Mac revolving note purchase agreement of \$4,500 million. The available borrowing amount totaled \$2,009 million as of November 30, 2017.

Under the terms of the second revolving note purchase agreement with Farmer Mac dated July 31, 2015, we can borrow up to \$300 million at any time through July 31, 2018 at a fixed spread over LIBOR. This agreement also allows us to borrow, repay and re-borrow funds at any time through maturity, provided that the outstanding principal amount at any time does not exceed the total available under the agreement. We had no outstanding notes payable under this agreement as of November 30, 2017 and May 31, 2017. We currently do not expect to renew this agreement.

Pursuant to both Farmer Mac revolving note purchase agreements, we are required to pledge eligible distribution system or power supply system loans as collateral in an amount at least equal to the total principal amount of notes outstanding. See "Consolidated Balance Sheet Analysis—Debt—Collateral Pledged" and "Note 4—Loans and Commitments" additional information on pledged collateral.

Short-Term Borrowings

We rely on short-term borrowings, which we refer to as our short-term funding portfolio, as a source to meet our daily, near-term funding needs. Our short-term funding portfolio consists of commercial paper, which we offer to members and dealers, select notes and daily liquidity fund notes offered to members, and bank-bid notes and medium-term notes offered to members and dealers. Table 27 displays the composition of our short-term borrowings as of November 30, 2017 and May 31, 2017.

Table 27: Short-Term Borrowings

	November	30, 20)17	May 31, 2017		
(Dollars in thousands)	Amount Outstandir	- .	Total t standing	Amount Outstanding	D 1.	Total tanding
Short-term borrowings:						
Commercial paper:						
Commercial paper sold through dealers, net of discounts	\$579,859	2	%	\$999,691	4	%
Commercial paper sold directly to members, at par	1,133,057	5		928,158	4	
Total commercial paper	1,712,916	7		1,927,849	8	
Select notes	770,376	3		696,889	3	
Daily liquidity fund notes	866,065	4		527,990	2	

Medium-term notes sold to members	207,835 1	190,172 1
Total short-term borrowings	\$3,557,192 15 %	\$3,342,900 14 %

Our short-term borrowings totaled \$3,557 million and accounted for 15% of total debt outstanding as of November 30, 2017, compared with \$3,343 million, or 14%, of total debt outstanding as of May 31, 2017. Of the total outstanding commercial paper, \$580 million and \$1,000 million was issued to dealers as of November 30, 2017 and May 31, 2017,

respectively. We intend to manage our short-term wholesale funding risk by maintaining outstanding dealer commercial paper at an amount below \$1,250 million for the foreseeable future.

Long-Term and Subordinated Debt

Long-term and subordinated debt represents the most significant component of our funding. The issuance of long-term debt allows us to reduce our reliance on short-term borrowings and manage our refinancing and interest rate risk, due in part to the multi-year contractual maturity structure of long-term debt. In addition to access to private debt facilities, we also issue debt in the public capital markets. Under the SEC rules, we are classified as a "well-known seasoned issuer." In November 2017, we filed a new shelf registration statement for our senior and subordinated debt securities under which we can register an unlimited amount of senior and subordinated debt securities, including medium-term notes, member capital securities and subordinated deferrable debt, until November 2020. Notwithstanding the foregoing, we have contractual limitations with respect to the amount of senior indebtedness we may incur. See "MD&A—Liquidity Risk" of our 2017 Form 10-K for additional information on our shelf registration statements with the SEC.

As discussed in "Consolidated Balance Sheet Analysis—Debt," long-term and subordinated debt totaled \$20,529 million and accounted for 85% of total debt outstanding as of November 30, 2017, compared with \$20,117 million, or 86%, of total debt outstanding as of May 31, 2017. The increase in total debt outstanding, including long-term and subordinated debt, was primarily due to the issuance of debt to fund loan portfolio growth. Table 28 summarizes long-term and subordinated debt issuances and principal maturities and amortizations, including repurchases and redemptions, during the six months ended November 30, 2017.

Table 28: Issuances and Maturities of Long-Term and Subordinated Debt⁽¹⁾

	Six Months Ended November 30, 201			
(Dollars in thousands)	Issuances	Maturities	Increase/Decre	ease
Long-term and subordinated debt activity:(1)				
Collateral trust bonds	\$ —	\$5,000	\$ (5,000)
Guaranteed Underwriter Program notes payable	100,000	25,556	74,444	
Farmer Mac notes payable		21,925	(21,925)
Medium-term notes sold to members	125,335	143,547	(18,212)
Medium-term notes sold to dealers	402,592	7,791	394,801	
Members' subordinated certificates	3,989	23,340	(19,351)
Total	\$631,916	\$227,159	\$ 404,757	

⁽¹⁾ Amounts exclude unamortized debt issuance costs and discounts.

Table 29 summarizes the scheduled amortization of the principal amount of long-term debt, subordinated deferrable debt and members' subordinated certificates as of November 30, 2017.

Table 29: Principal Maturity of Long-Term and Subordinated Debt

(Dollars in thousands)	Amount Maturing	% o	
Fiscal year ending:			
May 31, 2018	\$1,065,619	5	%
May 31, 2019	2,672,139	13	
May 31, 2020	1,428,928	7	
May 31, 2021	1,323,843	6	

May 31, 2022	1,573,604	8
Thereafter	12,463,802	61
Total	\$20,527,935	100%

(1)Excludes \$1 million in subscribed and unissued member subordinated certificates for which a payment has been received. Member loan subordinated certificates totaling \$290 million amortize annually based on the unpaid principal balance of the related loan.

On January 2, 2018, we provided notice to RUS that on January 16, 2018 we will redeem \$325 million of notes payable outstanding under the Guaranteed Underwriter Program, with an original maturity of April 15, 2026.

We provide additional information on our financing activities above under "Consolidated Balance Sheet Analysis—Debt."

Investment Portfolio

In addition to our primary sources of liquidity discussed above, we have an investment portfolio, composed of time deposits, available-for-sale investment securities and held-to-maturity investment securities, which totaled \$391 million and \$319 million as of November 30, 2017 and May 31, 2017, respectively. We intend for our investment portfolio to remain adequately liquid to serve as a contingent supplemental source of liquidity for unanticipated liquidity needs.

During the second quarter of fiscal year 2018, we commenced the purchase of additional investment securities, consisting primarily of certificates of deposit, commercial paper, corporate debt securities, commercial mortgage-backed securities, and other asset-backed securities. Pursuant to our investment policy guidelines, all fixed-income securities, at the time of purchase, must be rated at least investment grade based on external credit ratings, when available, or the corresponding equivalent, when not available. Securities rated investment grade, that is those rated Baa3 or higher by Moody's or BBB- or higher by S&P, are generally considered by the rating agencies to be of lower credit risk than non-investment grade securities. We have the positive intent and ability to hold these securities to maturity. As such, we have classified them as held to maturity on our condensed consolidated balance sheet.

Our investment portfolio is unencumbered and structured so that securities have active secondary or resale markets under normal market conditions. The objective of the portfolio is to achieve returns commensurate with the level of risk assumed subject to CFC's investment policy guidelines and liquidity requirements.

We provide additional information on available-for-sale and held-to-maturity investment securities held in our our investment portfolio in "Note 3—Investment Securities."

Projected Near-Term Sources and Uses of Liquidity

As discussed above, our primary sources of liquidity include cash flows from operations, our short-term funding portfolio, our liquidity reserve and the issuance of long-term and subordinated debt, as well as loan principal and interest payments. Our primary uses of liquidity include loan advances to members, principal and interest payments on borrowings, periodic settlement payments related to derivative contracts, costs related to the disposition of foreclosed assets and operating expenses.

Table 30 below displays our projected sources and uses of cash, by quarter, over the next six quarters through the quarter ending May 31, 2019. Our projected liquidity position, reflects our current plan to expand our investment portfolio. Our assumptions also include the following: (i) the estimated issuance of long-term debt, including collateral trust bonds and private placement of term debt, is based on maintaining a matched funding position within our loan portfolio with our bank revolving lines of credit serving as a backup liquidity facility for commercial paper and on maintaining outstanding dealer commercial paper at an amount below \$1,250 million; (ii) long-term loan

scheduled amortization payments represent the scheduled long-term loan payments for loans outstanding as of November 30, 2017, and our current estimate of long-term loan prepayments, which the amount and timing of are subject to change; (iii) other loan repayments and other loan advances primarily relate to line of credit repayments and advances; (iv) long-term debt maturities reflect scheduled maturities of outstanding term debt for the periods presented; and (v) long-term loan advances reflect our current estimate of member demand for loans, the amount and timing of which are subject to change.

Table 30: Projected Sources and Uses of Liquidity⁽¹⁾

v	Project	ed Sources of	Liqu	idity		Projecto	ed Uses of I	Liqu	idity			
(Dollars in millions)	Debt	Anticipated erm Long-Term Loan Repayments ⁽²	D _{O1}	ner Loan payments	Sources	Dobt	Edromg-Tern Loan ciesctVances	Ι.	0.12	Total Projected Uses of Liquidity	(Uses) o	of
3Q FY 2018	\$1,070	\$ 309	\$	36	\$ 1,415	\$1,141	\$ 741	\$	62	\$ 1,944	\$ 463	
4Q FY 2018	490	286	_		776	333	307			640	(141)
1Q FY 2019	385	305	52		742	162	313			475	(262)
2Q FY 2019	1,335	323			1,658	1,569	290	13		1,872	227	
3Q FY 2019	845	291			1,136	696	493	_		1,189	28	
4Q FY 2019	585	272			857	398	485	_		883	40	
Total	\$4,710	\$ 1,786	\$	88	\$ 6,584	\$4,299	\$ 2,629	\$	75	\$ 7,003	\$ 355	

⁽¹⁾ The dates presented represent the end of each quarterly period through the quarter ending May 31, 2019.

As displayed in Table 30, we currently project long-term advances of \$1,651 million over the next 12 months, which we anticipate will exceed anticipated loan repayments over the same period of \$1,223 million by approximately \$428 million. The estimates presented above are developed at a particular point in time based on our expected future business growth and funding. Our actual results and future estimates may vary, perhaps significantly, from the current projections, as a result of changes in market conditions, management actions or other factors.

Credit Ratings

Our funding and liquidity, borrowing capacity, ability to access capital markets and other sources of funds and the cost of these funds are partially dependent on our credit ratings. Rating agencies base their ratings on numerous factors, including liquidity, capital adequacy, industry position, member support, management, asset quality, quality of earnings and the probability of systemic support. Significant changes in these factors could result in different ratings. Table 31 displays our credit ratings as of November 30, 2017, which were unchanged as of the date of the filing of this Report.

Table 31: Credit Ratings

-	November 30, 2017			
	Moody's	sS&P	Fitch	
Long-term issuer credit rating ⁽¹⁾	A2	A	A	
Senior secured debt ⁽²⁾	A1	A	A+	
Senior unsecured debt ⁽³⁾	A2	A	A	
Commercial paper	P-1	A-1	F1	
Outlook	Stable	Stable	Stable	

⁽¹⁾ Based on our senior unsecured debt rating.

⁽²⁾ Anticipated long-term loan repayments include scheduled long-term loan amortizations, repricings and sales.

⁽³⁾ Other loan repayments include anticipated short-term loan repayments.

⁽⁴⁾ Long-term debt maturities also includes medium-term notes with an original maturity of one year or less and expected early redemptions of debt.

⁽⁵⁾ Other loan advances include anticipated short-term loan advances.

⁽⁶⁾ Includes net increase or decrease to dealer commercial paper, and purchases and maturity of investments.

- (2)Applies to our collateral trust bonds.
- (3)Applies to our medium-term notes.

During the three months ended November 30, 2017, Moody's and S&P affirmed our ratings and outlook. In order to access the commercial paper markets at attractive rates, we believe we need to maintain our current commercial paper credit ratings of P-1 by Moody's, A-1 by S&P and F1 by Fitch. In addition, the notes payable to the Federal Financing Bank and guaranteed by RUS under the Guaranteed Underwriter Program contain a provision that if during any portion of the fiscal

year, our senior secured credit ratings do not have at least two of the following ratings: (i) A3 or higher from Moody's, (ii) A- or higher from S&P, (iii) A- or higher from Fitch or (iv) an equivalent rating from a successor rating agency to any of the above rating agencies, we may not make cash patronage capital distributions in excess of 5% of total patronage capital. See "Credit Risk—Counterparty Credit Risk—Credit Risk-Related Contingent Features" above for information on credit rating provisions related to our derivative contracts.

Financial Ratios

Our debt-to-equity ratio decreased to 19.87-to-1 as of November 30, 2017, from 21.94-to-1 as of May 31, 2017, primarily due to an increase in equity resulting from our reported net income of \$188 million for the six months ended November 30, 2017, which was partially offset by patronage capital retirement of \$45 million in September 2017.

Our adjusted debt-to-equity ratio increased to 6.12-to-1 as of November 30, 2017, from 5.95-to-1 as of May 31, 2017, largely due to an increase in debt outstanding to fund loan growth. We provide a reconciliation of our adjusted debt-to-equity ratio to the most comparable GAAP measure and an explanation of the adjustments below in "Non-GAAP Financial Measures."

Debt Covenants

As part of our short-term and long-term borrowing arrangements, we are subject to various financial and operational covenants. If we fail to maintain specified financial ratios, such failure could constitute a default by CFC of certain debt covenants under our committed bank revolving line of credit agreements and senior debt indentures. We were in compliance with all covenants and conditions under our committed bank revolving line of credit agreements and senior debt indentures as of November 30, 2017.

As discussed above in "Summary of Selected Financial Data," the financial covenants set forth in our committed bank revolving line of credit agreements and senior debt indentures are based on adjusted financial measures, including adjusted TIER. We provide a reconciliation of adjusted TIER and other non-GAAP measures disclosed in this Report to the most comparable GAAP measures and an explanation of the adjustments below in "Non-GAAP Financial Measures."

MARKET RISK

Interest rate risk represents our primary market risk. Interest rate risk is the risk arising from movements in interest rates that may result in differences between the timing of contractual maturities, re-pricing characteristics and prepayments on our assets and their related liabilities.

Interest Rate Risk Management

Our interest rate risk exposure is primarily related to the funding of the fixed-rate loan portfolio. Our Asset Liability Committee provides oversight over maintaining our interest rate position within a prescribed policy range using approved strategies. The Asset Liability Committee reviews a complete interest rate risk analysis, reviews proposed modifications, if any, to our interest rate risk management strategy and considers adopting strategy changes. Our Asset Liability Committee monitors interest rate risk and meets quarterly to review and discuss information such as national economic forecasts, federal funds and interest rate forecasts, interest rate gap analysis, our liquidity position, loan and debt maturities, short-term and long-term funding needs, anticipated loan demands, credit concentration risk, derivative counterparty exposure and financial forecasts. The Asset Liability Committee also discusses the composition of fixed-rate versus variable-rate lending, new funding opportunities, changes to the nature and mix of assets and liabilities for structural mismatches, and interest rate swap transactions.

Matched Funding Objective

Our funding objective is to manage the matched funding of asset and liability repricing terms within a range of adjusted total assets (calculated by excluding derivative assets from total assets) deemed appropriate by the Asset Liability Committee based on the current environment and extended outlook for interest rates. We refer to the difference between fixed-rate loans

scheduled for amortization or repricing and the fixed-rate liabilities and equity funding those loans as our interest rate gap. Our primary strategies for managing our interest rate risk include the use of derivatives and limiting the amount of fixed-rate assets that can be funded by variable-rate debt to a specified percentage of adjusted total assets based on market conditions.

We provide our members with many options on loans with regard to interest rates, the term for which the selected interest rate is in effect and the ability to convert or prepay the loan. Long-term loans generally have maturities of up to 35 years. Borrowers may select fixed interest rates for periods of one year through the life of the loan. We do not match fund the majority of our fixed-rate loans with a specific debt issuance at the time the loans are advanced. We fund the amount of fixed-rate assets that exceed fixed-rate debt and members' equity with short-term debt, primarily commercial paper.

Interest Rate Gap Analysis

To monitor and mitigate interest rate risk in the funding of fixed-rate loans, we perform a monthly interest rate gap analysis that provides a comparison between fixed-rate assets repricing or maturing by year and fixed-rate liabilities and members' equity maturing by year.

We maintain an unmatched position on our fixed-rate assets within a targeted range of adjusted total assets. The limited unmatched position is intended to provide flexibility to ensure that we are able to match the current maturing portion of long-term fixed rate loans based on maturity date and the opportunity in the current low interest rate environment to increase the gross yield on our fixed rate assets without taking what we would consider to be excessive risk.

Table 32 displays the scheduled amortization and repricing of fixed-rate assets and liabilities outstanding as of November 30, 2017. We exclude variable-rate loans from our interest rate gap analysis as we do not consider the interest rate risk on these loans to be significant because they are subject to repricing at least monthly. Loans with variable interest rates accounted for 10% and 9% of our total loan portfolio as of November 30, 2017 and May 31, 2017, respectively. Fixed-rate liabilities include debt issued at a fixed rate as well as variable-rate debt swapped to a fixed rate using interest rate swaps. Fixed-rate debt swapped to a variable rate using interest rate swaps is excluded from the analysis since it is used to match fund the variable-rate loan pool. With the exception of members' subordinated certificates, which are generally issued with extended maturities, and commercial paper, our liabilities have average maturities that closely match the repricing terms (but not the maturities) of our fixed-rate loans.

Table 32: Interest Rate Gap Analysis

(Dollars in millions)	Prior to 5/31/18	Two Years 6/1/18 to 5/31/20	Two Years 6/1/20 to 5/31/22	Five Years 6/1/22 to 5/31/27	10 Years 6/1/27 to 5/31/37	6/1/37 and Thereafter	Total
Asset amortization and repricing	\$987	\$3,409	\$2,847	\$5,551	\$6,652	\$ 2,970	\$22,416
Liabilities and members' equity:							
Long-term debt	\$1,909	\$3,687	\$2,249	\$5,331	\$4,206	\$1,298	\$18,680
Subordinated certificates	11	36	69	946	162	665	1,889
Members' equity ⁽¹⁾	_	23	24	108	297	856	1,308
Total liabilities and members' equity ⁽²⁾	\$1,920	\$3,746	\$2,342	\$6,385	\$4,665	\$ 2,819	\$21,877
Gap (3)	\$(933)	\$(337)	\$505	\$(834)	\$1,987	\$ 151	\$539
Cumulative gap	(933)	(1,270)	(765)	(1,599)	388	539	
Cumulative gap as a % of total assets	(3.61)%	(4.91)%	(2.96)%	(6.18)%	1.50 %	2.08 %	

Cumulative gap as a % of adjusted total assets⁽⁴⁾ (3.62) (4.92) (2.97) (6.20) 1.50 2.09

⁽¹⁾Includes the portion of the allowance for loan losses and subordinated deferrable debt allocated to fund fixed-rate assets and excludes noncash adjustments from the accounting for derivative financial instruments.

⁽²⁾ Debt is presented based on call date.

⁽³⁾Calculated based on the amount of assets amortizing and repricing less total liabilities and members' equity.

⁽⁴⁾ Adjusted total assets represents total assets reported in our condensed consolidated balance sheets less derivative assets.

The difference, or interest rate gap, of \$539 million between the fixed-rate loans scheduled for amortization or repricing of \$22,416 million and the fixed-rate liabilities and equity funding the loans of \$21,877 million presented in Table 32 reflects the amount of fixed-rate assets that are funded with short-term and variable-rate debt as of November 30, 2017. The gap of \$539 million represented 2.08% of total assets and 2.09% of adjusted total assets (total assets excluding derivative assets) as of November 30, 2017. As discussed above, we manage this gap within a prescribed range because funding long-term, fixed-rate loans with short-term and variable-rate debt may expose us to higher interest rate and liquidity risk.

NON-GAAP FINANCIAL MEASURES

In addition to financial measures determined in accordance with GAAP, management evaluates performance based on certain non-GAAP measures, which we refer to as "adjusted" measures. We provide a discussion of each of these non-GAAP measures in our 2017 Form 10-K under "Item 7. MD&A—Non-GAAP Measures." Below we provide a reconciliation of our adjusted measures to the most comparable GAAP measures in this section. We believe our non-GAAP adjusted metrics, which are not a substitute for GAAP and may not be consistent with similarly titled non-GAAP measures used by other companies, provide meaningful information and are useful to investors because management uses these metrics to compare operating results across financial reporting periods, for internal budgeting and forecasting purposes, for compensation decisions and for short- and long-term strategic planning decisions. In addition, certain of the financial covenants in our committed bank revolving line of credit agreements and debt indentures are based on our adjusted measures.

Statements of Operations Non-GAAP Adjustments

Table 33 provides a reconciliation of adjusted interest expense, adjusted net interest income and adjusted net income to the comparable GAAP measures three and six months ended November 30, 2017 and 2016. The adjusted amounts are used in the calculation of our adjusted net interest yield and adjusted TIER.

Table 33: Adjusted Financial Measures — Income Statement						
	Three Mont	hs Ended	Six Months Ended			
	November 3	30,	November 30,			
(Dollars in thousands)	2017	2016	2017	2016		
Interest expense	\$(195,170)	\$(183,654)	\$(387,901)	\$(364,734)		
Include: Derivative cash settlements	(19,635)	(21,587)	(39,857)	(44,977)		
Adjusted interest expense	\$(214,805)	\$(205,241)	\$(427,758)	\$(409,711)		
Net interest income	\$70,653	\$73,502	\$143,837	\$149,257		
Include: Derivative cash settlements	(19,635)	(21,587)	(39,857)	(44,977)		
Adjusted net interest income	\$51,018	\$51,915	\$103,980	\$104,280		
Net income	\$178,723	\$395,304	\$187,738	\$263,043		
Exclude: Derivative forward value gains	145,228	362,247	119,252	197,344		
Adjusted net income	\$33,495	\$33,057	\$68,486	\$65,699		

We consider the cost of derivatives to be an inherent cost of funding and hedging our loan portfolio and, therefore, economically similar to the interest expense that we recognize on debt issued for funding. We therefore include derivative cash settlements in our adjusted interest expense and exclude the unrealized forward value of derivatives from our adjusted net income.

TIER and Adjusted TIER

TIER (1)

Table 34 presents our TIER and adjusted TIER for the three and six months ended November 30, 2017 and 2016.

Table 34: TIER and Adjusted TIER

Three	;	Six				
Mont	hs	Months				
Ende	d	Ende	d			
November		November				
30,		30,				
2017	2016	2017	2016			
1.92	3.15	1.48	1.72			

Adjusted TIER (2) 1.16 1.16 1.16 1.16

Debt-to-Equity and Adjusted Debt-to-Equity

Table 35 provides a reconciliation between the liabilities and equity used to calculate the debt-to-equity and the adjusted debt-to-equity ratios as of November 30, 2017 and May 31, 2017. As indicated in the table below, subordinated debt is treated in the same manner as equity in calculating our adjusted-debt-to-equity ratio.

Table 35: Adjusted Financial Measures — Balance Sheet

(Dollars in thousands)	November 30, 2017	May 31, 201	7
Total liabilities	\$24,640,195	\$24,106,887	
Exclude:			
Derivative liabilities	304,307	385,337	
Debt used to fund loans guaranteed by RUS	164,172	167,395	
Subordinated deferrable debt	742,341	742,274	
Subordinated certificates	1,399,675	1,419,025	
Adjusted total liabilities	\$22,029,700	\$21,392,856	
Total equity	\$1,240,048	\$1,098,805	
Include:			
Subordinated deferrable debt	742,341	742,274	
Subordinated certificates	1,399,675	1,419,025	
Total subordinated debt and certificates	2,142,016	2,161,299	
Exclude:			
Prior year-end cumulative derivative forward value losses	(340,976)	(520,357)
Current year derivative forward value gains	119,252	179,381	
Total cumulative derivative forward value losses	(221,724)	(340,976)
Accumulated other comprehensive income (1)	3,316	3,702	
Adjusted total equity	\$3,600,472	\$3,597,378	

⁽¹⁾ TIER is calculated based on net income plus interest expense for the period divided by interest expense for the period.

⁽²⁾ Adjusted TIER is calculated based on adjusted net income plus adjusted interest expense for the period divided by adjusted interest expense for the period.

(1) Represents the AOCI related to derivatives. See "Note 9—Equity" for a breakout of our AOCI components.

Table 36 displays the calculations of our debt-to-equity and adjusted debt-to-equity ratios as of November 30, 2017 and May 31, 2017.

Table 36: Debt-to-Equity Ratio

 $\begin{array}{ccc} & \text{November 30, May 31,} \\ 2017 & 2017 \\ \text{Debt-to-equity ratio} \, ^{(1)} & 19.87 & 21.94 \\ \text{Adjusted debt-to-equity ratio} \, ^{(2)} & 6.12 & 5.95 \\ \end{array}$

⁽¹⁾ Calculated based on total liabilities as of the end of the period divided by total equity as of the end of the period.

⁽²⁾ Calculated based on adjusted total liabilities at period end divided by adjusted total equity at period end.

Item 1. Financial Statements

	Page
Condensed Consolidated Statements of Operations	<u>45</u>
Condensed Consolidated Statements of Comprehensive Income	<u>46</u>
Condensed Consolidated Balance Sheets	<u>47</u>
Condensed Consolidated Statements of Changes in Equity	<u>48</u>
Condensed Consolidated Statements of Cash Flows	<u>49</u>
Notes to Condensed Consolidated Financial Statements	<u>50</u>
Note 1 — Summary of Significant Accounting Policies	<u>50</u>
Note 2 — Variable Interest Entities	<u>54</u>
Note 3 — Investment Securities	<u>55</u>
Note 4 — Loans and Commitments	<u>58</u>
Note 5 — Short-Term Borrowings	<u>67</u>
Note 6 — Long-Term Debt	<u>69</u>
Note 7 — Subordinated Deferrable Debt	<u>70</u>
Note 8 — Derivative Instruments and Hedging Activities	<u>70</u>
Note 9 — Equity	<u>73</u>
Note 10 — Guarantees	<u>76</u>
Note 11 — Fair Value Measurement	<u>77</u>
Note 12 — Business Segments	<u>80</u>

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Mon	ths Ended	Six Months Ended		
	November	30,	November 30,		
(Dollars in thousands)	2017	2016	2017	2016	
Interest income	\$265,823	\$257,156	\$531,738	\$513,991	
Interest expense	(195,170)	(183,654)	(387,901)	(364,734)	
Net interest income	70,653	73,502	143,837	149,257	
Benefit (provision) for loan losses	304	(738)	602	(2,666)	
Net interest income after benefit (provision) for loan losses	70,957	72,764	144,439	146,591	
Non-interest income:					
Fee and other income	5,542	5,097	9,487	9,627	
Derivative gains	125,593	340,660	79,395	152,367	
Results of operations of foreclosed assets	(10)	(549)	(34)	(1,661)	
Total non-interest income	131,125	345,208	88,848	160,333	
Non-interest expense:					
Salaries and employee benefits	(12,009)	(11,451)	(23,832)	(22,875)	
Other general and administrative expenses	(9,905)	(9,181)	(19,718)	(18,616)	
Other non-interest expense	(618)	(517)	(1,140)	(960)	
Total non-interest expense	(22,532)	(21,149)	(44,690)	(42,451)	
Income before income taxes	179,550	396,823	188,597	264,473	
Income tax expense	(827)	(1,519)	(859)	(1,430)	
Net income	178,723	395,304	187,738	263,043	
Less: Net income attributable to noncontrolling interests	(1,150)	(2,575)	(1,032)	(1,885)	
Net income attributable to CFC	\$177,573	\$392,729	\$186,706	\$261,158	

See accompanying notes to condensed consolidated financial statements.

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

	Three Mor	nths Ended	Six Months Ended		
	November	30,	November	30,	
(Dollars in thousands)	2017	2016	2017	2016	
Net income	\$178,723	\$395,304	\$187,738	\$263,043	
Other comprehensive income (loss):					
Unrealized gains (losses) on available-for-sale investment securities	8	(1,761) (1,143	(1,772)	
Reclassification of losses on foreclosed assets to net income	_	_		9,823	
Reclassification of derivative gains to net income	(194)	(199) (386	(396)	
Defined benefit plan adjustments	126	44	253	88	
Other comprehensive income (loss)	(60	(1,916) (1,276	7,743	
Total comprehensive income	178,663	393,388	186,462	270,786	
Less: Total comprehensive income attributable to noncontrolling interests	(1,150	(2,575) (1,032	(1,885)	
Total comprehensive income attributable to CFC	\$177,513	\$390,813	\$185,430	\$268,901	

See accompanying notes to condensed consolidated financial statements.

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(Dollars in thousands)	November 30, 2017	May 31, 2017
Assets:		
Cash and cash equivalents	\$280,315	\$166,615
Restricted cash	11,323	21,806
Time deposits	51,000	226,000
Investment securities:		
Available for sale, at fair value	91,411	92,554
Held to maturity, at amortized cost	248,155	_
Total investment securities	339,566	92,554
Loans to members	24,824,691	24,367,044
Less: Allowance for loan losses	(36,774)	(37,376)
Loans to members, net	24,787,917	24,329,668
Accrued interest receivable	116,770	111,493
Other receivables	38,410	45,469
Fixed assets, net	125,444	122,260
Derivative assets	87,453	49,481
Other assets	42,045	40,346
Total assets	\$25,880,243	\$25,205,692
Liabilities:		
Accrued interest payable	\$143,085	\$137,476
Debt outstanding:		
Short-term borrowings	3,557,192	3,342,900
Long-term debt	18,386,819	17,955,594
Subordinated deferrable debt	742,341	742,274
Members' subordinated certificates:	·	·
Membership subordinated certificates	630,391	630,098
Loan and guarantee subordinated certificates	548,187	567,830
Member capital securities	221,097	221,097
Total members' subordinated certificates	1,399,675	1,419,025
Total debt outstanding	24,086,027	23,459,793
Deferred income	67,690	73,972
Derivative liabilities	304,307	385,337
Other liabilities	39,086	50,309
Total liabilities	24,640,195	24,106,887
	,,	, ,
Commitments and contingencies		
-		
Equity:		
CFC equity:		
Retained equity	1,197,730	1,056,778

Accumulated other comprehensive income	11,899	13,175
Total CFC equity	1,209,629	1,069,953
Noncontrolling interests	30,419	28,852
Total equity	1,240,048	1,098,805
Total liabilities and equity	\$25,880,243	\$25,205,692

See accompanying notes to condensed consolidated financial statements.

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

(Dollars in thousands)	Member Fees and Education Fund	Patronage Capital Capital	Capıtal	Unallocated Net Income (Loss)	CFC Retained Equity	Accumula Other Comprehe Income	CEC	Non-con Interests	•	
Balance as of	\$2,900	\$761,701	\$630,305	\$(338,128)	\$1,056,778	\$13,175	\$1,069,953	\$28,852	\$1,098,805	5
May 31, 2017 Net income	_	_		186,706	186,706		186,706	1,032	187,738	
Other						(1 2 - ()	(4. 0.		4.05	
comprehensive loss	_	_	_	_	_	(1,276)	(1,276)		(1,276)
Patronage										
capital retirement	_	(45,220)	_	_	(45,220)	_	(45,220)		(45,220)
Other	(534)	_	_	_	(534)	_	(534)	535	1	
Balance as of	\$2.266	Ф 7 1 <i>С</i> 401	Φ.C20, 20 <i>5</i>	¢ (151 422)	¢1 107 720	¢11.000	¢1 200 (20	¢20.410	¢1 240 046)
November 30, 2017	\$2,366	\$716,481	\$630,303	\$(131,422)	\$1,197,730	\$11,899	\$1,209,629	\$30,419	\$1,240,048	,
Balance as of May 31, 2016	\$2,772	\$713,853	\$587,219	\$(513,610)	\$790,234	\$1,058	\$791,292	\$26,086	\$817,378	
Net income	_	_	_	261,158	261,158	_	261,158	1,885	263,043	
Other comprehensive income	_	_	_	_	_	7,743	7,743	_	7,743	
Patronage capital retirement	_	(42,129)	_	_	(42,129)	_	(42,129		(42,129)
Other	(578)	_	_	_	(578)	_	(578)	620	42	
Balance as of November 30, 2016	\$2,194	\$671,724	\$587,219	\$(252,452)	\$1,008,685	\$8,801	\$1,017,486	\$28,591	\$1,046,077	7

See accompanying notes to condensed consolidated financial statements.

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Six Months Ended	
	November	30,
(Dollars in thousands)	2017	2016
Cash flows from operating activities:		
Net income	\$187,738	\$263,043
Adjustments to reconcile net income to net cash provided by operating activities:		
Amortization of deferred loan fees	(6,149)	(6,024)
Amortization of debt issuance costs and deferred charges	5,148	4,619
Amortization of discount on long-term debt	4,943	4,666
Amortization of issuance costs for bank revolving bank line of credit	2,768	2,925
Depreciation and amortization of fixed assets	3,769	3,578
Provision (benefit) for loan losses	(602)	2,666
Results of operations of foreclosed assets	_	1,661
Derivative forward value gains	(119,252)	(197,344)
Changes in operating assets and liabilities:		
Accrued interest receivable	(5,277)	520
Accrued interest payable	5,609	2,559
Deferred income	(133	1,784
Other	(7,589)	(5,711)
Net cash provided by operating activities	70,973	78,942
Cash flows from investing activities:		
Advances on loans	(4,185,985	(3,925,089
Principal collections on loans		3,295,412
Net investment in fixed assets		(11,294)
Net cash proceeds from sale of foreclosed assets		47,094
Proceeds from foreclosed assets		4,036
Net proceeds from (investments in) time deposits	175,000	(300,000)
Purchases of held-to-maturity investments	(248,181)	
Change in restricted cash		(17,644)
Net cash used in investing activities	•	(907,485)
Cash flows from financing activities:		
Proceeds from short-term borrowings, net	181,501	750,466
Proceeds from short-term borrowings, net Proceeds from short-term borrowings with original maturity greater than 90 days	570,060	443,960
Repayments of short term-debt with original maturity greater than 90 days		(469,314)
Payments for issuance costs for revolving bank lines of credit	, , ,	(2,478)
Proceeds from issuance of long-term debt, net of issuance costs	625,021	690,277
Payments for retirement of long-term debt		(555,874)
Payments for issuance costs for subordinated deferrable debt	(203,019)	(68)
Proceeds from issuance of members' subordinated certificates	3,989	1,660
Payments for retirement of members' subordinated certificates	-	
·		(3,020) (41,510)
Payments for retirement of patronage capital	(44,667)	(41,510)

Net cash provided by financing activities	569,074	814,099
Net increase (decrease) in cash and cash equivalents	113,700	(14,444)
Beginning cash and cash equivalents	166,615	204,540
Ending cash and cash equivalents	\$280,315	\$190,096
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$374,098	\$349,965
Cash paid for income taxes	152	383

See accompanying notes to condensed consolidated financial statements.

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company

National Rural Utilities Cooperative Finance Corporation ("CFC") is a member-owned cooperative association incorporated under the laws of the District of Columbia in April 1969. CFC's principal purpose is to provide its members with financing to supplement the loan programs of the Rural Utilities Service ("RUS") of the United States Department of Agriculture ("USDA"). CFC makes loans to its rural electric members so they can acquire, construct and operate electric distribution, generation, transmission and related facilities. CFC also provides its members with credit enhancements in the form of letters of credit and guarantees of debt obligations. As a cooperative, CFC is owned by and exclusively serves its membership, which consists of not-for-profit entities or subsidiaries or affiliates of not-for-profit entities. CFC is exempt from federal income taxes.

Basis of Presentation and Use of Estimates

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and should be read in conjunction with the audited consolidated financial statements, and related notes thereto, included in CFC's Annual Report on Form 10-K for the fiscal year ended May 31, 2017 ("2017 Form 10-K"). We believe that all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and related disclosures. While management makes its best judgment, actual amounts or results could differ from these estimates. Our most significant estimates and assumptions involve determining the allowance for loan losses and the fair value of financial assets and liabilities. The results of operations in the interim financial statements is not necessarily indicative of the results that may be expected for other interim periods or for the full fiscal year ending May 31, 2018.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of CFC, variable interest entities ("VIEs") where CFC is the primary beneficiary and subsidiary entities created and controlled by CFC to hold foreclosed assets. CFC did not have any entities that held foreclosed assets as of November 30, 2017 or May 31, 2017. All intercompany balances and transactions have been eliminated. National Cooperative Services Corporation ("NCSC") and Rural Telephone Finance Cooperative ("RTFC") are VIEs which are required to be consolidated by CFC. NCSC is a taxable member-owned cooperative that may provide financing to members of CFC, government or quasi-government entities which own electric utility systems that meet the Rural Electrification Act definition of "rural", and for-profit and nonprofit entities that are owned, operated or controlled by, or provide significant benefits to certain members of CFC. RTFC is a taxable Subchapter T cooperative association that provides financing for its rural telecommunications members and their affiliates. Unless stated otherwise, references to "we," "our" or "us" relate to CFC and its consolidated entities.

Restricted Cash

Restricted cash, which totaled \$11 million and \$22 million as of November 30, 2017 and May 31, 2017, respectively, consisted primarily of funds held in escrow. On July 1, 2016, CFC completed the sale of Caribbean Asset Holdings, LLC ("CAH"), an entity that held foreclosed assets, to ATN VI Holdings, LLC. In connection with the sale, \$16 million of the sale proceeds was deposited into escrow to fund potential indemnification claims for a period of 15 months following the closing. On September 27, 2017, we received a claim notice from the purchaser of CAH asserting potential indemnification claims and seeking funding from the escrow. On November 10, 2017, funds held in escrow totaling \$13 million were released to CFC. The remaining \$3 million remains in escrow for claims under evaluation for indemnification.

Interest Income

The following table presents interest income, by interest-earning asset category, for the three and six months ended November 30, 2017 and 2016.

	Three Months Ended		Six Month	s Ended
	November	30,	November	30,
(Dollars in thousands)	2017	2016	2017	2016
Interest income by interest-earning asset type:				
Long-term fixed-rate loans ⁽¹⁾	\$248,926	\$243,817	\$498,290	\$487,945
Long-term variable-rate loans	6,097	4,987	11,960	9,514
Line of credit loans	8,588	5,553	17,295	11,519
TDR loans ⁽²⁾	222	231	448	449
Other income, net ⁽³⁾	(306)	(281)	(538)	(565)
Total loans	263,527	254,307	527,455	508,862
Cash, time deposits and investment securities	2,296	2,849	4,283	5,129
Total interest income	\$265,823	\$257,156	\$531,738	\$513,991

⁽¹⁾Includes loan conversion fees, which are generally deferred and recognized as interest income using the effective interest method.

Deferred income of \$68 million and \$74 million as of November 30, 2017 and May 31, 2017, respectively, consists primarily of deferred loan conversion fees totaling \$63 million and \$68 million, respectively.

Interest Expense

The following table presents interest expense, by debt product type, for the three and six months ended November 30, 2017 and 2016.

	Three Months Ended November 30,		Six Months Ended November 30,	
(Dollars in thousands)	2017	2016	2017	2016
Interest expense by debt product type:(1)(2)				
Short-term borrowings	\$10,116	\$5,409	\$20,655	\$10,291
Medium-term notes	27,544	24,705	52,660	48,290
Collateral trust bonds	85,321	84,951	170,598	170,000
Guaranteed Underwriter Program notes payable	35,688	36,216	71,290	71,988
Farmer Mac notes payable	11,947	7,587	23,437	14,486
Other notes payable	391	458	781	916
Subordinated deferrable debt	9,417	9,411	18,833	18,837
Subordinated certificates	14,746	14,917	29,647	29,926

⁽²⁾Troubled debt restructuring ("TDR") loans.

⁽³⁾Consists of late payment fees and net amortization of deferred loan fees and loan origination costs.

Total interest expense

\$195,170 \$183,654 \$387,901 \$364,734

⁽¹⁾ Includes amortization of debt discounts and debt issuance costs, which are generally deferred and recognized as interest expense using the effective interest method. Issuance costs related to dealer commercial paper, however, are recognized as interest expense immediately as incurred.

(2) Includes fees related to funding arrangements, such as up-front fees paid to banks participating in our committed bank revolving line of credit agreements. Depending on the nature of the fee, amounts may be deferred and recognized as interest expense ratably over the term of the arrangement or recognized immediately as incurred.

Recently Issued But Not Yet Adopted Accounting Standards and Tax Reform

Tax Cuts and Jobs Act

On December 22, 2017, the President of the United States signed and enacted into law H.R. 1, the Tax Cuts and Jobs Act ("The Act"), which, except for certain provisions, is effective for tax years beginning on or after January 1, 2018. The Act significantly changes existing U.S. tax law and includes numerous provisions that will affect businesses. One of the primary changes is a reduction in the federal statutory corporate U.S. income tax rate to 21% percent from 35% and other changes that impact business-related exclusions, deductions and credits. CFC is exempt from federal income tax under Section 501(c)(4) of the Internal Revenue Code. NCSC is subject to federal income tax; however, NCSC's annual taxable income and federal income tax is not material to our consolidated results of operations, financial position or liquidity. RTFC is subject to federal income tax; however, the allocation of patronage capital to its members is a deduction that historically has resulted in a significant reduction in its annual taxable income and federal income tax. Therefore, we do not expect The Act to have a material impact on our consolidated results of operations, financial condition or liquidity.

Derivatives and Hedging—Targeted Improvements to Accounting for Hedging Activities

In August 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-12, Derivatives and Hedging—Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity's risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting, reduce complexity in fair value hedges of interest rate risk and eases certain documentation and assessment requirements of hedge effectiveness. It also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The guidance is effective for us beginning June 1, 2019. We currently do not apply hedge accounting. If we continue to not apply hedge accounting to our derivatives, the adoption of the new guidance will have no impact on our consolidated financial statements.

Receivables—Nonrefundable Fees and Other Cost

In March 2017, FASB issued ASU 2017-08, Receivables—Nonrefundable Fees and Other Costs, which shortens the amortization period for the premium on certain purchased callable debt securities, that have a set call date and price, to the earliest call date. The guidance is effective for public entities in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. This update is effective for us beginning June 1, 2019. The adoption of this guidance will change the amortization period to the earliest call date for our purchased callable debt securities held at a premium; however, we do not expect that the adoption of this guidance will have a material impact on our consolidated financial statements.

Statement of Cash Flows—Restricted Cash

In November 2016, FASB issued ASU 2016-18, Statement of Cash Flows—Restricted Cash, which requires that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The guidance is effective for public entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. This update is effective for us beginning June

1, 2018. The adoption of this guidance will change the presentation of restricted cash presented on our statement of cash flows; however, it will have no impact on our consolidated results of operations, financial condition or liquidity.

Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, which changes the accounting for credit losses on certain financial assets to an expected loss model from the incurred loss model currently in use. The new guidance will likely result in earlier recognition of credit losses based on measuring the expected credit losses over the estimated life of financial assets held at each reporting date. The expected loss model will be the basis for determining the allowance for credit losses for loans and leases, unfunded lending commitments, held-to-maturity debt securities and other debt instruments measured at amortized cost. In addition, the new guidance modifies the other-than-temporary impairment model for available-for-sale debt securities to require the recognition of credit losses through a valuation allowance, which allows for the reversal of credit impairments in future periods. The ASU will also require enhanced disclosures to help users of financial statements better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. The new standard is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2019. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This update is effective for us beginning June 1, 2020. Upon adoption, we will be required to record a cumulative-effect adjustment to retained earnings. The impact on our consolidated financial statements from the adoption of this new guidance will depend on the composition and risk profile of our loan portfolio as of the date of adoption. We do not expect to early adopt this guidance.

Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities

In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of the recognition, measurement, presentation and disclosure of certain financial instruments, including equity investments and liabilities measured at fair value under the fair value option. The guidance also updates fair value presentation and disclosure requirements for financial instruments measured at amortized cost. The ASU requires investments in equity securities that do not result in consolidation and are not accounted for under the equity method to be measured at fair value with changes in the fair value recognized through net income, unless one of two available exceptions apply. For financial liabilities where the fair value option has been elected, the portion of the total change in fair value caused by changes in the company's own credit risk is required to be presented separately in OCI. The classification and measurement guidance is effective for public entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. This update will be effective for us beginning June 1, 2018. Upon adoption, we will be required to reclassify the gain (loss) related to our equity investment securities classified as available-for-sale from accumulated other comprehensive income ("AOCI") to retained earnings as a cumulative-effect adjustment and begin recording future changes in fair value through earnings. We had a gain of \$11 million recorded in AOCI for our available-for-sale equity investments as of November 30, 2017. The impact on our consolidated financial statements at adoption will depend on the net unrealized gains (losses) recorded in AOCI for these equity investments as of the date of adoption.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which modifies the guidance used to recognize revenue from contracts with customers for transfers of goods or services and transfers of nonfinancial assets, unless those contracts are within the scope of other guidance. The new guidance is effective for us beginning June 1, 2018. Because the scope of the guidance explicitly excludes net interest income as well as many other revenues for financial assets and liabilities including loans, securities, and derivatives, which account for the substantial majority of our revenues, we do not expect that the adoption of the guidance will have a material impact, if any, on our consolidated financial statements.

NOTE 2—VARIABLE INTEREST ENTITIES

NCSC and RTFC meet the definition of a VIE because they do not have sufficient equity investment at risk to finance their activities without financial support. CFC is the primary source of funding for NCSC and the sole source of funding for RTFC. Under the terms of management agreements, CFC manages the business operations of NCSC and RTFC. CFC also unconditionally guarantees full indemnification for any loan losses of NCSC and RTFC pursuant to guarantee agreements with each company. CFC earns management and guarantee fees from its agreements with NCSC and RTFC.

NCSC and RTFC creditors have no recourse against CFC in the event of a default by NCSC and RTFC, unless there is a guarantee agreement under which CFC has guaranteed NCSC or RTFC debt obligations to a third party. The following table provides information on incremental consolidated assets and liabilities of VIE's included in CFC's condensed consolidated financial statements, after applying intercompany eliminations, as of November 30, 2017 and May 31, 2017.

(Dollars in thousands)	November 30, 2017	May 31, 2017
Total loans outstanding	\$1,111,438	\$968,343
Other assets	10,477	10,157
Total assets	\$1,121,915	\$978,500
Long-term debt	\$10,000	\$10,000
Other liabilities	38,202	36,899
Total liabilities	\$48,202	\$46,899

The following table provides information on CFC's credit commitments to NCSC and RTFC, and its potential exposure to loss as of November 30, 2017 and May 31, 2017.

(De	ollars in thousands)	November 30, 2017	May 31, 2017
CF	C credit commitments	\$5,500,000	\$5,500,000
Ou	tstanding commitments:		
Bo	rrowings payable to CFC ⁽¹⁾	1,075,319	931,686
CF	C third-party guarantees	16,801	14,697
Otl	ner credit enhancements	19,052	20,963
To	tal credit enhancements	35,853	35,660
To	tal outstanding commitments	1,111,172	967,346
CF	C available credit commitments	\$4,388,828	\$4,532,654

⁽¹⁾ Borrowings payable to CFC are eliminated in consolidation.

CFC loans to NCSC and RTFC are secured by all assets and revenues of NCSC and RTFC. CFC's maximum potential exposure for the credit enhancements totaled \$39 million. The maturities for obligations guaranteed by CFC extend

NOTE 3—INVESTMENT SECURITIES

We record purchases and sales of securities on a trade-date basis. The accounting and measurement framework for investment securities differs depending on the security classification. We currently classify and account for our investment securities as either available for sale ("AFS") or held to maturity ("HTM") based on our investment strategy and management's assessment of our intent and ability to hold the securities until maturity. Securities that we may sell prior to maturity in response to changes in our investment strategy, liquidity needs, credit risk mitigating considerations, market risk profile or for other reasons are classified as AFS. Securities that we have the positive intent and ability to hold until maturity are classified as HTM.

We report securities classified as AFS on our condensed consolidated balance sheets at fair value with unrealized gains or losses recorded as a component of accumulated other comprehensive income ("AOCI"). We report securities classified as HTM on our condensed consolidated balance sheets at amortized cost. Interest income on fixed-income securities, including amortization of premiums and accretion of discounts, is generally recognized over the contractual life of the securities based on the effective yield method.

We did not have any securities classified as HTM as of May 31, 2017. During the second quarter of fiscal year 2018, we commenced the purchase of additional investment securities, consisting primarily of certificates of deposit, commercial paper, corporate debt securities, commercial mortgage-backed securities ("MBS") and other asset-backed securities ("ABS"). We have the positive intent and ability to hold these securities to maturity. As such, we have classified them as held to maturity on our condensed consolidated balance sheet.

Pursuant to our investment policy guidelines, all fixed-income securities, at the time of purchase, must be rated at least investment grade based on external credit ratings, when available, or the corresponding equivalent, when not available. Securities rated investment grade, that is those rated Baa3 or higher by Moody's Investors Service ("Moody's") or BBB- or higher by S&P Global Ratings ("S&P"), are generally considered by the rating agencies to be of lower credit risk than non-investment grade securities.

Amortized Cost and Fair Value of Investment Securities

The following tables present the amortized cost and fair value our investment securities and the corresponding gross unrealized gains and losses, by classification category and major security type, as of November 30, 2017 and May 31, 2017.

	November 30, 2017			
(Dollars in thousands)	Amortized Cost	dGross Unrealized Gains	Gross Unrealized Losses	Fair Value
Available for sale:				
Farmer Mac—Series A Non-Cumulative Preferred Stoc	k\$30,000	\$ 1,032	\$ —	\$31,032
Farmer Mac—Series B Non-Cumulative Preferred Stoc	k25,000	1,924		26,924
Farmer Mac—Series C Non-Cumulative Preferred Stoc	k25,000	2,750		27,750
Farmer Mac—Class A Common Stock	538	5,167		5,705
Total investment securities, available-for-sale	80,538	10,873		91,411
Held to maturity:				
Certificates of deposit	4,146	1	(1)	4,146
Commercial paper	7,196	1	(1)	7,196
Corporate bonds	210,099	5	(872)	209,232
Commercial MBS, non-agency	4,041	_	(3)	4,038
Other ABS ⁽¹⁾	22,673		(28)	22,645
Total investment securities, held-to-maturity	248,155	7	(905)	247,257
Total investment securities	\$328,693	\$ 10,880	\$ (905)	\$338,668

⁽¹⁾Consists primarily of securities backed by auto lease loans, equipment-backed loans, auto loans and credit card loans.

	May 31,		_	
(Dollars in thousands)	Amortize Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Available for sale:				
Farmer Mac—Series A Non-Cumulative Preferred Stoc		\$ 1,585	\$ -	-\$31,585
Farmer Mac—Series B Non-Cumulative Preferred Stoc	k25,000	1,940	_	26,940
Farmer Mac—Series C Non-Cumulative Preferred Stock	k25,000	4,150		29,150
Farmer Mac—Class A Common Stock	538	4,341		4,879
Total investment securities, available-for-sale	\$80,538	\$ 12,016	\$ -	-\$92,554

For additional information on the unrealized gains (losses) losses recorded on our available-for-sale investment securities, see "Note 9—Equity—Accumulated Other Comprehensive Income."

Investment Securities in Gross Unrealized Loss Position

An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. The following table presents the fair value and gross unrealized losses for investments in a gross loss position, aggregated by security type, and the length of time the securities have been in a continuous unrealized loss position as of

November 30, 2017. The securities are segregated between investments that have been in a continuous unrealized loss position for less than twelve months and twelve months or more based on the point in time that the fair value declined below the amortized cost basis. We did not have any investment securities in a gross unrealized loss position as of May 31, 2017.

	Unrealize	r 30, 2017 d Loss Less than 12	2	Positi	lized Loss on 12 as or Longer	Total		
(Dollars in thousands)	Fair Value	Gross Unrealized Losses	1	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealiz Losses	ed
Held to maturity:								
Certificates of deposit	\$1,898	\$ (1)	\$ —	-\$ —	-\$1,898	\$ (1)
Commercial paper	5,594	(1)	_	_	5,594	(1)
Corporate bonds	200,170	(872)			200,170	(872)
Commercial MBS, non-agency	4,038	(3)	_	_	4,038	(3)
Other asset-backed securities ⁽¹⁾	22,645	(28)	_	_	22,645	(28)
Total	\$234,345	\$ (905)	\$ —	-\$ —	-\$234,345	\$ (905)

⁽¹⁾Consists primarily of securities backed by auto lease loans, equipment-backed loans, auto loans and credit card loans.

Other-Than-Temporary Impairment

We conduct periodic reviews of all securities with unrealized losses to evaluate whether the impairment is other than temporary. The number of individual securities in an unrealized loss position was 170 as of November 30, 2017. We have assessed each security with gross unrealized losses included in the above table for credit impairment. As part of that assessment, we concluded that the unrealized losses are primarily driven by changes in market interest rates rather than by adverse changes in the credit quality of these securities. Based on our assessment, we expect to recover the entire amortized cost basis of these securities, as we do not intend to sell any of the securities and believe that it is more likely than not that we will not be required to sell prior to recovery of the amortized cost basis. Accordingly, we currently consider the impairment of these securities to be temporary.

Contractual Maturity and Yield

The following table presents, by major security type, the remaining contractual maturity based on amortized cost and fair value as of November 30, 2017 of our HTM investment securities. Because borrowers may have the right to call or prepay certain obligations, the expected maturities of our investments may differ from the scheduled contractual maturities presented below.

	November	30, 2017			
(Dollars in thousands)	Due in 1 Year or Less	Due > 1 Year through 5 Years	Due > 5 Years through 10 Years	Due >10 Years	Total
Amortized cost:					
Certificates of deposit	\$4,146	\$ —	\$ —	\$ —	\$4,146
Commercial paper	7,196		_		7,196
Corporate bonds		193,477	16,622		210,099
Commercial MBS, non-agency			_	4,041	4,041
Other asset-backed securities ⁽¹⁾	_	20,681	1,992		22,673
Total	\$11,342	\$214,158	\$18,614	\$4,041	\$248,155
Fair value:					
Certificates of deposit	\$4,146	¢	\$ —	\$ —	\$4,146
Commercial paper	7,196	ψ—	φ—	φ—	7,196
Corporate bonds	7,190	— 192,677	<u> </u>		209,232
Commercial MBS, non-agency		172,077		4,038	4,038
Other ABS ⁽¹⁾		20,653	1,992	- -,030	22,645
Total	\$11,342	\$213,330	\$18,547	\$4,038	\$247,257
	. ,	, - ,	,-	. ,	,
Weighted average coupon ⁽²⁾	0.60 %	2.68 %	2.95 %	2.20 %	2.60 %

⁽¹⁾Consists primarily of securities backed by auto lease loans, equipment-backed loans, auto loans and credit card loans.

The average contractual maturity and weighted average coupon of our HTM investment securities was four years and 2.60%, respectively, as of November 30, 2017. The average credit rating of these securities, based on their lowest credit rating by Moody's and S&P was A3 and A-, respectively, as of November 30, 2017.

Realized Gains and Losses

We have not sold any of our investment securities during the three and six months ended November 30, 2017 and 2016, and therefore have not recorded any realized gains or losses.

NOTE 4—LOANS AND COMMITMENTS

Loans, which are classified as held for investment, are carried at the outstanding unpaid principal balance net of unamortized loan origination costs. The following table presents loans outstanding, by loan type and by member class, as of November 30, 2017 and May 31, 2017.

⁽²⁾Calculated based on the weighted average coupon rate, which excludes the impact of amortization of premium and accretion of discount.

	November 30	0, 2017	May 31, 2017		
(Dollars in thousands)	Loans	Unadvanced	Loans	Unadvanced	
	Outstanding	Commitments ⁽¹⁾	Outstanding	Commitments ⁽¹⁾	
Loan type:					
Long-term loans:					
Fixed rate	\$22,415,833	\$ <i>—</i>	\$22,136,690	\$ —	
Variable rate	906,453	4,950,905	847,419	4,802,319	
Total long-term loans	23,322,286	4,950,905	22,984,109	4,802,319	
Lines of credit	1,491,256	7,575,116	1,372,221	7,772,655	
Total loans outstanding	24,813,542	12,526,021	24,356,330	12,574,974	
Deferred loan origination costs	11,149	_	10,714	_	
Loans to members	\$24,824,691	\$ 12,526,021	\$24,367,044	\$ 12,574,974	
Member class:					
CFC:					
Distribution	\$19,230,740	\$ 8,098,698	\$18,825,366	\$ 8,295,146	
Power supply	4,414,257	3,412,557	4,504,791	3,276,113	
Statewide and associate	57,107	127,622	57,830	144,406	
Total CFC	23,702,104	11,638,877	23,387,987	11,715,665	
NCSC	739,707	591,119	613,924	584,944	
RTFC	371,731	296,025	354,419	274,365	
Total loans outstanding	24,813,542	12,526,021	24,356,330	12,574,974	
Deferred loan origination costs	11,149	_	10,714	_	
Loans to members	\$24,824,691	\$ 12,526,021	\$24,367,044	\$ 12,574,974	

⁽¹⁾The interest rate on unadvanced loan commitments is not set until an advance is made; therefore, all long-term unadvanced loan commitments are reported as variable-rate. However, the borrower may select either a fixed or a variable rate when an advance on a commitment is made.

Unadvanced Loan Commitments

Unadvanced loan commitments represent approved and executed loan contracts for which funds have not been advanced to borrowers. The following table summarizes the available balance under unadvanced loan commitments as of November 30, 2017 and the related maturities by fiscal year and thereafter by loan type:

	Available	Notional Maturities of Unadvanced Loan Commitments						
(Dollars in thousands)	Balance	2018	2019	2020	2021	2022	Thereafter	
Line of credit loans	\$7,575,116	\$342,159	\$4,343,222	\$641,613	\$950,998	\$773,772	\$523,352	
Long-term loans	4,950,905	215,806	986,952	649,436	676,899	1,885,338	536,474	
Total	\$12,526,021	\$557,965	\$5,330,174	\$1,291,049	\$1,627,897	\$2,659,110	\$1,059,826	

Unadvanced line of credit commitments accounted for 60% of total unadvanced loan commitments as of November 30, 2017, while unadvanced long-term loan commitments accounted for 40% of total unadvanced loan commitments. Unadvanced line of credit commitments are typically revolving facilities for periods not to exceed five

line of credit commitments generally serve as supplemental back-up liquidity to our borrowers. Historically, borrowers have not drawn the full commitment amount for line of credit facilities, and we have experienced a very low utilization rate on line of credit loan facilities regardless of whether or not we are obligated to fund the facility where a material adverse change exists. Our unadvanced long-term loan commitments have a five-year draw period under which a borrower may advance funds prior to the expiration of the commitment. We expect that the majority of the long-term unadvanced loan commitments of \$4,951 million will be advanced prior to the expiration of the commitment.

Because we historically have experienced a very low utilization rate on line of credit loan facilities, which account for the majority of our total unadvanced loan commitments, we believe the unadvanced loan commitment total of \$12,526 million as of November 30, 2017 is not necessarily representative of our future funding cash requirements.

Unadvanced Loan Commitments—Conditional

The substantial majority of our line of credit commitments and all of our unadvanced long-term loan commitments include material adverse change clauses. Unadvanced loan commitments subject to material adverse change clauses totaled \$9,741 million and \$9,973 million as of November 30, 2017 and May 31, 2017, respectively. Prior to making an advance on these facilities, we confirm that there has been no material adverse change in the business or condition, financial or otherwise, of the borrower since the time the loan was approved and confirm that the borrower is currently in compliance with loan terms and conditions. In some cases, the borrower's access to the full amount of the facility is further constrained by the designated purpose, imposition of borrower-specific restrictions or by additional conditions that must be met prior to advancing funds.

Unadvanced Loan Commitments—Unconditional

Unadvanced loan commitments not subject to material adverse change clauses at the time of each advance consisted of unadvanced committed lines of credit totaling \$2,785 million and \$2,602 million as of November 30, 2017 and May 31, 2017, respectively. As such, we are required to advance amounts on these committed facilities as long as the borrower is in compliance with the terms and conditions of the facility.

The following table summarizes the available balance under unconditional committed lines of credit, and the related maturities by fiscal year and thereafter, as of November 30, 2017.

	Arrailabla	Notional	Maturities	of Uncond	litional Co	mmitted Li	ines of
	Available	Credit					
(Dollars in thousands)	Balance	2018	2019	2020	2021	2022	Thereafter
Committed lines of credit	\$2,784,511	\$130,000	\$517,130	\$395,711	\$630,631	\$677,818	\$433,221

Loan Sales

We transfer, from time to time, loans to third parties under our direct loan sale program. We sold CFC loans with outstanding balances totaling \$110 million and \$31 million, at par for cash, during the six months ended November 30, 2017 and 2016, respectively. We recorded immaterial losses upon the sale of these loans, attributable to the unamortized deferred loan origination costs associated with the transferred loans.

Pledging of Loans

We are required to pledge eligible mortgage notes in an amount at least equal to the outstanding balance of our secured debt. The following table summarizes our loans outstanding as collateral pledged to secure our collateral trust bonds, Clean Renewable Energy Bonds, notes payable to Farmer Mac and notes payable to the Federal Financing Bank and guaranteed by RUS under the Guaranteed Underwriter Program of the USDA ("Guaranteed Underwriter Program") and the amount of the

corresponding debt outstanding as of November 30, 2017 and May 31, 2017. See "Note 5—Short-Term Borrowings" and "Note 6—Long-Term Debt" for information on our borrowings.

(Dollars in thousands)	November 30, 2017	May 31, 2017
Collateral trust bonds: 2007 indenture:		
Distribution system mortgage notes	\$ 8,527,458	\$8,740,572
RUS-guaranteed loans qualifying as permitted investments	143,564	146,373
Total pledged collateral	\$ 8,671,022	\$8,886,945
Collateral trust bonds outstanding	7,697,711	7,697,711
1994 indenture:		
Distribution system mortgage notes	\$ 253,323	\$263,007
Collateral trust bonds outstanding	220,000	225,000
C	•	
Farmer Mac:		
Distribution and power supply system mortgage notes	\$ 2,876,351	\$2,942,456
Notes payable outstanding	2,491,464	2,513,389
Clean Renewable Energy Bonds Series 2009A:		
Distribution and power supply system mortgage notes	\$ 13,950	\$14,943
Cash	1,225	481
Total pledged collateral	\$ 15,175	\$15,424
Notes payable outstanding	13,214	13,214
Federal Financing Bank:		
Distribution and power supply system mortgage notes	\$ 5,876,050	\$5,833,515
Notes payable outstanding	5,060,192	4,985,748

Credit Concentration

We serve electric and telecommunications members throughout the United States and its territories, including 49 states, the District of Columbia, American Samoa and Guam. Texas had the largest concentration of outstanding loans to borrowers in any one state, with approximately 15% of total loans outstanding as of both November 30, 2017 and May 31, 2017. Our consolidated membership totaled 1,459 members and 217 associates as of November 30, 2017. As such, we have a loan portfolio with single-industry and single-obligor concentration risk. Outstanding loans to electric utility organizations represented approximately 99% of the total outstanding loan portfolio as of November 30, 2017, unchanged from May 31, 2017. The remaining outstanding loans in our portfolio were to RTFC members, affiliates and associates in the telecommunications industry.

Single-Obligor Concentration

The outstanding exposure of the 20 largest borrowers was 23% and 24% as of November 30, 2017 and May 31, 2017, respectively. The 20 largest borrowers consisted of 10 distribution systems, 9 power supply systems and 1 NCSC associate member as of both November 30, 2017 and May 31, 2017. The largest total outstanding exposure to a single borrower or controlled group represented approximately 2% of total loans and guarantees outstanding as of both November 30, 2017 and May 31, 2017.

Credit Quality

We closely monitor loan performance trends to manage and evaluate our credit risk exposure. We seek to provide a balance between meeting the credit needs of our members, while also ensuring the sound credit quality of our loan portfolio. Payment status and internal risk ratings are key indicators, among others, of the level of credit risk in our loan portfolio.

As part of our strategy in managing our credit risk exposure, we entered into a long-term standby purchase commitment agreement with Farmer Mac. Under this agreement, we may designate certain long-term loans to be covered under the commitment, subject to approval by Farmer Mac, and in the event any such loan later goes into payment default for at least 90 days, upon request by us, Farmer Mac must purchase such loan at par value. The aggregate unpaid principal balance of designated and Farmer Mac approved loans was \$792 million and \$843 million as of November 30, 2017 and May 31, 2017, respectively. Under the agreement, we are required to pay Farmer Mac a monthly fee based on the unpaid principal balance of loans covered under the purchase commitment. No loans had been put to Farmer Mac for purchase, pursuant to this agreement, as of November 30, 2017. Also, we had long-term loans totaling \$164 million and \$167 million as of November 30, 2017 and May 31, 2017, respectively, that were guaranteed by the Rural Utilities Service ("RUS") of the United States Department of Agriculture.

Payment Status of Loans

The tables below present the payment status of loans outstanding by member class as of November 30, 2017 and May 31, 2017. As indicated in the table, we did not have any past due loans as of either November 30, 2017 or May 31, 2017.

	November 30, 2	2017				
(Dollars in thousands)	Current	30-89 Days Past Due	90 Days or More Past Due	Past	Total Financing Receivables	Nonaccrual Loans
CFC:						
Distribution	\$19,230,740	\$ —	\$ —	\$ —	\$19,230,740	\$ —
Power supply	4,414,257				4,414,257	
Statewide and associate	57,107				57,107	
CFC total	23,702,104			_	23,702,104	_
NCSC	739,707			_	739,707	_
RTFC	371,731			_	371,731	_
Total loans outstanding	\$24,813,542	\$ —	\$ —	\$ —	\$24,813,542	\$ —
Percentage of total loans	100.00 %	%	%	%	100.00 %	%

	May 31, 2017					
(Dollars in thousands)	Current	30-89 Days Past Due	90 Days or More Past Due	Past	Total Financing Receivables	Nonaccrual Loans
CFC:						
Distribution	\$18,825,366	\$ —	\$ —	\$ —	\$18,825,366	\$ —
Power supply	4,504,791				4,504,791	
Statewide and associate	57,830				57,830	
CFC total	23,387,987				23,387,987	_
NCSC	613,924				613,924	_
RTFC	354,419				354,419	
Total loans outstanding	\$24,356,330	\$ —	\$ —	\$ —	\$24,356,330	\$ —
Percentage of total loans	100.00 %	%	%	%	100.00 %	%

⁽¹⁾ All loans 90 days or more past due are on nonaccrual status.

Troubled Debt Restructured ("TDR") Loans

We did not have any loans modified as TDRs during the six months ended November 30, 2017. The following table provides a summary of loans modified as TDRs in prior periods, the performance status of these loans and the unadvanced loan commitments related to the TDR loans, by member class, as of November 30, 2017 and May 31, 2017.

	Novemb	er 30, 2	017	May 31,	2017		
(Dollars in thousands)	Loans Outstand	% of Total ling Loans	Unadvanced Commitmen	Loans ts Outstand	% of Total ling Loans	Unadvance Commitme	
TDR loans:							
Performing TDR loans:							
CFC/Distribution	\$6,507	0.03%	\$	- \$6,581	0.02%	\$	
RTFC	6,341	0.02	_	6,592	0.03	_	
Total performing TDR loans	12,848	0.05		13,173	0.05	_	
Total TDR loans	\$12,848	0.05%	\$	-\$13,173	0.05%	\$	_

We did not have any TDR loans classified as nonperforming as of November 30, 2017 or May 31, 2017. TDR loans classified as performing as of November 30, 2017 and May 31, 2017 were performing in accordance with the terms of their respective restructured loan agreement and on accrual status as of the respective reported dates. One borrower with a TDR loan also had a line of credit facility, restricted for fuel purchases only, totaling \$6 million as of both November 30, 2017 and May 31, 2017. The outstanding amount under this facility totaled approximately \$1 million

and \$0.5 million as of November 30, 2017 and May 31, 2017, respectively, and was classified as performing as of each respective date.

Nonperforming Loans

In addition to TDR loans that may be classified as nonperforming, we also may have nonperforming loans that have not been modified as a TDR loan. We did not have any loans classified as nonperforming as of November 30, 2017 or May 31, 2017.

We had no foregone interest income for loans on nonaccrual status during the three and six months ended November 30,

2017. We had foregone interest income for loans on nonaccrual status totaling \$31 thousand during the six months ended November 30, 2016.

Impaired Loans

The following table provides information on loans classified as individually impaired loans as of November 30, 2017 and May 31, 2017.

(Dollars in thousands)	Recorded	dRelated	May 31, 2017 RecordedRelated InvestmerAllowance	
With no specific allowance recorded: CFC	\$6,507	\$ —	\$6,581	\$ —
With a specific allowance recorded: RTFC Total impaired loans	6,341 \$12.848	*	6,592 \$13,173	1,640 \$ 1.640

The following table presents, by company, the average recorded investment for individually impaired loans and the interest income recognized on these loans for the three and six months ended November 30, 2017 and 2016.

interest income recogn	izea on tn	ese ioans	for the	three a
	Three M	onths End	led	
	Novemb	er 30,		
	2017	2016	2017	2016
	Average		Interes	st
(Dollars in thousands)	Recorded	d	Incom	e
	Investme	ent	Recog	nized
CFC	\$6,507	\$6,581	\$ 142	\$ 144
RTFC	6,423	6,924	80	87
Total impaired loans	\$12,930	\$13,505	\$222	\$231
	Six Mon	ths Ended	l Novei	nber
	30,			
	2017	2016	2017	2016
	Average		Interes	st
(Dollars in thousands)	Recorded	d	Incom	e
	Investme	ent	Recog	nized
CFC	\$6,541	\$6,645	\$286	\$274
RTFC	6,486	8,729	162	175
Total impaired loans	\$13,027	\$15,374	\$448	\$449

Internal Risk Ratings of Loans

We evaluate the credit quality of our loans using an internal risk rating system that employs similar criteria for all member classes. Our internal risk rating system is based on a determination of a borrower's risk of default utilizing

both quantitative and qualitative measurements. Each risk rating is reassessed annually following the receipt of the borrower's audited financial statements; however, interim risk rating downgrades or upgrades may occur as a result of significant developments or trends. Our borrower risk ratings fall into the following four categories based on the criteria identified below.

Pass: Borrowers that are not experiencing difficulty and/or not showing a potential or well-defined credit weakness. Special Mention: Borrowers that may be characterized by a potential credit weakness or deteriorating financial condition that is not sufficiently serious to warrant a classification of substandard or doubtful.

Substandard: Borrowers that display a well-defined credit weakness that may jeopardize the full collection of principal and interest.

Doubtful: Borrowers that have a well-defined weakness and the full collection of principal and interest is questionable or improbable.

Loans to borrowers in the pass and special mention categories are generally included in the collective loan portfolio for purposes of determining the allowance for loan losses. Loans to borrowers in the substandard and doubtful categories are generally considered to be individually impaired and therefore reflected in the impaired loan portfolio. The special mention, substandard, and doubtful categories are intended to comply with the definition of criticized loans by the banking regulatory authorities.

The following tables present total loans outstanding, by member class and borrower risk rating category, based on the risk ratings used in the estimation of our allowance for loan losses as of November 30, 2017 and May 31, 2017.

C	November 30, 2017					
(Dollars in thousands)	Pass	Special Mention	Substandard	Doubtful	Total	
CFC:						
Distribution	\$19,122,976	\$107,764	\$ —	\$ -	-\$19,230,740	
Power supply	4,414,257		_		4,414,257	
Statewide and associate	57,107		_		57,107	
CFC total	23,594,340	107,764			23,702,104	
NCSC	739,707				739,707	
RTFC	365,390		6,341		371,731	
Total loans outstanding	\$24,699,437	\$107,764	\$ 6,341	\$ -	-\$24,813,542	
	May 31, 201	7				
(Dollars in thousands)	May 31, 2017 Pass	7 Special Mention	Substandard	Doubtful	Total	
(Dollars in thousands) CFC:	•	Special	Substandard	Doubtful	Total	
	•	Special Mention			Total -\$18,825,366	
CFC:	Pass	Special Mention				
CFC: Distribution	Pass \$18,715,810 4,504,791	Special Mention			-\$18,825,366	
CFC: Distribution Power supply	Pass \$18,715,810 4,504,791	Special Mention \$109,556			-\$18,825,366 4,504,791	
CFC: Distribution Power supply Statewide and associate	Pass \$18,715,810 4,504,791 56,654	Special Mention \$109,556 — 1,176	\$ — —		-\$18,825,366 4,504,791 57,830	
CFC: Distribution Power supply Statewide and associate CFC total	Pass \$18,715,810 4,504,791 56,654 23,277,255	Special Mention \$109,556 — 1,176 110,732	\$ — —		-\$18,825,366 4,504,791 57,830 23,387,987	

Allowance for Loan Losses

We maintain an allowance for loan losses at a level estimated by management to provide for probable losses inherent in the loan portfolio as of each balance sheet date. Our allowance for loan losses consists of an amount for loans collectively evaluated for impairment, referred to as our collective allowance, and an amount for loans designated as individually impaired, referred to as our specific allowance.

The following tables summarize changes, by company, in the allowance for loan losses as of and for the three and six months ended November 30, 2017 and 2016.

	Three Months Ended November 30, 2017
(Dollars in thousands)	CFC NCSC RTFC Total
Balance as of August 31, 2017	\$29,521 \$2,736 \$4,821 \$37,078
Provision (benefit) for loan losses	(722) 381 37 (304)
Balance as of November 30, 2017	\$28,799 \$3,117 \$4,858 \$36,774
	Three Months Ended November
	30, 2016
(Dollars in thousands)	CFC NCSC RTFC Total
Balance as of August 31, 2016	\$25,062 \$3,281 \$4,777 \$33,120
Provision (benefit) for loan losses	742 383 (387) 738
Recoveries	53 — — 53
Balance as of November 30, 2016	\$25,857 \$3,664 \$4,390 \$33,911
	Six Months Ended November 30,
	2017
(Dollars in thousands)	CFC NCSC RTFC Total
Balance as of May 31, 2017	\$29,499 \$2,910 \$4,967 \$37,376
Provision (benefit) for loan losses	(700) 207 (109) (602)
Balance as of November 30, 2017	\$28,799 \$3,117 \$4,858 \$36,774
	Six Months Ended November 30,
	2016
(Dollars in thousands)	CFC NCSC RTFC Total
Balance as of May 31, 2016	\$24,559 \$3,134 \$5,565 \$33,258
Provision for loan losses	1,192 530 944 2,666
Charge-offs	— — (2,119) (2,119)
Recoveries	106 — — 106
Net (charge-offs) recoveries	106 — (2,119) (2,013)
Balance as of November 30, 2016	\$25,857 \$3,664 \$4,390 \$33,911

The tables below present, by company, the components of our allowance for loan losses and the recorded investment of the related loans as of November 30, 2017 and May 31, 2017.

	November 30), 2017		
(Dollars in thousands)	CFC	NCSC	RTFC	Total
Allowance by company:				
Collective allowance	\$28,799	\$3,117	\$3,528	\$35,444
Specific allowance			1,330	1,330
Total allowance for loan losses	\$28,799	\$3,117	\$4,858	\$36,774
Recorded investment in loans:				
Collectively evaluated loans	\$23 695 597	\$739 707	\$365 390	\$24,800,694
Individually evaluated loans	6,507	_	6,341	12,848
Total recorded investment in loans	,	\$739,707	*	\$24,813,542
	, , ,	. ,	. ,	. , ,
Total recorded investment in loans, net ⁽¹⁾	\$23,673,305	\$736,590	\$366,873	\$24,776,768
	M 21 201	7		
	May 31, 201		DEFEC	T . 1
(Dollars in thousands)	May 31, 2017 CFC	7 NCSC	RTFC	Total
Allowance by company:	CFC	NCSC		
Allowance by company: Collective allowance	•		\$3,327	\$35,736
Allowance by company: Collective allowance Specific allowance	CFC \$29,499	NCSC \$2,910	\$3,327 1,640	\$35,736 1,640
Allowance by company: Collective allowance	CFC	NCSC	\$3,327	\$35,736
Allowance by company: Collective allowance Specific allowance	CFC \$29,499	NCSC \$2,910	\$3,327 1,640	\$35,736 1,640
Allowance by company: Collective allowance Specific allowance Total ending balance of the allowance Recorded investment in loans:	CFC \$29,499 — \$29,499	NCSC \$2,910 — \$2,910	\$3,327 1,640 \$4,967	\$35,736 1,640
Allowance by company: Collective allowance Specific allowance Total ending balance of the allowance	CFC \$29,499 — \$29,499	NCSC \$2,910 — \$2,910	\$3,327 1,640 \$4,967	\$35,736 1,640 \$37,376
Allowance by company: Collective allowance Specific allowance Total ending balance of the allowance Recorded investment in loans: Collectively evaluated loans	CFC \$29,499 — \$29,499 \$23,381,406 6,581	NCSC \$2,910 — \$2,910 \$613,924 —	\$3,327 1,640 \$4,967 \$347,827 6,592	\$35,736 1,640 \$37,376 \$24,343,157
Allowance by company: Collective allowance Specific allowance Total ending balance of the allowance Recorded investment in loans: Collectively evaluated loans Individually evaluated loans	CFC \$29,499 - \$29,499 \$23,381,406 6,581 \$23,387,987	NCSC \$2,910 - \$2,910 \$613,924 - \$613,924	\$3,327 1,640 \$4,967 \$347,827 6,592 \$354,419	\$35,736 1,640 \$37,376 \$24,343,157 13,173

⁽¹⁾ Excludes unamortized deferred loan origination costs \$11 million as of both November 30, 2017 and May 31, 2017.

Reserve for Unadvanced Commitments

We also maintain a reserve for unadvanced loan commitments at a level estimated by management to provide for probable losses under these commitments as of each balance sheet dated. Unadvanced loan commitments are analyzed and segregated by loan type and risk using our internal risk rating scales. We use these risk classifications, in combination with the probability of commitment usage, and any other pertinent information to estimate a reserve for unadvanced loan commitments, which we record as a liability on our condensed consolidated balance sheets. The reserve for these commitments was \$0.1 million as of both November 30, 2017 and May 31, 2017. NOTE

5—SHORT-TERM BORROWINGS

Short-term borrowings consist of borrowings with an original contractual maturity of one year or less and do not include the current portion of long-term debt. Our short-term borrowings totaled \$3,557 million and accounted for 15% of total debt outstanding as of November 30, 2017, compared with \$3,343 million, or 14%, of total debt outstanding as of May 31, 2017.

Committed Bank Revolving Line of Credit Agreements

We had \$3,085 million and \$3,165 million of commitments under committed bank revolving line of credit agreements as of November 30, 2017 and May 31, 2017, respectively. Under our current committed bank revolving line of credit agreements, we have the ability to request up to \$300 million of letters of credit, which would result in a reduction in the remaining available amount under the facilities.

On November 20, 2017, we amended and restated the three-year and five-year committed bank revolving line of credit agreements to extend the maturity dates to November 20, 2020 and November 20, 2022, respectively, and to terminate certain third-party bank commitments totaling \$40 million under the three-year agreement and \$40 million under the five- year agreement. As a result, the total commitment amount from third-parties under the three-year facility and the five-year facility is \$1,493 million and \$1,592 million, respectively, resulting in a combined total commitment amount under the two facilities of \$3,085 million.

The following table presents the total commitment, the net amount available for use and the outstanding letters of credit under our committed bank revolving line of credit agreements as of November 30, 2017 and May 31, 2017.

	Novem	nber 30, 2	017	May 31	, 201	17			,
(Dollars in millions)	Total Comm	Letters (Credit itment Outstan		Total Commi		ers of dit it standi		e Maturity	Annual Facility Fee (1)
3-year agreement	\$—	\$ —	\$ —	\$1,533			\$ 1,533	November 19, 2019	7.5 bps
3-year agreement	1,493	_	1,493	_	_		_	November 20, 2020	7.5 bps
Total 3-year agreement	1,493	_	1,493	1,533	_		1,533		
5-year agreement		_	_	1,632	1		1,631	November 19, 2021	10 bps
5-year agreement	1,592	2	1,590		_		_	November 20, 2022	10 bps
Total 5-year agreement	1,592	2	1,590	1,632	1		1,631		
Total	\$3,085	5 \$ 2	\$ 3,083	\$3,165	\$	1	\$ 3,164		

⁽¹⁾ Facility fee determined by CFC's senior unsecured credit ratings based on the pricing schedules put in place at the inception of the related agreement.

We were in compliance with all covenants and conditions under our committed bank revolving line of credit agreements and there were no borrowings outstanding under these agreements as of November 30, 2017 and May 31, 2017.

NOTE 6—LONG-TERM DEBT

The following table displays long-term debt outstanding, by debt type, as of November 30, 2017 and May 31, 2017.

(Dollars in thousands)	November 30, 2017	May 31, 2017
Unsecured long-term debt:		
Medium-term notes sold through dealers	\$2,781,757	\$2,386,956
Medium-term notes sold to members	404,567	422,779
Subtotal medium-term notes	3,186,324	2,809,735
Unamortized discount	(375)	(382)
Debt issuance costs	(23,192)	(21,903)
Total unsecured medium-term notes	3,162,757	2,787,450
Unsecured notes payable	22,799	22,799
Unamortized discount	(324)	(379)
Debt issuance costs	(80)	(94)
Total unsecured notes payable	22,395	22,326
Total unsecured long-term debt	3,185,152	2,809,776
Secured long-term debt:		
Collateral trust bonds	7,917,711	7,922,711
Unamortized discount	(253,449)	(258,329)
Debt issuance costs	(26,938)	(30,334)
Total collateral trust bonds	7,637,324	7,634,048
Guaranteed Underwriter Program notes payable	5,060,192	4,985,748
Debt issuance costs	(249)	(264)
Total Guaranteed Underwriter Program notes payable	5,059,943	4,985,484
Farmer Mac notes payable	2,491,463	2,513,389
Other secured notes payable	13,214	13,214
Debt issuance costs	(277)	(317)
Total other secured notes payable	12,937	12,897
Total secured notes payable	7,564,343	7,511,770
Total secured long-term debt	15,201,667	15,145,818
Total long-term debt	\$18,386,819	\$17,955,594

Secured Notes Payable

We had outstanding secured notes payable totaling \$5,060 million and \$4,985 million as of November 30, 2017 and May 31, 2017, respectively, under bond purchase agreements with Federal Financing Bank and a bond guarantee agreement with RUS issued under the Guaranteed Underwriter Program, which provides guarantees to Federal Financing Bank. We pay RUS a fee of 30 basis points per year on the total amount outstanding. On November 9, 2017, we closed on a \$750 million committed loan facility ("Series M") from the Federal Financing Bank under the Guaranteed Underwriter Program. Pursuant to this facility, we may borrow any time before July 15, 2022. Each

advance is subject to quarterly amortization and a final maturity not longer than 20 years from the advance date. The closing of this committed loan facility increased the amount available for access under the Guaranteed Underwriter Program to \$1,375 million as of November 30, 2017.

We are required to pledge eligible distribution system or power supply system loans as collateral in an amount at least equal to the total principal amount of notes outstanding under the Guaranteed Underwriter Program. See "Note 4—Loans and Commitments" for additional information on the collateral pledged to secure notes payable under this program.

We have two revolving note purchase agreements with Farmer Mac, which together allow us to borrow up to \$4,800 million from Farmer Mac. Under the terms of the first revolving note purchase agreement with Farmer Mac dated March 24, 2011, as amended, we can borrow, subject to market conditions, up to \$4,500 million at any time through January 11, 2020, and such date shall automatically extend on each anniversary date of the closing for an additional year, unless prior to any such anniversary date, Farmer Mac provides us with a notice that the draw period will not be extended beyond the remaining term. This revolving note purchase agreement allows us to borrow, repay and re-borrow funds at any time through maturity, as market conditions permit, provided that the outstanding principal amount at any time does not exceed the total available under the agreement. Each borrowing under the revolving note purchase agreement is evidenced by a pricing agreement setting forth the interest rate, maturity date and other related terms as we may negotiate with Farmer Mac at the time of each such borrowing. We may select a fixed rate or variable rate at the time of each advance with a maturity as determined in the applicable pricing agreement. Under this note purchase agreement with Farmer Mac, we had outstanding secured notes payable totaling \$2,491 million and \$2,513 million as of November 30, 2017 and May 31, 2017, respectively.

Under the terms of the second revolving note purchase agreement with Farmer Mac dated July 31, 2015, we can borrow up to \$300 million at any time through July 31, 2018 at a fixed spread over LIBOR. This agreement also allows us to borrow, repay and re-borrow funds at any time through maturity, provided that the outstanding principal amount at any time does not exceed the total available under the agreement. We had no notes payable outstanding under this revolving note purchase agreement with Farmer Mac as of November 30, 2017 and May 31, 2017.

We are required to pledge eligible distribution system or power supply system loans as collateral in an amount at least equal to the total principal amount of notes outstanding under each of our Farmer Mac revolving note purchase agreements. See "Note 4—Loans and Commitments" for additional information on the collateral pledged to secure notes payable under these programs.

We were in compliance with all covenants and conditions under our senior debt indentures as of November 30, 2017 and May 31, 2017.

NOTE 7—SUBORDINATED DEFERRABLE DEBT

The following table presents subordinated deferrable debt outstanding as of November 30, 2017 and May 31, 2017.

	November 30	, May 31,
	2017	2017
(Dollars in thousands)	Amount	Amount
4.75% due 2043 with a call date of April 30, 2023	\$ 400,000	\$400,000
5.25% due 2046 with a call date of April 20, 2026	350,000	350,000
Debt issuance costs	(7,659)	(7,726)
Total subordinated deferrable debt	\$ 742,341	\$742,274

NOTE 8—DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

Use of Derivatives

We are an end user of derivative financial instruments and do not engage in derivative trading. We use derivatives, primarily interest rate swaps and Treasury rate locks, to manage interest rate risk. Derivatives may be privately negotiated contracts, which are often referred to as over-the-counter ("OTC") derivatives, or they may be listed and traded on an exchange. We generally engage in OTC derivative transactions.

Accounting for Derivatives

In accordance with the accounting standards for derivatives and hedging activities, we record derivative instruments at fair value as either a derivative asset or derivative liability on our condensed consolidated balance sheets. We report derivative asset and liability amounts on a gross basis based on individual contracts, which does not take into consideration the effects of master netting agreements or collateral netting. Derivatives in a gain position are reported as derivative assets on our condensed consolidated balance sheets, while derivatives in a loss position are reported as derivative liabilities. Accrued interest related to derivatives is reported on our condensed consolidated balance sheets as a component of either accrued interest and other receivables or accrued interest payable.

If we do not elect hedge accounting treatment, changes in the fair value of derivative instruments, which consist of net accrued periodic derivative cash settlements and derivative forward value amounts, are recognized in our consolidated statements of operations under derivative gains (losses). If we elect hedge accounting treatment for derivatives, we formally document, designate and assess the effectiveness of the hedge relationship. Changes in the fair value of derivatives designated as qualifying fair value hedges are recorded in earnings together with offsetting changes in the fair value of the hedged item and any related ineffectiveness. Changes in the fair value of derivatives designated as qualifying cash flow hedges are recorded as a component of OCI, to the extent that the hedge relationships are effective, and reclassified AOCI to earnings using the effective interest method over the term of the forecasted transaction. Any ineffectiveness in the hedging relationship is recognized as a component of derivative gains (losses) in our consolidated statement of operations.

We generally do not designate interest rate swaps, which currently represent all of our outstanding derivatives, for hedge accounting. Accordingly, changes in the fair value of interest rate swaps are reported in our consolidated statements of operations under derivative gains (losses). Net periodic cash settlements related to interest rate swaps are classified as an operating activity in our consolidated statements of cash flows.

Outstanding Notional Amount of Derivatives

The notional amount provides an indication of the volume of our derivatives activity, but this amount is not recorded on our condensed consolidated balance sheets. The notional amount is used only as the basis on which interest payments are determined and is not the amount exchanged. The following table shows the outstanding notional amounts and the weighted-average rate paid and received for our interest rate swaps, by type, as of November 30, 2017 and May 31, 2017. The substantial majority of our interest rate swaps use an index based on the London Interbank Offered Rate ("LIBOR") for either the pay or receive leg of the swap agreement.

	November 30, 2017			May 31, 201		
(Dollars in thousands)	Notional Amount	Weighted Average Rate Paid	Average Rate	Notional Amount	Weighted- Average Rate Paid	Weighted- Average Rate Received
Pay-fixed swaps	\$6,974,906	2.84 %	1.39 %	\$6,807,013	2.85 %	1.16 %
Receive-fixed swaps	3,849,000	1.94	2.63	3,699,000	1.72	2.64
Total interest rate swaps	10,823,906	2.52	1.83	10,506,013	2.46	1.68
Forward pay-fixed swaps	226,255			285,383		

Total \$11,050,161 \$10,791,396

Impact of Derivatives on Condensed Consolidated Balance Sheets

The following table displays the fair value of the derivative assets and derivative liabilities recorded on our condensed consolidated balance sheets and the related outstanding notional amount of our interest rate swaps as of November 30, 2017 and May 31, 2017.

	November 3	30, 2017	May 31, 2017		
(Dollars in thousands)	Foir Walna	Notional	Fair Value	Notional	
(Dollars III tilousalius)	raii vaiue	Balance	raii vaiue	Balance	
Derivative assets	\$87,453	\$3,916,647	\$49,481	\$3,754,120	
Derivative liabilities	(304,307)	7,133,514	(385,337)	7,037,276	
Total	\$(216,854)	\$11,050,161	\$(335,856)	\$10,791,396	

All of our master swap agreements include legally enforceable netting provisions that allow for offsetting of all contracts with a given counterparty in the event of default by one of the two parties. However, as indicated above, we report derivative asset and liability amounts on a gross basis by individual contracts. The following table presents the gross fair value of derivative assets and liabilities reported on our condensed consolidated balance sheets as of November 30, 2017 and May 31, 2017, and provides information on the impact of netting provisions and collateral pledged.

	November 30, 2017					
			Net	Gross An	nount	
	Gross	Gross	Amount of	Not Offse	et in the	
	Amount	Amount	Assets/	Balance S	Sheet	
	of	Offset in	Liabilities			
	Recogniz	z ela le	Presented	Financial	Cash	Net
(Dollars in thousands)	Assets/	Balance	in the		Collateral	Amount
	Liabilitie	Sheet	Balance	Instrumer	Pledged	Amount
			Sheet			
Derivative assets:						
Interest rate swaps	\$87,453	\$ -	-\$ 87,453	\$79,373	\$ -	-\$ 8,080
Derivative liabilities:						
Interest rate swaps	304,307	_	304,307	79,373	_	224,934
	Mar. 21	2017				
	May 31,	2017	Nat	Cross Am	. ovent	
	•		Net Amount of	Gross An		
	Gross	Gross	Amount of	Not Offse	et in the	
	Gross Amount	Gross Amount	Amount of Assets/		et in the	
	Gross Amount of	Gross Amount Offset in	Amount of Assets/ Liabilities	Not Offse	et in the Sheet	
(Dollars in thousands)	Gross Amount of Recogniz	Gross Amount Offset in	Amount of Assets/ Liabilities Presented	Not Offse Balance S Financial	ct in the Sheet Cash	Net
(Dollars in thousands)	Gross Amount of Recognic Assets/	Gross Amount Offset in zetale Balance	Amount of Assets/ Liabilities Presented in the	Not Offse Balance S Financial	ct in the Sheet Cash	Net Amount
(Dollars in thousands)	Gross Amount of Recogniz	Gross Amount Offset in zetale Balance	Amount of Assets/ Liabilities Presented in the Balance	Not Offse Balance S	ct in the Sheet Cash	
	Gross Amount of Recognic Assets/	Gross Amount Offset in zetale Balance	Amount of Assets/ Liabilities Presented in the	Not Offse Balance S Financial	ct in the Sheet Cash	
Derivative assets:	Gross Amount of Recogniz Assets/ Liabilitie	Gross Amount Offset in zelue Balance esSheet	Amount of Assets/ Liabilities Presented in the Balance Sheet	Not Offse Balance S Financial Instrumen	et in the Sheet Cash Collateral Its Pledged	Amount
Derivative assets: Interest rate swaps	Gross Amount of Recognic Assets/	Gross Amount Offset in zelue Balance esSheet	Amount of Assets/ Liabilities Presented in the Balance	Not Offse Balance S Financial	et in the Sheet Cash Collateral Its Pledged	
Derivative assets:	Gross Amount of Recogniz Assets/ Liabilitie	Gross Amount Offset in zetale Balance essheet	Amount of Assets/ Liabilities Presented in the Balance Sheet	Not Offse Balance S Financial Instrumen	et in the Sheet Cash Collateral Its Pledged	Amount

Impact of Derivatives on Condensed Consolidated Statements of Operations

Derivative gains (losses) reported in our condensed consolidated statements of operations consist of derivative cash settlements and derivative forward value gains (losses). Derivative cash settlements represent net contractual interest expense accruals on interest rate swaps during the period. The derivative forward value gains (losses) represent the change in fair value of our interest rate swaps during the reporting period due to changes in the estimate of future interest rates over the remaining life of our derivative contracts.

The following table presents the components of the derivative gains (losses) reported in our condensed consolidated statements of operations for our interest rate swaps for the three and six months ended November 30, 2017 and 2016.

	Three Mon	ths Ended	Six Months Ended	
	November	30,	November 30,	
(Dollars in thousands)	2017	2016	2017	2016
Derivative cash settlements	\$(19,635)	\$(21,587)	\$(39,857)	\$(44,977)
Derivative forward value gains	145,228	362,247	119,252	197,344
Derivative gains	\$125,593	\$340,660	\$79,395	\$152,367

Credit-Risk-Related Contingent Features

Our derivative contracts typically contain mutual early termination provisions, generally in the form of a credit rating trigger. Under the mutual credit rating trigger provisions, either counterparty may, but is not obligated to, terminate and settle the agreement if the credit rating of the other counterparty falls to a level specified in the agreement. If a derivative contract is terminated, the amount to be received or paid by us would be equal to the mark-to-market value, as defined in the agreement, as of the termination date.

Our senior unsecured credit ratings from Moody's and S&P were A2 and A, respectively, as of November 30, 2017. Both Moody's and S&P had our ratings on stable outlook as of November 30, 2017. The following table displays the notional amounts of our derivative contracts with rating triggers as of November 30, 2017 and the payments that would be required if the contracts were terminated as of that date because of a downgrade of our unsecured credit ratings or the counterparty's unsecured credit ratings below A3/A-, below Baa1/BBB+ to or below Baa2/BBB, below Baa3/BBB- or to or below Ba2/BB+ by Moody's or S&P, respectively. In calculating the payment amounts that would be required upon termination of the derivative contracts, we assumed that the amounts for each counterparty would be netted in accordance with the provisions of the master netting agreements for each counterparty. The net payment amounts are based on the fair value of the underlying derivative instrument, excluding the credit risk valuation adjustment, plus any unpaid accrued interest amounts.

(Dollars in thousands)	Notional Amount	Payable Due From CFC	Receivable Due to CFC	Net (Payable)/Receival	ble
Impact of rating downgrade trigger:					
Falls below A3/A-(1)	\$56,985	\$(11,670)	\$ —	\$ (11,670)
Falls below Baa1/BBB+	7,236,383	(143,459)	7,428	(136,031)
Falls to or below Baa2/BBB (2)	455,152		1,577	1,577	
Falls below Baa3/BBB-	264,981	(18,102)	_	(18,102)
Total	\$8,013,501	\$(173,231)	\$ 9,005	\$ (164,226)

⁽¹⁾ Rating trigger for CFC falls below A3/A-, while rating trigger for counterparty falls below Baa1/BBB+ by Moody's or S&P, respectively.

Our largest counterparty exposure, based on the outstanding notional amount, represented approximately 23% of the total outstanding notional amount of derivatives as of both November 30, 2017 and May 31, 2017, respectively. The aggregate fair value amount, including the credit risk valuation adjustment, of all interest rate swaps with rating

⁽²⁾ Rating trigger for CFC falls to or below Baa2/BBB, while rating trigger for counterparty falls to or below Ba2/BB+ by Moody's or S&P, respectively.

triggers that were in a net liability position was \$173 million as of November 30, 2017. NOTE 9—EQUITY

Total equity increased by \$141 million to \$1,240 million as of November 30, 2017. The increase was primarily attributable to our reported net income of \$188 million for the six months ended November 30, 2017, which was partially offset by patronage capital retirement of \$45 million in September 2017. The following table presents the components of equity as of November 30, 2017 and May 31, 2017.

(Dollars in thousands)	November 30, 2017	May 31, 2017
Membership fees	\$968	\$971
Educational fund	1,398	1,929
Total membership fees and educational fund	2,366	2,900
Patronage capital allocated	716,481	761,701
Members' capital reserve	630,305	630,305
Unallocated net loss:		
Prior year-end cumulative derivative forward value losses ⁽¹⁾	(332,525)	(507,904)
Current year derivative forward value gains (1)	117,340	175,379
Current period-end cumulative derivative forward value losses ⁽¹⁾	(215,185)	(332,525)
Other unallocated net income (loss)	63,763	(5,603)
Unallocated net loss	(151,422)	(338,128)
CFC retained equity	1,197,730	1,056,778
Accumulated other comprehensive income	11,899	13,175
Total CFC equity	1,209,629	1,069,953
Noncontrolling interests	30,419	28,852
Total equity	\$1,240,048	\$1,098,805

⁽¹⁾ Represents derivative forward value gains (losses) for CFC only, as total CFC equity does not include the noncontrolling interests of the consolidated variable interest entities NCSC and RTFC. See "Note 12—Business Segments" for the separate statements of operations for CFC.

In July 2017, the CFC Board of Directors authorized the allocation of the fiscal year 2017 adjusted net income as follows: \$90 million to members in the form of patronage capital; \$43 million to members' capital reserve; and \$1 million to the Cooperative Educational Fund. The amount of patronage capital allocated each year by CFC's Board of Directors is based on adjusted net income, which excludes the impact of derivative forward value gains (losses). See "MD&A—Non-GAAP Financial Measures" for information on adjusted net income.

In July 2017, the CFC Board of Directors authorized the retirement of patronage capital totaling \$45 million, which represented 50% of the fiscal year 2017 allocation of patronage capital of \$90 million. We returned the \$45 million to members in cash in September 2017. The remaining portion of the allocated amount will be retained by CFC for 25 years under guidelines adopted by the CFC Board of Directors in June 2009.

The CFC Board of Directors is required to make annual allocations of adjusted net income, if any. CFC has made annual retirements of allocated net earnings in 38 of the last 39 fiscal years; however, future retirements of allocated amounts are determined based on CFC's financial condition. The CFC Board of Directors has the authority to change the current practice for allocating and retiring net earnings at any time, subject to applicable laws. See "Item 1. Business—Allocation and Retirement of Patronage Capital" of our 2017 Form 10-K for additional information.

Accumulated Other Comprehensive Income

The following tables summarize, by component, the activity in AOCI as of and for the three and six months ended November 30, 2017 and 2016.

	Three Months Ended November 30, 2017
	Unrealized Unrealized
	Gains Unrealized Losses Losses D. G. 1. T. 1.
(Dollars in thousands)	(Losses) Gains Defined Lotal
	AFS Derivatives Foreclosed Benefit
	Securities Assets Plan
Beginning balance	\$10,865 \$ 3,510 \$ —\$ (2,416) \$11,959
Unrealized gains	8 — — 8
Losses reclassified into earnings	<u> </u>
Gains reclassified into earnings	- (194) $-$ (194)
Other comprehensive income (loss)	8 (194) — 126 (60)
Ending balance	\$10,873 \$ 3,316 \$ —\$ (2,290) \$11,899
	Three Months Ended November 30, 2016
	Unrealized Unrealized
	Gains Unrealized Unrealized Losses
(Dollars in thousands)	(Losses) Gains Losses Defined Total
	AFS Derivatives Foreciosed Benefit
	Securities Assets Plan
Beginning balance	\$7,391 \$4,290 \$ —\$ (964) \$10,717
Unrealized losses	(1,761) — $(1,761)$
Losses reclassified into earnings	44 44
Gains reclassified into earnings	— (199) — — (199)
Other comprehensive income (loss)	(1,761)(199) — 44 $(1,916)$
Ending balance	\$5,630 \$4,091 \$ —\$ (920) \$8,801
	Six Months Ended November 30, 2017
	Unrealized Unrealized
	Gains Unrealized Losses
(Dollars in thousands)	(Losses) Gains Losses Defined Total
	AFS Derivatives Foreclosed Benefit
	Securities Assets Plan
Beginning balance	\$12,016 \$ 3,702 \$ —\$ (2,543) \$13,175
Unrealized losses	(1,143) — $(1,143)$
Losses reclassified into earnings	<u> </u>
Gains reclassified into earnings	- (386) $-$ (386)
Other comprehensive income (loss)	
Ending balance	\$10,873 \$ 3,316 \$ —\$ (2,290) \$11,899
	Six Months Ended November 30, 2016
	Unrealized Unrealized
	Gains Unrealized Losses
(Dollars in thousands)	(Losses) Gains Losses Defined Total
	AFS Derivatives Foreclosed Benefit
	Securities Assets Plan
Beginning balance	\$7,402 \$ 4,487 \$ (9,823) \$ (1,008) \$1,058
- G -	τ (×,υ=υ) ψ (x,υυυ) ψ 1,0υυ

Unrealized losses	(1,772) —			(1,772)
Losses reclassified into earnings		9,823	88	9,911
Gains reclassified into earnings	— (396) —		(396)
Other comprehensive income (loss)	(1,772) (396) 9,823	88	7,743
Ending balance	\$5,630 \$4,091	\$ —	\$ (920) \$8,801

We expect to reclassify approximately \$0.5 million of amounts in AOCI related to unrealized derivative gains into earnings over the next 12 months.

NOTE 10—GUARANTEES

The following table summarizes total guarantees, by type of guarantee and by member class, as of November 30, 2017 and May 31, 2017.

(Dollars in thousands)	November 30, 2017	•
Total by type:		
Long-term tax-exempt bonds ⁽¹⁾	\$318,425	\$468,145
Letters of credit ⁽²⁾	230,117	307,321
Other guarantees	113,954	114,151
Total	\$662,496	\$889,617

Total by member class:

CFC:

\$129,066	\$126,188
511,624	743,678
5,005	5,054
645,695	874,920
15,227	13,123
1,574	1,574
\$662,496	\$889,617
	511,624 5,005 645,695 15,227 1,574

⁽¹⁾Represents the outstanding principal amount of long-term fixed-rate and variable-rate guaranteed bonds.

Long-term tax-exempt bonds of \$318 million and \$468 million as of November 30, 2017 and May 31, 2017, respectively, consisted of \$251 million and \$400 million, respectively, of adjustable or variable-rate bonds that may be converted to a fixed rate as specified in the applicable indenture for each bond offering. We are unable to determine the maximum amount of interest that we may be required to pay related to the remaining adjustable and variable-rate bonds. Many of these bonds have a call provision that allows us to call the bond in the event of a default, which would limit our exposure to future interest payments on these bonds. Our maximum potential exposure generally is secured by mortgage liens on the members' assets and future revenue. If a member's debt is accelerated because of a determination that the interest thereon is not tax-exempt, the member's obligation to reimburse us for any guarantee payments will be treated as a long-term loan. The remaining long-term tax-exempt bonds of \$67 million as of November 30, 2017 are fixed-rate. The maximum potential exposure for these bonds, including the outstanding principal of \$67 million and related interest through maturity, totaled \$96 million as of November 30, 2017. The maturities for long-term tax-exempt bonds and the related guarantees extend through calendar year 2042.

Of the outstanding letters of credit of \$230 million and \$307 million as of November 30, 2017 and May 31, 2017, respectively, \$42 million and \$125 million, respectively, was secured. We did not have any letters of credit

⁽²⁾Reflects our maximum potential exposure for letters of credit.

outstanding that provided for standby liquidity for adjustable and floating-rate tax-exempt bonds issued for the benefit of our members as of November 30, 2017. Letters of credit include \$76 million to provide the standby liquidity for adjustable and floating-rate tax-exempt bonds issued for the benefit of our members as of May 31, 2017. Security provisions include a mortgage lien on

substantially all of the member's assets, future revenue and the member's investment in our commercial paper. The maturities for the outstanding letters of credit as November 30, 2017 extend through calendar year 2027.

In addition to the letters of credit listed in the table above, under master letter of credit facilities in place as of November 30, 2017, we may be required to issue up to an additional \$65 million in letters of credit to third parties for the benefit of our members. All of our master letter of credit facilities were subject to material adverse change clauses at the time of issuance as of November 30, 2017. Prior to issuing a letter of credit, we would confirm that there has been no material adverse change in the business or condition, financial or otherwise, of the borrower since the time the loan was approved and confirm that the borrower is currently in compliance with the letter of credit terms and conditions.

The maximum potential exposure for other guarantees was \$115 million as of both November 30, 2017 and May 31, 2017, all of which were unsecured. The maturities for these other guarantees listed in the table above extend through calendar year 2025.

Guarantees under which our right of recovery from our members was not secured totaled \$302 million and \$297 million and represented 46% and 33% of total guarantees as of November 30, 2017 and May 31, 2017, respectively.

In addition to the guarantees described above, we were also the liquidity provider for \$251 million of variable-rate tax-exempt bonds as of November 30, 2017, issued for our member cooperatives. While the bonds are in variable-rate mode, in return for a fee, we have unconditionally agreed to purchase bonds tendered or put for redemption if the remarketing agents are unable to sell such bonds to other investors. We were not required to perform as liquidity provider pursuant to these obligations during the six months ended November 30, 2017 or the prior fiscal year.

Guarantee Liability

As of November 30, 2017 and May 31, 2017, we recorded a guarantee liability of \$8 million and \$15 million respectively, which represents the contingent and noncontingent exposures related to guarantees and liquidity obligations. The contingent guarantee liability was \$1 million as of both November 30, 2017 and May 31, 2017, based on management's estimate of exposure to losses within the guarantee portfolio. The remaining balance of the total guarantee liability of \$7 million and \$14 million as of November 30, 2017 and May 31, 2017, respectively, relates to our noncontingent obligation to stand ready to perform over the term of our guarantees and liquidity obligations that we have entered into or modified since January 1, 2003.

NOTE 11—FAIR VALUE MEASUREMENT

We use fair value measurements for the initial recording of certain assets and liabilities and periodic remeasurement of certain assets and liabilities on a recurring or nonrecurring basis. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy that prioritizes the inputs into the valuation techniques used to measure fair value. The levels of the fair value hierarchy, in priority order, include Level 1, Level 2 and Level 3. For additional information regarding the fair value hierarchy and a description of the methodologies we use to measure fair value, see "Note 14—Fair Value Measurement" to the Consolidated Financial Statements in our 2017 Form 10-K.

The following tables present the carrying value and fair value for all of our financial instruments, including those carried at amortized cost, as of November 30, 2017 and May 31, 2017. The tables also display the classification within the fair value hierarchy of the valuation technique used in estimating fair value.

	November 3	30, 2017	Fair Value	Measuremen	t Level
(Dollars in thousands)	Carrying Value	Fair Value	Level 1	Level 2	Level 3
Assets: Cash and cash equivalents	\$280,315	\$280,315	\$280,315	\$—	\$ —
Restricted cash Time deposits	11,323 51,000	11,323 51,000	11,323		_
Investment securities, available-for-sale Investment securities, held-to-maturity	91,411 248,155	91,411 247,257	91,411 —	— 247,257	_
Deferred compensation investments Loans to members, net	5,176 24,787,917	5,176 24,351,976	5,176 —		<u></u>
Accrued interest receivable	116,770	116,770		116,770	<u>-</u>
Debt service reserve funds Derivative assets	17,151 87,453	17,151 87,453	17,151 —		_
Liabilities:					
Short-term borrowings Long-term debt		\$3,556,637 18,975,545	\$1,446,065 —	\$2,110,572 11,452,351	
Accrued interest payable Guarantee liability	143,085 8,211	143,085 8,423	_	143,085	— 8,423
Derivative liabilities Subordinated deferrable debt	304,307 742,341	304,307 789,430	_	304,307 789,430	_
Members' subordinated certificates	1,399,675	1,399,697	_	——————————————————————————————————————	1,399,697
	May 31, 20	17	Fair Value	Measuremen	t Level
(Dollars in thousands)	Carrying Value	Fair Value	Level 1	Level 2	Level 3
Assets: Cash and cash equivalents	\$166,615	\$166,615	\$166,615	\$ —	\$ —
Restricted cash Time deposits	21,806 226,000	21,806 226,000	21,806	<u> </u>	_
Investment securities, available-for-sale	92,554	92,554	92,554	_	_
Deferred compensation investments Loans to members, net	4,693 24,329,668	4,693 24,182,724	4,693 —	_	<u></u> 24,182,724
Accrued interest receivable Debt service reserve funds	111,493 17,151	111,493 17,151	— 17,151	111,493	_
Derivative assets	49,481	49,481	_	49,481	_
Liabilities:	¢2 242 000	¢2 242 000	¢1 507 000	¢1 015 000	¢
Short-term borrowings Long-term debt	17,955,594	18,744,331	\$1,527,990 —	11,215,290	
Accrued interest payable Guarantee liability	137,476 15,241	137,476 16,204	_	137,476	 16,204

Derivative liabilities	385,337	385,337	_	385,337	_
Subordinated deferrable debt	742,274	788,079		788,079	
Members' subordinated certificates	1,419,025	1,419,048	_		1,419,048

Investment Securities, Held-to-Maturity, Fair Value

As discussed above in "Note 3—Investment Securities," we did not have any securities classified as HTM as of May 31, 2017. During the second quarter of fiscal year 2018, we commenced the purchase of additional investment securities, consisting primarily of certificates of deposit, commercial paper and corporate debt securities, commercial MBS and other ABS traded in secondary markets. We designated these securities as HTM.

Management estimates the fair value of our HTM securities utilizing the assistance of third-party pricing services. Methodologies employed, controls relied upon and inputs used by third-party pricing vendors are subject to management review when such services are provided. This review may consist of, in part, obtaining and evaluating control reports issued and pricing methodology materials distributed. We review the pricing methodologies provided by the vendors in order to determine if observable market information is being used to determine the fair value versus unobservable inputs. Investment securities traded in secondary markets are typically valued using unadjusted vendor prices. These investment securities, which include those measured using unadjusted vendor prices, are generally classified as Level 2 because the valuation typically involves using quoted market prices for similar securities, pricing models, discounted cash flow analyses using significant observable market where available or a combination of multiple valuation techniques for which all significant assumptions are observable in the market.

Transfers Between Levels

We monitor the availability of observable market data to assess the appropriate classification of financial instruments within the fair value hierarchy and transfer between Level 1, Level 2, and Level 3 accordingly. Observable market data includes but is not limited to quoted prices and market transactions. Changes in economic conditions or market liquidity generally will drive changes in availability of observable market data. Changes in availability of observable market data, which also may result in changes in the valuation technique used, are generally the cause of transfers between levels. We did not have any transfers between levels for financial instruments measured at fair value on a recurring basis for the six months ended November 30, 2017 and 2016.

Recurring Fair Value Measurements

The following table presents the carrying value and fair value of financial instruments reported in our condensed consolidated financial statements at fair value on a recurring basis as of November 30, 2017 and May 31, 2017, and the classification of the valuation technique within the fair value hierarchy.

	Novemb	er 30, 201	17	May 31,	2017	
(Dollars in thousands)	Level 1	Level 2	Total	Level 1	Level 2	Total
Investment securities, available for sale	\$91,411	\$ -	\$91,411	\$92,554	\$ -	\$92,554
Deferred compensation investments	5,176	_	5,176	4,693	_	4,693
Derivative assets	_	87,453	87,453	_	49,481	49,481
Derivative liabilities		304,307	304,307		385,337	385,337

Nonrecurring Fair Value

We did not have any assets reported in our condensed consolidated financial statements at fair value on a nonrecurring basis as of November 30, 2017 and May 31, 2017 and there were no unrealized losses for the three and six months ended November 30, 2017 and 2016 related to these assets.

Significant Unobservable Level 3 Inputs

Impaired Loans

We utilize the fair value of estimated cash flows or the collateral underlying the loan to determine the fair value and specific allowance for impaired loans. The valuation technique used to determine fair value of the impaired loans provided by both our internal staff and third-party specialists includes market multiples (i.e., comparable companies). The significant unobservable inputs used in the determination of fair value for individually impaired loans is a multiple of earnings before interest, taxes, depreciation and amortization based on various factors (i.e., financial condition of the borrower). In estimating the fair value of the collateral, we may use third-party valuation specialists, internal estimates or a combination of both. The significant unobservable inputs for estimating the fair value of impaired collateral-dependent loans are reviewed by our Credit Risk Management group to assess the reasonableness of the assumptions used and the accuracy of the work performed. In cases where we rely on third-party inputs, we use the final unadjusted third-party valuation analysis as support for any adjustments to our consolidated financial statements and disclosures.

Because of the limited amount of impaired loans as of November 30, 2017 and May 31, 2017, we do not believe that potential changes in the significant unobservable inputs used in the determination of the fair value for impaired loans will have a material impact on the fair value measurement of these assets or our results of operations.

NOTE 12—BUSINESS SEGMENTS

The following tables display segment results for the three and six months ended November 30, 2017 and 2016, and assets attributable to each segment as of November 30, 2017 and November 30, 2016.

	Three Months Ended November 30, 2017			
(Dollars in thousands)	$ \begin{array}{ccc} \text{CFC} & \text{Other} & \text{Elimination} & \begin{array}{c} \text{Consolidated} \\ \text{Total} \end{array} $			
Statement of operations:				
Interest income	\$263,180 \$12,257 \$ (9,614) \$ 265,823			
Interest expense	(194,943) (9,841) 9,614 (195,170)			
Net interest income	68,237 2,416 — 70,653			
Benefit for loan losses	304 — — 304			
Net interest income after benefit for loan losses	68,541 2,416 — 70,957			
Non-interest income:				
Fee and other income	5,490 301 (249) 5,542			
Derivative gains (losses):				
Derivative cash settlements	(18,990) (645) — (19,635)			
Derivative forward value gains	143,452 1,776 — 145,228			
Derivative gains	124,462 1,131 — 125,593			
Results of operations of foreclosed assets	(10) -			
Total non-interest income	129,942 1,432 (249) 131,125			
Non-interest expense:				
General and administrative expenses	(20,292)(1,622)— $(21,914)$			
Losses on early extinguishment of debt				
Other non-interest expense	(618) (249) 249 (618)			
Total non-interest expense	(20,910) (1,871) 249 (22,532)			
Income before income taxes	177,573 1,977 — 179,550			
Income tax expense	— (827) — (827)			
Net income	\$177,573 \$1,150 \$— \$178,723			

	Three Months Ended November 30, 2016				
(Dollars in thousands)	CFC	Other	Elimination	Consolidate Total	ed
Statement of operations:					
Interest income	\$254,689	\$11,129	\$ (8,662)	\$ 257,156	
Interest expense	(183,395)	(8,934)	8,675	(183,654)
Net interest income	71,294	2,195	13	73,502	
Provision for loan losses	(738)			(738)
Net interest income after provision for loan losses	70,556	2,195	13	72,764	
Non-interest income:					
Fee and other income	4,628	1,727	(1,258)	5,097	
Derivative gains (losses):					
Derivative cash settlements	(20,821)	(766)		(21,587)
Derivative forward value gains	358,423	3,824		362,247	
Derivative gains	337,602	3,058		340,660	
Results of operations of foreclosed assets	(549)			(549)
Total non-interest income	341,681	4,785	(1,258)	345,208	
Non-interest expense:					
General and administrative expenses	(18,991)	(1,641)		(20,632)
Other non-interest expense	(517)	(1,245)	1,245	(517)
Total non-interest expense	(19,508)	(2,886)	1,245	(21,149)
Income before income taxes	392,729	4,094		396,823	
Income tax expense		(1,519)		(1,519)
Net income	\$392,729	\$2,575	\$ <i>—</i>	\$ 395,304	

	Six Months E	Ended Novem	ber 30, 2017	
(Dollars in thousands)	CFC	Other	Elimination	Consolidated Total
Statement of operations:				
Interest income	\$526,591	\$23,206	\$(18,059)	\$531,738
Interest expense	(387,448	(18,512	18,059	(387,901)
Net interest income	139,143	4,694	<u> </u>	143,837
Benefit for loan losses	602	_	_	602
Net interest income after benefit for loan losses	139,745	4,694	_	144,439
Non-interest income:	,	•		•
Fee and other income	9,378	701	(592)	9,487
Derivative gains (losses):	,		,	,
Derivative cash settlements	(38,554	(1,303) —	(39,857)
Derivative forward value gains	117,341	1,911	<u> </u>	119,252
Derivative gains	78,787	608	_	79,395
Results of operations of foreclosed assets	-) —	_	(34)
Total non-interest income	88,131	1,309	(592)	88,848
Non-interest expense:	,	,	,	,
General and administrative expenses	(40,030	(3,520) —	(43,550)
Other non-interest expense			592	(1,140)
Total non-interest expense	(41,170	(4,112	592	(44,690)
Income before income taxes	186,706	1,891		188,597
Income tax expense		(859) —	(859)
Net income	\$186,706	\$1,032	\$	\$187,738
	November 30	2017		
				Consolidated
	CFC	Other	Elimination	Total
Assets:				
Loans to members	\$24,788,572	\$1,111,438	\$(1,075,319)	\$24,824,691
Less: Allowance for loan losses	(36,774) —		(36,774)
Loans to members, net	24,751,798	1,111,438	(1,075,319)	24,787,917
Other assets	1,081,850	107,516	(97,040)	1,092,326
Total assets	\$25,833,648	\$1,218,954	\$(1,172,359)	\$25,880,243
83				

	Six Months I	Ended Novemb	ber 30, 2016	
(Dollars in thousands)	CFC	Other	Elimination	Consolidated Total
Statement of operations:				
Interest income	\$508,706	\$22,351	\$(17,066)	\$513,991
Interest expense	(364,227) (17,610	17,103	(364,734)
Net interest income	144,479	4,741	37	149,257
Provision for loan losses	(2,666) —	_	(2,666)
Net interest income after provision for loan losses	141,813	4,741	37	146,591
Non-interest income:				
Fee and other income	8,956	2,624	(1,953)	9,627
Derivative gains (losses):				
Derivative cash settlements	(43,430) (1,547) —	(44,977)
Derivative forward value gains	194,210	3,134		197,344
Derivative gains	150,780	1,587	_	152,367
Results of operations of foreclosed assets	(1,661) —		(1,661)
Total non-interest income	158,075	4,211	(1,953)	160,333
Non-interest expense:				
General and administrative expenses	(37,770) (3,721) —	(41,491)
Other non-interest expense	(960) (1,916	1,916	(960)
Total non-interest expense	(38,730) (5,637	1,916	(42,451)
Income before income taxes	261,158	3,315	_	264,473
Income tax expense		(1,430) —	(1,430)
Net income	\$261,158	\$1,885	\$	\$263,043
	November 30	0, 2016		
	CFC	Other	Elimination	Consolidated Total
Assets:				Total
Loans to members	\$23,813,591	\$1,037,545	\$(1,000,424)	\$23,850,712
Less: Allowance for loan losses	*	ψ1,037,3 1 3	\$(1,000,424)	(33,911)
Loans to members, net	23,779,680	1,037,545	(1,000,424)	
Other assets	1,318,908	1,037,343		1,330,920
Total assets	\$25,098,588	•		\$25,147,721
Total assets	Ψ23,070,300	Ψ1,17,009	ψ(1,100,070)	$\Psi 23,177,721$

Item 3. Quantitative and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, see "Part I—Item 2. MD&A—Market Risk" and "Note 8—Derivative Instruments and Hedging Activities."

Item 4. Controls and Procedures

As of the end of the period covered by this report, senior management, including the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on this evaluation process, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting that occurred during the three months ended November 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, CFC is subject to certain legal proceedings and claims in the ordinary course of business, including litigation with borrowers related to enforcement or collection actions. Management presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, liquidity, or results of operations. CFC establishes reserves for specific legal matters when it determines that the likelihood of an unfavorable outcome is probable and the loss is reasonably estimable. Accordingly, no reserve has been recorded with respect to any legal proceedings at this time.

Item 1A. Risk Factors

Refer to "Part I— Item 1A. Risk Factors" in our 2017 Form 10-K for information regarding factors that could affect our results of operations, financial condition and liquidity. We are not aware of any material changes in the risk factors set forth under "Part I— Item 1A. Risk Factors" in our 2017 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following exhibits are incorporated by reference or filed as part of this Report.

EXHIBIT INDEX

LAIIDII	INDEX
Exhibit No.	Description
10.1*	Amendment No. 2 dated as of November 20, 2017 to the Amended and Restated Revolving Credit Agreement dated as of November 19, 2015 maturing on November 20, 2020.
10.2*	Amendment No. 2 dated as of November 20, 2017 to the Amended and Restated Revolving Credit Agreement dated as of November 19, 2015 maturing on November 20, 2022.
10.3*	Service dated as of November 9, 2017 for up to \$750,000,000.
10.4*	Series M Future Advance Bond from the Registrant to the Federal Financing Bank dated as of November 9, 2017 for up to \$750,000,000 maturing on July 15, 2042.
10.5*	Fourth Amended, Restated and Consolidated Pledge Agreement dated as of November 9, 2017 between the Registrant, the Rural Utilities Service and U.S. Bank National Association.
10.6*	Fourth Amended, Restated and Consolidated Bond Guarantee Agreement dated as of November 9, 2017 <u>between the Registrant and the Rural Utilities Service.</u>
12*	-Computation of Ratio of Earnings to Fixed Charges
31.1*	-Certification of the Chief Executive Officer required by Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	-Certification of the Chief Financial Officer required by Section 302 of the Sarbanes-Oxley Act of 2002
32.1†	-Certification of the Chief Executive Officer required by Section 906 of the Sarbanes-Oxley Act of 2002
32.2†	-Certification of the Chief Financial Officer required by Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	-XBRL Instance Document
101.SCH*	-XBRL Taxonomy Extension Schema Document
101.CAL*	-XBRL Taxonomy Calculation Linkbase Document
101.LAB*	-XBRL Taxonomy Label Linkbase Document
101.PRE*	-XBRL Taxonomy Presentation Linkbase Document
101.DEF*	-XBRL Taxonomy Definition Linkbase Document

^{*}Indicates a document being filed with this Report.

[†]Indicates a document that is furnished with this Report, which shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION

Date: January 11, 2018

By:/s/ J. ANDREW DON

J. Andrew Don

Senior Vice President and Chief Financial Officer

By: /s/ ROBERT E. GEIER Robert E. Geier Controller (Principal Accounting Officer)